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ABSTRACT
Olfactory ensheathing cells (OECs) are non-myelinating glial cells that provide
ensheathment for axons of the olfactory nerve in vivo.  OECs have been shown to
facilitate the regeneration of CNS axons, to assemble a myelin sheath around
demyelinated axons, and it has been suggested OECs migrate very well within the
microenvironment of the injured CNS.  However, there has been no direct test of their
migratory ability in vivo. The aims of this study were to determine whether: 1) OECs
can be induced to migrate towards an ethidium bromide (EtBr)-induced focal (~1 mm
long) demyelination of the spinal cord white matter; 2) OECs migrate away from a focal
demyelination either into normal CNS tissue or towards a second demyelinated lesion;
3) microglial reactivity is required for the generation of the migratory signal(s) inducing
OECs to migrate towards a focal demyelination; 4) OECs grafted into the subarachnoid
space surrounding the spinal cord will migrate into the neuropil in the absence of
demyelination.
To achieve these aims, we developed an in vivo model for studying the
migratory ability of OECs within the adult rat spinal cord.  A small focal EtBr-induced
demyelination of the dorsal funiculus (unilaterally) of the spinal cord was made at
variable distances from the site of a DiI-labelled OEC graft.  The major findings were:
i) the strength of the migratory signal(s) inducing OECs to migrate increased as the
demyelinated lesion was located closer to the grafting site; ii) the OEC migration
towards a distal demyelinated lesion was greatly enhanced when the cells were grafted
directly into a second demyelinated lesion; iii) the cell migration occurred along a
migratory path containing many reactive astrocytes and microglia; iv) the migration of
OECs was significantly reduced when the microglial reactivity was dampened using
minocycline; and v) OECs survived grafting into cerebrospinal fluid (i.e. subarachnoid
space) and migrated into the neuropil of the brain and spinal cord.   The major
conclusions are that OECs can respond to migratory signal(s) arising as a result of a
focal EtBr-induced demyelination and that microglia are one potential source of these
migratory signal(s).
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1 INTRODUCTION
1.1 The Primary Olfactory Pathway
The primary olfactory pathway consists of the olfactory epithelium, the olfactory nerve,
and the olfactory bulb.  Primary olfactory neurons are located in the olfactory epithelium,
which is the epithelial component of the olfactory mucosa and lines part of the nasal cavity, and
project their axons via the first cranial nerve, the olfactory nerve, to the olfactory bulb.  In the
bulb, the olfactory axons innervate a discrete lamina near the pial surface of the ipsilateral
olfactory bulb where they form synaptic connections with neurons of the bulb in specialized
areas of neuropil called glomeruli.  The olfactory epithelium is the part of the adult mammalian
nervous system in which it was first discovered that neurogenesis continued past the early
postnatal period of development and into adulthood (Barber, 1982; Calof et al., 1998; Graziadei
and Monti Graziadei, 1979).  New olfactory receptor neurons continue to be generated
throughout the life of mammals, a process that provides new neurons to replace those lost from
injury or disease (Graziadei and Monti Graziadei, 1979; Schwob, 2002).  In rodents, olfactory
receptor neurons have a life span of approximately one month (Costanzo and Graziadei, 1983;
Graziadei and Monti Graziadei, 1978; Moulton et al., 1970; Simmons et al., 1981).
1.1.1 The olfactory mucosa
The olfactory mucosa lines the superior part of the nasal cavity and consists of two
layers, a superficial olfactory epithelium and a deeper lamina propria (Morrisson and Costanzo,
1992). The former is an avascular pseudostratified columnar epithelium containing three
principal cell types: olfactory receptor neurons, sustentacular (supporting) cells, and horizontal
basal cells.  The olfactory epithelium is mainly sensory in function and is specialized for the
detection of odorants.  The lamina propria contains numerous fascicles of olfactory axons,
which are all unmyelinated, multicellular Bowman’s glands and blood vessels (Getchell et al.,
1984); in addition to these elements being embedded within the loose connective tissue of the
lamina propria, there is also an occasional small fascicle of myelinated and unmyelinated axons
originating from the trigeminal nerve.  Sustentacular cells of the olfactory epithelium and
2Bowman’s glands, the ducts of which course through the epithelium enroute to the apical
surface of the epithelium, are believed to be responsible for producing the layer of mucus that
covers the free surface of the olfactory mucosa (Getchell et al., 1984).
Three main neuronal populations have been identified in the olfactory epithelium of
adult mammals (Graziadei and Monti Graziadei, 1978, 1979), with each population
representing a different stage in the maturation of newly formed olfactory receptor neurons.
Globose basal cells comprise the first population and are believed to be the youngest neurons in
the olfactory epithelium, with the most immature of these just beginning to emit an axon from
the basal surface of the cell (Graziadei and Monti Graziadei, 1978, 1979).  These cells are
situated near the base of the epithelium, immediately superficial to a single layer of horizontal
basal cells.  The second neuronal population is made up of immature olfactory receptor neurons
that have extended their axons into the lamina propria of the olfactory mucosa, with some of
the axons reaching as far as the olfactory bulb.  Although the neurons of this second population
may respond to odor molecules, their activation does not contribute to the perception of smell
because the axons of these neurons have not yet formed synaptic contacts in the olfactory bulb.
Neurons of the first two neuronal populations share several phenotypic features with immature
neurons from other regions of the developing nervous system, expressing for example vimentin
(Schwob et al., 1986), microtubule associated proteins (MAPs) characteristic of immature
neurons (i.e. MAP5 and MAP1B; Schoenfeld et al., 1989; Tucker et al., 1989; Viereck et al.,
1989), the embryonic form of the neural cell adhesion molecule (N-CAM; Miragall et al., 1988,
1989), and the 43 Kd growth-associated protein that is better known as GAP-43 (Verhaagen  et
al., 1989, 1990).  In addition, the second progenitor cell in the continuum of globose basal cell
population expresses MASH-1 (Calof et al., 1996, 2002; Schwob, 2002), which is required for
commitment to the neuronal lineage (Murray et al., 2003).  In MASH-/- mice, most of the
progenitors develop along the sustentacular cell pathway instead (Murray et al., 2003).  Later,
the third distinct subclass of globose basal cells, an immediate neuronal precursor expresses
neurogenin-1 (Calof et al., 1996, 2002; Schwob, 2002).
Mature olfactory receptor neurons comprise the third neuronal population and are
bipolar cells that possess a fusiform cell body.  A single unmyelinated axon arises from the
basal pole of each neuron and projects without axon collaterals to the olfactory bulb where it
makes synaptic contacts with neurons in the olfactory bulb.  Most of the olfactory receptor
3neurons are believed to never fully mature because they retain the expression of MAP5,
MAP1B (Schoenfeld et al., 1989; Tucker et al., 1989; Viereck et al., 1989), and vimentin
(Schwob et al., 1986); they do, however, stop expressing GAP-43 (Verhaagen  et al., 1989,
1990) and the embryonic form of N-CAM (Miragall et al., 1988, 1989).  Mature olfactory
receptor neurons also exclusively express olfactory marker protein (OMP; Margolis, 1985).
OMP-deficient mice showed decreased ability to respond to odorants compared with wild type
mice, thus OMP was demonstrated to modulate the odor detection and signal transduction
cascade in these cells (Buiakova et al., 1996).
A single dendrite arises from the apical pole of the cell body of each olfactory receptor
neuron and projects towards the free surface of the olfactory epithelium where it terminates in
an apical knob from which extend several cilia.  These olfactory receptor neurons express
chemoreceptors on the surface of their dendrites, which enable the neurons to detect the
presence of volatile stimuli in the surrounding environment (Getchell et al., 1984).  When
odorants reach the superior aspect of the nasal cavity they must traverse a layer of mucus
before they can bind to odorant receptors in the chemosensitive plasma membrane of the
olfactory receptor neurons (Getchell et al., 1984).  This binding of odorant molecules by the
receptors initiates a series of membrane events leading to sensory transduction and initiation of
an action potential.  Olfactory receptor neurons encode information about the intensity,
duration and quality of the odorant and transmit this information to the brain.
At the base of the olfactory epithelium there are horizontal basal cells that lie directly
against the basal lamina separating the epithelium from the lamina propria.  The horizontal
basal cells express the epidermal growth factor (EGF) receptor, keratin and a surface
glycoprotein called alpha-N-acetyl galactosamine that binds Iβ-4 isolectin from Banderaea
simplicifolia-1 (Holbrook et al., 1995).  These cells are attached by desmosomes to
sustentacular cells and globose basal cells, and by hemidesmosomes to the basal lamina.  The
horizontal basal cells enfold virtually all bundles of olfactory axons within tunnels formed
when horizontal basal cells arch over the basement membrane (DeLorenzo, 1957; Frisch, 1967;
Graziadei and Monti Graziadei, 1978, 1979; Holbrook et al., 1995).  The horizontal basal cells
are suggested to be the stem cell for olfactory neurogenesis (Calof and Chikaraishi, 1989; Satoh
and Takeuchi, 1995).
4The sustentacular cells extend from the basement membrane to the epithelial surface
and are described by several authors (Getchell et al., 1984; Rafols and Getchell, 1983) as
modified ependymal cells.  Rafols and Getchell (1983) characterized these cells in the olfactory
mucosa of the salamander as two morphological types with type I resembling ependymal
tanycytes and type II resembling protoplasmic astrocytes.  The apical portions of the
sustentacular cells are bound together with adjacent sustentacular cells or with the olfactory
receptor neuron dendrites by tight junctions at the mucosal surface, where each dendrite is
surrounded by sustentacular cells and thus is isolated from adjacent dendrites (DeLorenzo,
1957; Frish, 1967; Graziadei and Monti Graziadei, 1979).  At the basement membrane, the
basal portion of sustentacular cells lies very close to capillaries and to Bowman’s glands that lie
immediately on the lamina propria side of the basement membrane.  Sustentacular cells are
believed to (1) isolate olfactory receptor neurons from one another for electrical purposes
(Graziadei and Metcalf, 1971); (2) secrete mucopolysaccharides from the apical pole (Getchell
et al., 1984); (3) transport molecules from the lamina propria through the olfactory epithelium
to its free surface and vice versa (Rafols and Getchell, 1983), and (4) guide the migration of
postmitotic neurons towards the apical surface of the epithelium (Simmons et al., 1981; Rafols
and Getchell, 1983).
1.1.2 The olfactory nerves
The axons, arising from the basal pole of olfactory receptor neurons, course through the
olfactory epithelium en route to the lamina propria where they join with other axons to form the
peripheral olfactory fascicles (fila olfactoria)  (Graziadei and Monti Graziadei, 1978).  In the
lamina propria, the unmyelinated olfactory axons are ensheathed by glial cells referred to as
olfactory ensheathing cells (OECs; see Section 1.2).  The olfactory fascicles eventually
coalesce in the submucosa to form the olfactory nerve bundles that penetrate the cribriform
plate of the ethmoid bone, enter the cranial cavity, travel within the nerve fiber layer (i.e. the
most superficial layer; ONL) of the olfactory bulb, and synapse in the olfactory glomerulus.
Newly formed olfactory receptor neurons send out their axons that are able to form functional
connections in the adult olfactory bulb (Costanzo, 1985; Oley et al., 1975; Simmons and
Getchell, 1981).  Connective tissue sheaths surround each olfactory fascicle within the lamina
propria.  Several of these olfactory fascicles and their connective tissue sheaths fuse together to
form much larger fascicles, which in turn enter and usually almost completely fill each
5foramina of the cribriform plate (Doucette, 1991).  The olfactory fascicles then travel within the
subarachnoid space bridging the gap between the foramina of the cribriform plate and the ONL
of the olfactory bulb.  The connective tissue sheaths of the intracranial portion of these fascicles
fuse with both the dural and leptomeningeal linings of the cranial cavity (Doucette, 1991).
Olfactory axons are small, being only 0.1 to 0.5 µm in cross-sectional diameter, and
never branch until they approach their target in the olfactory bulb (Graziadei and Monti
Graziadei, 1978).  Numerous axons are grouped together in one common mesaxon formed by
the OEC (DeLorenzo, 1957).  OECs are the only glial cells present in the peripheral olfactory
fascicles (DeLorenzo, 1957; Doucette, 1990; Field et al., 2003).  The cell membrane of an OEC
forms one mesaxon for a large number of axons rather than for each individual axon and
separates fascicles from each other by OEC cytoplasm (DeLorenzo, 1957).  The OECs of each
peripheral olfactory fascicle are enclosed within a common basal lamina, which surrounds the
entire fascicle (DeLorenzo, 1957; Frisch, 1967).  Adjacent fascicles are separated from one
another by fibroblasts and collagen (Doucette, 1993).  In contrast, OECs within the ONL of the
olfactory bulb are apposed to a basal lamina only where these cells contribute to the formation
of the glia limitans (Barber and Lindsay, 1982; Doucette, 1984, 1986).  Astrocytes, but not
fibroblasts and collagen fibers, occupy the spaces between adjacent olfactory fascicles in the
central nervous system (CNS; Doucette, 1984, 1986).
1.1.3 The olfactory bulb
The axons of olfactory receptor neurons enter the olfactory bulb through its ventral
surface, which lies on the intracranial side of the cribriform plate immediately ventral to the
surface of the frontal lobe.  The olfactory axons grow through this part of the CNS to synapse
with their targets (Barber and Linsday, 1982; Graziadei and Monti Graziadei, 1978).  The
olfactory bulb is a bilateral oblong structure attached to the rest of the brain by means of the
olfactory tract.  The olfactory bulb has a laminated structure and arises embryologically as an
evagination of the rostral wall of the cerebral vesicle.
Proceeding from the pial surface inward, the laminar pattern of the olfactory bulb
comprises the following layers: a) ONL, b) glomerular layer, c) external plexiform layer, d)
mitral cell layer, e) internal plexiform layer, and f) granule cell layer.  The ONL forms a
superficial lamina, which extends around the entire outer circumference of the bulb and
contains glial cells and fascicles of densely packed unmyelinated olfactory axons (Barber and
6Linsday, 1982; Doucette, 1984, 1986, 1990).  Astrocytes and OECs are the glial cells of the
ONL.  The synaptic terminals of the axons cluster in spherical structures know as glomeruli,
and each glomerulus receives input primarily from different olfactory receptor neurons.  In the
glomerulus, olfactory neuron axons synapse on dendrites of the mitral, tufted and
periglomerular cells.  Periglomerular cells are interneurons, the axons of which synapse on the
dendrites of mitral and tufted cells as well as on the cell bodies and dendrites of other
periglomerular cells (Pinching and Powell, 1971).  Thus, the periglomerular cells influence the
transmission of the olfactory information between neighboring glomeruli.  The largest (20 – 30
µm in diameter) neurons in the olfactory bulb are the mitral cells, which are arranged in a layer
of one to two cell bodies thick and which are separated from the glomerular layer by their own
dendrites forming the external plexiform layer.  Tufted cells, also known as displaced mitral
cells, can be found sparsely scattered throughout the external plexiform layer and even in parts
of the periglomerular region.  Dendrites and axons of the tufted cells make connections similar
to those of mitral cells, respectively.  However, collaterals of tufted cell axons ramify around
several adjacent glomeruli, where they terminate on the cell bodies and dendrites of
periglomerular cells (Pinching and Powell, 1971).  The axons of mitral and tufted cells leave
the olfactory bulb through the granule cell layer to enter the olfactory tract (Haberly and Price,
1977) and innervate the anterior olfactory nucleus, olfactory tubercle, amygdaloid nucleus,
piriform cortex (White, 1965, Heimer, 1968; Price and Powell, 1971) and entorhinal cortex
(White, 1965, Heimer, 1968).  The granule cell layer forms the innermost lamina of the
olfactory bulb.  Granule cells extend their dendrites into the external plexiform layer where
they make reciprocal dendro-dendritic contacts with mitral and tufted cells.
1.1.4 Embryonic and fetal development
The development of the olfactory system has been extensively studied in a variety of
animals including mice (Hinds, 1972), frog (Byrd and Burd, 1991), ducks (Rebiere and Dainat,
1981), lungfish (Derivot, 1984), and snakes (Holtzman and Halpern, 1990).  During the second
week of gestation two olfactory placodes, the thick areas of cranial ectoderm situated
rostrolateral to the developing cerebral vesicles, invaginate to form the olfactory pits, which
will give rise to the olfactory epithelium (Graziadei, 1973; Hinds, 1972).  At the base of the
epithelium, processes of the epithelial cells penetrate the basal lamina and, surrounded by glial
progenitor cells, extend into the mesenchyme adjacent to the olfactory epithelium (Cuschieri
7and Bannister, 1975).  At the end of the second week of gestation of mouse embryos, OMP can
be detected using immunohistological methods in cell bodies near the surface of the olfactory
epithelium (Farbman and Margolis, 1980; Graziadei et al., 1980a).  Since only mature olfactory
receptor neurons express OMP in the adult (Monti-Graziadei et al., 1977), the presence of
OMP in cells of developing olfactory epithelium indicates that these cells have formed synaptic
contacts and have reached maturity.  In the third week of gestation OMP is found in an
increased number of cells at the epithelial surface, in the olfactory nerve fascicles of the lamina
propria, in the ONL and by the end of the third week in the glomeruli of the bulb (Graziadei et
al., 1980a).
During embryogenesis, olfactory receptor neurons influence the development of the
olfactory bulb, the initial formation of which from the rostral wall of the cerebral vesicle occurs
near the end of the second week of gestation  (Hinds, 1972).   At this time the number of
olfactory axons and mitral/tufted cells in the olfactory bulb increases in developing Xenopus
larvae (Byrd and Burd, 1991).  During the early developmental stages of the mouse embryos,
the olfactory axons make their initial contact with the rostral wall of the cerebral vesicle,
referred to as the olfactory bulb primordium (Doucette, 1989).  Once the olfactory axons and
peripheral glial progenitor cells of the olfactory fascicle cover the external exposed surface of
the bulb primordium, they form the presumptive ONL.  At this time point, which corresponds
to Theiler stages 19 and 21 (Theiler, 1972), the cellular constituents of the ONL are separated
from those of the mouse bulb primordium by a relatively intact glia limitans.  This glia limitans
eventually disappears thus leaving no physical barrier between the cellular constituents of the
definitive ONL and the marginal zone of the developing olfactory bulb (Doucette, 1989).
Present at the early developmental stages, olfactory axons are found to penetrate the
bulb reaching its deep intermediate zone.  Here they make contact with neuronal precursor cells
of the olfactory bulb and possibly influence their development (Stout and Graziadei, 1980).
Later the olfactory axons retract to their final location in the olfactory nerve and glomerular
layers.  Olfactory afferent innervation is critical for the differentiation and maintenance of the
dopamine phenotype of interneurons in the olfactory bulb (Baker and Farbman, 1993).
Decreasing the numbers of the olfactory axons by partial deafferentation of the olfactory bulb
results in a reduction in the number of mitral neurons in the olfactory bulb of either Xenopus
embryos (Byrd and Burd, 1993) or the moth, Manduca sexta (Hildebrand et al., 1997).
8Complete removal of the olfactory placode in amphibians resulted in formation of a small or no
olfactory bulb (Stout and Graziadei, 1980).  Vasculature plays an important role in neuronal
development and responds to alterations in sensory stimulations early in life.
Doucette (1989) described the development of the ONL in the olfactory bulb of mouse
embryos, when Marin-Padilla and Amieva (1989) characterized the early neurogenesis of the
mouse olfactory nerve.  The olfactory axons are identified in the mesenchyme growing
dorsocaudally toward the cerebral vesicle.  Peripheral glial progenitor cells, which ensheath
adjacent axons, accompany them.  Olfactory axons and OECs from the same regions of the
nasal mucosa establish an early association, which is maintained up to their glomerular
terminal.  Marin-Padilla and Amieva (1989) suggested that simple anatomical arrangement
between olfactory axons and OECs allows establishing a topographic map of the sensory
olfactory epithelium in the developing olfactory bulb.  Thus, the axons of newly formed
olfactory neurons from different nasal regions could be guided by their OEC conduits toward
their target glomeruli; hence, the olfactory map may be maintained undisturbed through the
animal’s life span.  Axons, but not the glial progenitors, penetrate into the marginal zone
through small breaks in the glia limitans of the bulb primordium.  Doucette (1989) suggested
that the ONL of the olfactory bulb forms superficial to, rather than within, the marginal zone of
the rostral wall of the cerebral vesicle.  The peripheral glial progenitor cells contributed to the
formation of the ONL and presumably differentiated into OECs.  Arising from the peripheral
nervous system (PNS), OECs are one of the two glial cell types in the ONL, with astrocytes
being the second cell type and having a CNS origin.  However, by Theiler stage 24 (embryonic
day 18) of developing rat embryos and stage 16 of mouse embryos the OECs are the only glial
cells present in the ONL (Doucette, 1989).  Therefore, OECs are the only glial cells present in
the OEC cultures initiated using the ONL of E18 rat olfactory bulbs.
1.1.5 Neuronal regeneration
Generation of new sensory neurons in the olfactory epithelium is an ongoing process,
which continuous throughout life (Barber, 1982; Calof et al., 2002; Graziadei and Monti
Graziadei, 1978, 1979; Schwob, 2002).  The neuronal turnover occurs both spontaneously and
in response to cellular and tissue trauma (Schwob, 2002).  New neurons arise as a result of the
proliferation and differentiation of stem/progenitor cells located near the base of the epithelium
(Graziadei and Monti Graziadei, 1978, 1983; Graziadei et al., 1980b).  Neurogenesis in the
9olfactory epithelium is in a state of dynamic equilibrium between positive and negative
regulators.  Indirectly controlling the generation of new neurons, the mature neurons of the
olfactory epithelium appear to be a source of negative feedback signals, which regulate the
proliferation of the precursor cells.  A presumptive stem cell divides asymmetrically
approximately every 50 days producing another stem cell, which stays close to the basal
lamina, and a neuronal precursor cell.  The latter cell further divides rapidly several times
producing many immature neurons, each of which migrate away from the basal lamina
(Mackay-Sim and Kittel, 1991).  Because in the olfactory epithelium neurogenesis is a
continuous process, there are neurons at varying stages of differentiation, reflecting different
stages of maturation.  Therefore, there are olfactory receptor neurons with different
morphological (Graziadei and Monti Graziadei, 1978), biochemical (Harding et al., 1977), and
physiological (Simmons and Getchell, 1981) characteristics residing within the same part of the
olfactory epithelium.  Caggiano et al. (1994) and Schwob et al. (1994) used a retroviral vector
to label proliferating cells in the olfactory epithelium and obtained data consistent with the
neurons arising from horizontal basal cells.  An additional in vivo study suggests that a stem
cell resides in the olfactory epithelium very close to the basal lamina, which is where the
horizontal basal cells are localized (Mackay-Sim and Kittel, 1991).  Olfactory receptor neurons
can also be generated in vitro with the evidence suggesting they may arise from horizontal
basal cells (Mahanthappa and Schwarting, 1993; Satoh and Takeuchi, 1995).  However, the
actual identity of the stem and progenitor cells in the olfactory epithelium is yet to be resolved.
1.2 Olfactory Ensheathing Cells
OECs are the non-myelinating glial cells that ensheath olfactory axons within both the
PNS and CNS portions of the primary olfactory pathway (DeLorenzo, 1957; Doucette, 1990;
Field et al., 2003; Frisch, 1967).  OECs are located in a region of the mammalian nervous
system where axonal growth occurs throughout the lifetime of the organism.  They are
distributed within the lamina propria of the olfactory mucosa, the olfactory nerve, and the first
two layers of the olfactory bulb (Cancalon, 1985; Doucette, 1990; Gong et al., 1994).  Rafols
and Getchell (1983) examined the morphological relationship between the receptor neurons and
nonneuronal cells, i.e. glial fibrillary acidic protein (GFAP) expressing OECs, which surround
the unmyelinated olfactory axons and suggested that these OECs contribute to the guidance of
10
the olfactory axons to their synaptic targets in the olfactory bulb.  Although Rafols and Getchell
(1983) described these cells as astrocytes they were later named as OECs (Doucette, 1984).
In both the olfactory nerves and the olfactory bulbs the OECs display a very
characteristic morphology (Bailey and Shipley, 1993; Doucette, 1984, 1986, 1990, 1991, 1993).
Golgi in 1875 and Blanes in 1898 (as described in Ramon-Cueto and Avila, 1998) were the
first to describe the glial population of the olfactory bulb of adult mammals.  They observed
two types of macroglia in the olfactory bulb, one stellate in morphology and the other fusiform.
Stellate cells were distributed throughout the entire olfactory bulb, whereas the fusiform cells
were located only in the first two layers.  More recent studies have revealed the stellate cells are
astrocytes and the fusiform cells are the OECs (Barber and Lindsay, 1982; Doucette, 1984,
1986, 1991, 1993).  More recently, Bailey and Shipley (1993) described unipolar and irregular
subtypes of astrocytes that were exclusively located in the ONL of the olfactory bulb.  These
astrocytes separated olfactory nerve fascicles, and had long, unbranched cytoplasmic processes
(irregular subtype).  The unipolar or unbranched astrocytes were different from most white
matter fibrous astrocytes that elongate in a bipolar arrangement along axons in other white
matter tracts.
The OECs reside within olfactory fascicles in both the PNS and CNS portions of the
primary olfactory pathway, aligning their perikarya along the longitudinal axis of the fascicles
(Barber and Lindsay, 1982).  On the basis of ultrastructural criteria, OECs have a characteristic
indented nucleus with uniformly distributed heterochromatin.  Free ribosomes and large
inclusion bodies are abundant in the cytoplasm as well.  Compared to astrocytes, the cytoplasm
of OECs is more electron dense, which may be due to the presence of more water-soluble
proteins in the cytoplasm of the latter cells (Doucette, 1984).  The intermediate filaments of
OECs are fewer in number and are scattered throughout the cytoplasm instead of being grouped
into closely packed bundles the way they are in astrocytes (Barber and Lindsay, 1982;
Doucette, 1984, 1986, 1990, 1991).  At the glia limitans, the plasma membranes of end-feet of
OECs lack the orthogonal arrays of intramembranous particles (Barber and Lindsay, 1982;
Doucette, 1991, 1993) that are so characteristic of astrocytic end-feet forming the glia limitans
in other parts of the CNS (Peters et al., 1976).
OECs are a potential source of growth-promoting and neurite-promoting factors during
development and in the postnatal period (reviewed in Ramon-Cueto and Avila, 1998).  These
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cells express platelet-derived growth factor (Kott et al., 1994), neuropeptide Y (Ubink et al.,
1994), and the calcium-binding protein S100 (Cummings and Brunjes, 1995), which is
suggested to facilitate the growth and survival of neurons (Bhattacharyya et al., 1992; Van
Eldik et al., 1991).  A neurite-promoting factor referred to as glia-derived nexin is also
synthesized by both the astrocytes of the nerve fiber layer of the bulb (Scotti et al., 1994) and
by OECs (Reinhard, 1988; Scotti et al., 1994).  The low-affinity neurotrophin receptor
(p75NGFR) is also expressed by OECs, with the expression of this receptor being under strong
developmental regulation (Barnett et al., 1993; Franceschini and Barnett, 1996; Gong et al.,
1994; Miwa et al., 1993; Turner and Perez-Polo, 1993, 1994; Vickland et al., 1991).  At all
embryonic and fetal stages of development in rodents, p75NGFR expression is associated with
the OECs ensheathing olfactory axons.  In neonatal rodents, OECs show an intense expression
of p75NGFR at the light and electron microscope levels that decreases to almost undetectable
levels in the adult.  Ramon-Cueto and Nieto-Sampedro (1992) identify four subpopulations of
OECs in cultures obtained from adult rat olfactory nerve and glomerular layers of the olfactory
bulb.  One subpopulation expresses both p75NGFR and fibronectin (5% of the total
population), while a second subpopulation is p75NGFR positive and fibronectin negative
(26%).  The remaining two subpopulations do not express p75NGFR, although one is
fibronectin positive (50%) and the other is fibronectin negative (19%).
At all developmental stages, OECs express in their plasma membranes the L1 cell
adhesion molecule (Miragall et al., 1988), the embryonic polysialic acid containing N-CAM
(PSA-N-CAM), as well as adult forms of N-CAM (Franceschini and Barnett, 1996; Miragall et
al., 1988); they also synthesize and secrete laminin into the extracellular matrix (Doucette,
1996; Kafitz and Greer, 1997; Liesi, 1985).  All of these molecules are known to be involved in
cell adhesion and axonal growth (Bixby et al., 1988).  The CAMs presumably mediate
olfactory axon elongation on OECs (Barnett et al., 1993; Chuah and Au, 1994; Franceschini
and Barnett, 1996; Key and Akeson, 1990; Miragall et al., 1988; Ramón-Cueto and Nieto-
Sampedro, 1992) since N-CAM and L1 are only found in that part of the OEC plasma
membrane in direct contact with the axons (Miragall et al., 1988).  Only those OECs forming
part of the glia limitans express PSA-N-CAM, with this molecule being present in the part of
their plasma membrane that is not apposed to the basal lamina (Miragall et al., 1988).  On the
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other hand, type IV collagen and fibronectin are expressed in the region of the OEC plasma
membrane that is in contact with the basal lamina (Doucette, 1995).
Vimentin is the major constituent of the OEC intermediate filaments during
development and in the adult (Barnett et al., 1993; Franceschini and Barnett, 1996; Ramón-
Cueto and Nieto-Sampedro, 1992; Schwob et al., 1986).  Besides vimentin, OECs also express
nestin in the embryo and neonate (Doucette, 1993; Valverde et al., 1992), and GFAP in the
neonate and adult (Barber, 1982; Barnett et al., 1993; Franceschini and Barnett, 1996; Pixley,
1992).
1.2.1 Ensheathment of olfactory axons
OECs envelop multiple axons in a common mesaxon with their inner process-bearing
(adaxonal) surface, which has no basal lamina (DeLorenzo, 1957; Doucette, 1990; Field et al.,
2003; Frisch, 1967).  Winding, sheet-like inner OEC cytoplasmic processes separate the
unmyelinated axons into smaller groups within the inner compartment of each fascicle
(Valverde and Lopez-Mascaraque, 1991).  In cross section, each peripheral olfactory fascicle is
seen to contain several glial cells, with the cytoplasmic processes of these cells extending
towards the center of the fascicle to enclose variable numbers of olfactory axons within
common mesaxons (Doucette, 1990).  The outer (abaxonal) surface of OECs is smooth and
faces the connective tissue, which in the PNS portion of the pathway contains fibroblasts and
collagen fibers and from which they are separated by a basal lamina.  This basal lamina is
continuous with the epithelial basal lamina at the numerous points where small bundles of
olfactory axons leave the olfactory epithelium and are first ensheathed by OECs (DeLorenzo,
1957; Doucette, 1984, 1990).  Raisman (1985) suggested that the peculiar multiaxonal
sheathing arrangement allows the newly growing axons to slide in along existing axonal
surfaces without requiring them to make direct contact with the glial cell membrane.
Throughout their length in both the PNS (fila olfactoria) and CNS (ONL and glomerular
layers) portions of the primary olfactory pathway, the olfactory axons are ensheathed by OECs,
such that the axons do not contact any other glial cell type (Barber and Lindsay, 1982; Carr and
Farbman, 1993; Doucette, 1984, 1986, 1990, 1991, 1993; Pixley, 1992; Raisman, 1985).
Unlike Schwann cells, OECs do not ensheath individual axons; instead, the mesaxon of each
OEC encloses densely packed bundles of unmyelinated axons (Barber and Lindsay, 1982;
Doucette, 1993; Farbman and Squinto, 1985; Peters, 1976).  Similarly, at variance with the
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manner in which Schwann cells ensheath unmyelinated non-olfactory axons, OECs within the
ONL of the olfactory bulb are only apposed to a basal lamina in those regions where they
contribute to the formation of the external glial limiting membrane.  However, similar to other
peripheral nerves (Bunge et al., 1986), the olfactory fascicles in the lamina propria are enclosed
within a basal lamina that separates the OECs from the cells and matrix of the surrounding
connective tissue.
The ability of the olfactory nerves to re-establish synaptic connection with central adult
neurons of the olfactory bulb in adult mammals has been attributed to OECs and to the glial
arrangements at the olfactory glomerulus (Barber, 1981; Barber and Raisman, 1978; Graziadei
et al., 1980b; Graziadei and Monti Graziadei, 1978, 1979; Wilson and Raisman, 1981).
Unmyelinated axons of the spinal nerves and cranial nerves 3 to 12 cross from the PNS into the
CNS and are “handed” directly from a Schwann cell to an astrocyte (Berthold and Carlstedt,
1977).  In contrast, olfactory axons are never “handed” from OECs to another glial cell as the
axons enter the CNS.  Olfactory axons do, however, lose their glial ensheathment as they enter
a glomerulus where the cytoplasmic processes of astrocytes may come into close apposition to
the entering axon fascicles although the axons are never actually ensheathed by these glial cells
(Doucette, 1984; Raisman, 1985).  OECs extend their cytoplasmic processes in the shape of
“prongs” that penetrate deeply along the periphery of each glomerulus.  However, OEC
processes do not enter the neuropil of the glomerulus (Raisman, 1985).
1.2.2 Embryonic and fetal development
The differentiation of OECs during embryonic and fetal development is intimately
related to the development of the first cranial nerve.  Progenitor cells originating from the
olfactory placode give rise to OECs (Doucette, 1989, 1990; Farbman and Squinto, 1985;
Marin-Padilla and Amieva, 1989).  During the development of the embryo and later of the
fetus, the OEC progenitors migrate away from the olfactory placodes toward the rostral wall of
the telencephalic vesicle where they eventually contribute to the formation of the ONL of the
presumptive olfactory bulb (Doucette, 1989; Marin-Padilla and Amieva, 1989).  As these
immature OECs enter the telencephalic vesicle during early embryonic development, they
begin to express the N-CAM and L1 cell adhesion molecules (Miragall et al., 1989).  Doucette
(1993) suggested that these CAMs facilitate the adhesion and growth of olfactory axons from
the olfactory epithelium into the developing olfactory bulb with the growing axons being able
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to use the cell surface of OECs as a substrate.  On the other hand, OECs ensheath multiple
axons, most of which do not come in a close contact with OEC plasma membrane (DeLorenzo,
1957; Doucette, 1990; Field et al., 2003; Frisch, 1967).  Such arrangement of olfactory axons
within an OEC mesaxon allows newly formed axons to extend to the olfactory bulb using other
axons for guidance (Doucette, 1984, 1990; Raisman, 1985).  These OECs also begin to express
the p75NGFR (Gong et al., 1994) and the L14 lectin (Mahanthappa et al., 1994).  Although the
function of p75NGFR remains to be determined, it is thought to provide a chemotactic
guidance to growing olfactory axons (Doucette, 1993; Li et al., 1997).  Mahanthappa et al.
(1994) showed that the L14 lectin also promotes the adhesion of primary olfactory neurons to
laminin in vitro in an integrin-independent manner.
During the development of the rodent olfactory system, peripheral glial progenitor cells
accompany and ensheath olfactory axons growing dorsocaudally toward the cerebral vesicle
(Doucette, 1989).  In Theiler stage 19-21 embryos, the peripheral glial progenitor cells and
olfactory axons are located under the pia matter along the external surface of the bulb
primordium forming a presumptive ONL immediately superficial to the bulb’s external glial
limiting membrane.  By the first part of stage 21, the peripheral progenitor cells are identified
within the presumptive ONL with an electron-dense cytoplasmic matrix filled with expanded
rough endoplasmic reticulum, mitochondria, numerous free ribosoms and polyribosomes, and a
well-developed Golgi apparatus.  Some cells acquire bipolar shape with their long axis oriented
parallel to the direction of axonal growth.  Olfactory axons but not peripheral glial progenitors
penetrate the marginal zone of the bulb primordium.  The only glial cells found within the ONL
by Theiler stage 24 of developing rat and mouse embryos are the peripheral glial progenitor
cells.
1.2.3 PNS-CNS transitional zone
OECs are the only glial cells known to ensheath axons on both sides of the PNS-CNS
transitional zone (Doucette, 1984, 1986, 1990, 1991; Fraher, 1999).  In contrast, when
myelinated primary sensory axons enter the CNS, their ensheathment abruptly changes from
Schwann cell ensheathment to that of oligodendrocytes or astrocytes (Berthold and Carlstedt,
1977; Maxwell et al., 1969; Steer, 1971).  The relationship of unmyelinated non-olfactory
primary sensory axons to surrounding glial cells is similar to that of myelinated fibers at the
PNS-CNS transitional zone with the axons being ensheathed in pockets of the Schwann cells in
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the PNS and those of astrocytes in the CNS.  The axons of spinal cord and cranial nerve
rootlets pass through pores or openings in the glia limitans at the transitional zone between
PNS and CNS.  Each Schwann cell within the PNS compartment is surrounded by basal lamina
and collagen fibers.  The basal lamina of each Schwann cell at the PNS-CNS junction is
continuous with that of the glia limitans of the subpial astrocytes (reviewed in Fraher, 1999).
Each olfactory nerve rootlet travels within the subarachnoid space after leaving
foramina of the cribriform plate before entering the ONL of the olfactory bulb.  The basal
lamina covering the external surface of each of these rootlets is continuous with that covering
the external surface of the glia limitans of the ONL.  Within the PNS, the OECs within each
olfactory fascicle are enclosed within a common basal lamina, which surrounds the entire
fascicle (DeLorenzo, 1957; Frisch, 1967).  Fibroblasts and collagen fibers separate adjacent
peripheral olfactory fascicles from one another (Doucette, 1993).  In contrast, the OECs within
the CNS portion of the primary olfactory pathway are opposed to a basal lamina only where
these glial cells contribute to the formation of the glia limitans (Barger and Lindsay, 1982;
Doucette, 1984, 1986).  Furthermore, in the ONL astrocytes are found between adjacent
olfactory fascicles instead of fibroblasts and collagen fibers (Doucette, 1984, 1986, 1993).  In
addition, astrocytes are excluded from the inside of these fascicles and from the PNS-CNS
transitional zone of the first cranial nerve, which is where OECs have the exclusive role of
forming the glia limitans (Doucette, 1991), even though elsewhere this functions is the
exclusive domain of astrocytes.  At the surface of the olfactory bulb, the cytoplasmic processes
and plasma membrane of OECs mingle and come into close contact, respectively, with those of
astrocytes, and form part of the glial limiting membrane with no intervening basal lamina
between the two types of glial cell (Doucette, 1984, 1990).
1.2.4 Tissue culture protocols
OECs have attracted the attention of researchers as potential candidates for the
treatment of different neurological diseases such as multiple sclerosis and spinal cord injury.
When grafted into demyelinated lesions, OECs were found to form myelin around naked axons
(Franklin et al., 1996; Imaizumi et al., 1998).  Transplantation of these cells into a
mechanically damaged spinal cord resulted in axonal regeneration, remyelination of axons in
the damaged spinal cord tracts and functional recovery of locomotion in the animals (reviewed
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by Boyd et al., 2003; Franklin and Barnett, 2000; Plant et al., 2003; Raisman, 2001; Ramon-
Cueto et al., 2000).
OECs can be isolated from 18 day (E18) rat embryos (Boyd et al., 2004; Devon and
Doucette, 1992, 1995; Doucette, 1993; Doucette and Devon, 1994, 1995), newborn rats
(Barnett et al., 1993; Chuah and Au, 1993, 1994; Franceschini and Barnett, 1996; Pixley and
Pun, 1990) and from adult rats (Gudino-Cabrera and Nieto-Samperdro, 1999; Nash et al., 2002;
Ramon-Cueto and Nieto-Sampedro, 1992) and humans (Barnett et al., 2000; Kato et al., 2000).
The main advantage of using embryonic tissue is that at day 18 of embryonic development all
of the glial cells in the ONL of the olfactory bulb of rats are OECs (Doucette, 1989).  On the
other hand, cell cultures obtained from the olfactory bulbs of newborn and adult animals
require additional purification procedures, such as immunopanning (Ramon-Cueto and Nieto-
Sampedro, 1994) or using a cell sorter (Pascual et al., 2002), to eliminate contaminating cells.
Primary cultures of OECs have been obtained from different parts of the olfactory
system including the olfactory mucosa, olfactory nerve, and olfactory bulb.  Pixley and Pun
(1990) harvested olfactory mucosa from newborn Sprague Dawley rat pups, whereas Lu et al.
(2002) used the lamina propria of olfactory mucosa they obtained from adult rats.  Devon and
Doucette (1992, 1995), Boyd et al. (2004), Chuah and Au (1993), Barnett et al. (1993), Ramon-
Cueto and Nieto Sampedro (1992) used the ONL of the olfactory bulb as the source of tissue to
initiate OEC cultures.  Another way to acquire OECs for transplantation is a creation of a cell
line.  Boruch et al. (2001) generated a cell line of OECs producing nerve growth factor (NGF)
whereas Goodman et al. (1993) generated a p75NGFR-positive OEC clonal cell line from
neonatal Sprague-Dawley rats using the SV40 large T antigen.  In order to break intercellular
connection, Ramon-Cueto and Nieto Sampedro (1992) treated their cell cultures with trypsin
containing medium, whereas others utilized a combination of trypsin and collagenase (Chuah
and Au, 1991; Pixley and Pun, 1990).  There are advantages and disadvantages to using
primary cultures or cell lines.  Engineering the cell line prevents contamination present in
primary cultures and provides a long-term stable supply of a purified cell population.  On the
other hand, OEC cell lines are unlikely to be useful in future treatments of patients with
demyelinating diseases and CNS injury unless we know that grafted cells will not form tumors
or cause any other disorders as a consequence of uncontrolled cellular growth.
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Most studies have used pure population of OECs, whereas Li et al. (1997, 1998)
utilized unpurified OECs and Lakatos et al. (2003) implemented a mixture of OECs with other
cells, i.e. meningeal cells, in their experiments.  Unsatisfactory results in OEC harvesting
procedures or OEC transplantation studies have prompted researchers to implement additional
techniques (i.e. immunoadsorbtion, enzymatic cell separation) or chemicals (i.e. growth
factors). Chuah and Teague (1999) used bovine pituitary extract in order to increase the number
of OECs.
A marker specific to OECs is still unavailable for identifying these cells in both in vivo
and in vitro experiments.  This has prompted researchers to use various cell labelling
techniques.  Prelabelling OECs with a nuclear fluorochrome bisbenzimide (Hoechst 33342 dye;
Imaizumi et al., 2000; Lu et al., 2002; Pascual et al., 2002; Ramon-Cueto et al., 1998, 2000), a
fluorescent dye 1,1’- dioctadecyl - 3,3,3’,3’ - tetramethylindocarbocyanine perchlorate (DiI)
(Skihar and Doucette, 2001, 2003), and Cell-Tracker probes (Li et al., 1997, 1998) were used
before transplanting cells into the CNS of animals.  Even though researchers did not find
evidence that these dyes can be transferred directly to surrounding cells within the experimental
time frame; macrophages could phagocytose dying OECs at the implantation site.  For
example, Hoechst prelabelling of cells prior to transplantation can result in false positive
signals (Ruitenberg et al., 2002); therefore, the survival and migration of Hoechst-prelabelled
transplanted cells may be overestimated.  Adenoviral-mediated (Ruitenberg et al., 2002, 2003)
and retroviral-transfer (Boyd et al., 2004; Lakatos et al., 2003) of LacZ or adenoviral transfer
of green florescent protein (Li et al., 2003) were used to identify cells with fluorescent, light, or
electron microscopy.  The microscopy observations revealed that adult (Li et al., 2003;
Ruitenberg et al., 2002, 2003) and neonatal (Boyd et al., 2004; Lakatos et al., 2003) rat OECs
survived the implantation.  Retroviral transfection of OECs with LacZ containing viral vector
also allowed in-depth characterization of these cells at both the light and electron microscopic
level.  These observations provided unequivocal ultrastructural identification that LacZ-
expressing OECs neither associated directly with central axons nor did they form myelin
sheaths or basal lamina after transplantation into the damaged spinal cord of adult rats, even
when regeneration and remyelination of lesioned axons were evident (Boyd et al., 2004).
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1.2.5 Therapeutic potential
Several approaches to enhance the remyelination of demyelinated axons in the adult
mammalian CNS have been considered, with one approach being the transplantation of myelin-
forming cells (Akiyama et al., 2001, 2002a, 2002b; Barnett et al., 2000; Franklin et al., 1996;
Imaizumi et al., 1998, 2000; Smith et al., 2002).  One myelinating cell that is attracting
increasing attention is the OEC.  These glial cells have been transplanted into the
electrolytically lesioned rat corticospinal tract (Li et al., 1997, 1998), into proximal and distal
stumps of the transected rat spinal cord with a guidance channel containing Schwann cells
embedded in Matrigel replacing a transected thoracic segment (Ramón-Cueto et al., 1998), into
stumps of the completely transected adult rat spinal cord (Ramón-Cueto et al., 2000), and into
the spinal cord dorsal column that had been demyelinated by ethidium bromide (EtBr) and x-
irradiated to prevent host cells from contributing to its repair (Imaizumi et al., 1998).  The
grafted OECs adopted a myelinating phenotype that persisted throughout the lesion site
(Franklin et al., 1996; Imaizumi et al., 1998).  They assemble a myelin sheath around single
regenerating or remyelinated axons.  Examinations of the morphology of the remyelinating
glial cells indicated substantial structural differences in comparison with that of the normal
spinal cord white matter.  The OECs established an end-to-end PNS type myelinating
relationship with individual axonal segments.  An outer sheath was formed around groups of
myelinated axons; it was suggested that the outer sheath arose from the grafted OECs
(Imaizumi et al., 1998; Li et al., 1997, 1998; Ramón-Cueto et al., 1998).  However, authors
failed to provide evidence that transplanted OECs remyelinated axons and formed an outer
sheath for these regenerating axons.
In the experiments of Ramon-Cueto et al. (1998, 2000), transplanted OECs were found
to facilitate the regeneration of axons in descending motor pathways (i.e. corticospinal,
raphespinal, and coeruleospinal).  Regenerating motor fibers surrounded by OECs not only
crossed the gliotic tissue formed at the proximal cut surface of the spinal cord but also grew
across the scar formed between the proximal and distal stumps; some of these regenerating
axons (noradrenergic and serotonergic) grew for up to 3 cm (approximately 6 spinal cord
segments) distal to the lesion.
Kato et al. (2000) demonstrated that transplanted OECs derived from adult human
olfactory nerves were capable of extensive remyelination of demyelinated axons after being
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grafted into the adult rat spinal cord.  Human OECs remyelinated axons in the x-irradiated and
EtBr-induced demyelinated lesion (see Section 1.6.1).  As had been reported previously for
grafted rat OECs, the remyelinating human cells assembled a PNS-type myelin sheath around
the axons (see Section 1.3.1).
OECs have features of both Schwann cells, a glial cell of the PNS, and astrocytes, one
of the macroglia of the CNS (Doucette, 1990, 1995; Franklin and Barnett, 1997; Franklin,
2002b; Ramon-Cueto and Avila, 1998; Ramon-Cueto and Valverde, 1995).  Similar to
Schwann cells, which secrete growth-promoting and neurite-promoting factors that support the
regeneration of both PNS and CNS axons (Aguayo, 1985), OECs facilitate the growth of the
olfactory axons (Doucette, 1990).  On the other hand, CNS glial cells and the
microenvironment they create are believed to be primarily responsible for the failure of axonal
regrowth in the adult mammalian CNS (Reier et al., 1989; Schwab, 1990).
OECs express growth- and neurite-promoting factors such as platelet derived growth
factor (PDGF; Kott et al., 1994) neuropeptide Y (Ubink et al., 1994; Ubink and Hokfelt, 2000),
protein S-100 (Cummings and Brunjes, 1995; Franceschini and Barnett, 1996; Gong et al.,
1996), p75NGFR (Gong et al., 1994; Treloar et al., 1999; Vickland et al., 1991) and glia-
derived netrin (Reinhard et al., 1988; Treloar et al., 1999).  Extracellular matrix and cell
adhesion molecules such as N-CAM (Franceschini and Barnett, 1996), laminin (Doucette,
1996), and tenascin (Kafitz and Greer, 1998) are suggested to facilitate axonal growth and
guidance in the olfactory nerve and in the ONL of the olfactory bulb, where the OECs are
found.
A great amount of research data have been collected over the past decade on clinical
relevance of using OEC for promoting neural repair in the CNS of adult mammals (Doucette,
1990, 1995; Franklin and Barnett, 1997; Franklin et al., 2002a, 2002b).  OECs have been
shown to promote long-distance regeneration of axons in the adult mammalian spinal cord and
facilitate remyelination of CNS axons such that conduction velocities of previously
demyelinated axons are restored to normal levels.  OECs can be easily obtained from
extracranial sources, such as from olfactory epithelium of human (Feron et al., 1998; Jafek et
al., 2002; Lanza et al., 1993, 1994) or from similar tissue in the nasal cavity of rodents
(Franklin et al., 2002a; Lu et al., 2002).  Thus, patients can provide their own olfactory tissue
for autologous transplantations, which will avoid unnecessary immunosuppression.
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Furthermore, OECs can more easily integrate into CNS tissue after grafting into the injured or
demyelinated spinal cord (Lakatos et al., 2000; Li et al., 1998) than Schwann cells (Baron-Van
Evercooren et al., 1992; Blakemore, 1992; Duncan and Milward, 1995).
1.3 Myelinating Glia
In addition to OECs there are two additional cell types, namely oligodendrocytes
(Baumann and Pham-Dinh, 2001) and Schwann cells (Bunge et al., 1968), possessing the
ability to myelinate axons.  Oligodendrocytes are myelinating glia of the CNS whereas
Schwann cells perform the same role in the PNS.  All three types of myelinating glia could
potentially contribute to neural repair in areas where CNS myelin is damaged or absent (see
Section 1.8).
1.3.1 Myelin
Myelin, which was named so by Virchow (reviewed in Baumann and Pham-Dinh,
2001), is a very important constituent of both CNS and PNS axons providing electrical
insulation for these axons.  Rich in lipids and low in water content, the myelin sheath has a
unique segmental structure, which permits the saltatory conduction of nerve impulses, thus
supporting fast nerve conduction over long distances.  Myelin is very important for the
development and function of the human CNS and PNS.  Myelin structure and/or function are
perturbed in a number of different neurological disorders of the CNS and PNS such as in
multiple sclerosis and in peripheral neuropathies, respectively (Fazakerley and Buchmeier,
1993; Wekerle, 1993).
Both oligodendrocytes and Schwann cells extend cytoplasmic processes, to ensheath a
segment of axon in a “jelly-roll” form (Morell et al., 1994; Peters et al., 1991).  The
cytoplasmic leaflets of each concentric layer of myelin membrane becomes closely apposed as
the myelin is compacted, thus forming the major dense line.  The extracellular leaflets of
adjacent concentric layers of the myelin membrane fuse together to form the intraperiodic line
(or minor dense lines).  A narrow extracellular cleft, the periaxonal space, separates the myelin
sheath from the axonal membrane.  Myelin sheaths in the PNS have cytoplasmic pockets,
called Schmidt-Lantermann clefts or incisures, containing cytoplasm between myelin
membrane; such cytoplasmic pockets are rarely found in CNS myelin.  At the inner (i.e.
adaxonal) and outer (i.e. abaxonal) end of the spiral, myelin is less compact and forms inner
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and outer loops, which retain small amounts of either oligodendrocyte or Schwann cell
cytoplasm.  Each myelin sheath, or internode, for example in rat optic nerve is about 150-200
µm in length (Butt and Ransom, 1989) and is separated by a short length of axon where there is
no myelin, the node of Ranvier, from an adjacent internode (Bunge, 1968).  The myelin and
nodes of Ranvier ensure fast saltatory conduction allowing the nerve impulses to jump from
node to node, rather than more slowly progressing along the axon as they do in unmyelinated or
demyelinated fibers.
The insulating properties of the myelin sheath that facilitate the saltatory conduction of
action potentials are largely due to its structure, its thickness, its low water content, and its
richness in lipids (Ritchie, 1984).  Oligodendrocytes and Schwann cells produce the specific
constituents of myelin, such as myelin lipids and myelin proteins.  Myelin lipids are
represented by galactolipids (i.e. cholesterol, cerebroside, sulfatide) and phospholipids
(ethanolamine phosphatides, lecithin, sphingomyelin, phosphatidylserine, phosphatidylinositol,
plasmalogens).   Both CNS and PNS myelin lipids comprise up to 70 % and protein molecules
approximately 30% of myelin dry weight, whereas other cellular membranes have a higher
ratio of proteins to lipids (Morell et al., 1994, Norton, 1981).  The PNS myelin has many of the
same lipids as myelin of the CNS, although myelin in the PNS contains less cerebroside and
sulfatide but more sphingomyelin than that in CNS (Smith et al., 1983).  In oligodendrocytes,
myelin lipids are especially rich in glycosphingolipids, galactosylceramides, in particular
galactocerebroside (e.g. GAL-C) and their sulfated derivatives, sulfatides (i.e.
sulfogalactosylceramides) (Raff et al., 1978, Zalc et al., 1981).  Deficiencies in some lysosomal
enzymes result in an abnormal degradation of sulfatides, galactocerebrosides, or proteins and
accumulation of these undegraded fatty acids. These disturbances of myelin metabolism result
in leukodystrophies (Kolodny, 1993).
Myelin proteins are specific membrane components of the myelin sheath in both the
PNS and CNS.  The PNS and CNS myelin proteins include myelin basic protein (MBP) (Kies
et al., 1972) and proteolipid protein (PLP) (Folch and Lees, 1951).  2’,3’-Cyclic nucleotide-
3’phosphohydrolase (CNPase; Trapp et al., 1988)  and several glycoproteins including myelin-
associated glycoprotein (MAG; Quarles, 1997)  and connexin 32 (Cx32) are also present in
peripheral and central myelin (Scherer et al., 1995).  However, the expression of peripheral
myelin protein 22 (PMP22) and P0 is found only in PNS myelin, whereas
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myelin/oligodendrocyte glycoprotein (MOG; Brunner et al., 1989) can only be detected in the
CNS.
MBP is a family of protein isoforms with different molecular masses and plays a major
role in myelin compaction in the CNS (Wood and Moscarello, 1989).  The MBP gene has been
identified on chromosome 18 and assigned to 18q22-qter in the human genome (Saxe et al.,
1985; Sparkes et al., 1987).  Posttranslational modifications of MBP including in particular
acetylation, phosphorylation, and methylation, are important for compaction of the myelin
membrane (Wood and Moscarello, 1989).  In the shiverer mutant mouse, which presents with a
deletion of a large part (five out of six exons) of the MBP gene (Roach et al., 1985), CNS
myelin lacks a major dense line, whereas PNS myelin appears normal (Privat et al., 1979).
PLPs are lipid-protein complexes, so they were given the generic name of proteolipids
to distinguish them from water-soluble lipoproteins. In addition to the main 25kDa isoform of
PLP, there is a second PLP isoform called DM-20 (i.e. 20kDa).  Both the PLP and the DM-20
isoforms are expressed in the CNS and PNS, with the former being predominant over DM-20 in
CNS myelin and DM-20, on the other hand, being the dominant form in PNS myelin (Pham-
Dinh et al., 1991).  In contrast to PLP/DM-20 expression in oligodendrocytes, neither of these
lipid proteins is incorporated into Schwann cell myelin of wild type mice (Anderson et al.,
1997).  The cohort study on patients with peripheral neuropathy who were diagnosed with
Pelizaeus-Merzbacher disease, a leukodystrophy, demonstrated that expression of PLP but not
DM-20 was necessary to prevent peripheral neuropathy (Shy et al., 2003).  DM-20 expression
appears earlier than PLP during development and it is thought that it might have a role in
oligodendrocyte differentiation in addition to a structural role in the formation of a myelin
sheath (Ikenaka et al., 1992; Peyron et al., 1997; Timsit et al., 1992).  The gene coding for PLP
is located on the X chromosome in humans (Willard and Riordan, 1985) at position Xq22
(Mattei et al., 1986) and in mice in the H2C area (Dautigny et al., 1986).  Jimpy mice and
myelin deficient rats have sex-linked recessive mutations located in the PLP gene.  In humans
such spontaneous mutation occurs in Pelizaeus-Merzbacher disease, also known as an X-
chomosome-linked dysmyelinating disorder, which is characterized by abnormal formation and
maintenance of myelin (Nave and Boespflug-Tanguy, 1996; Seitelberger, 1995).  In PLP
knockout mice, oligodendrocytes can still assemble a myelin sheath around large diameter
axons, but the concentric layers of myelin membrane are loosely wrapped with wide
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extracellular spaces between the layers (Boison et al., 1995).  Therefore, PLP is suggested to be
responsible for the tight adhesion of the outer leaflets of the myelin membrane surfaces leading
to the formation of the minor dense line (Boison et al., 1995; Duncan et al., 1987, 1989).  In
addition, axonal swelling followed later by axonal degeneration associated with motor
impairment was observed in 16 month old PLP/DM-20 null mice (Griffiths et al., 1998).
 CNPase represents 4% of total CNS myelin protein.  Although the biological role of
CNPase remains obscure, this protein is present in the periaxonal membrane, inner mesaxon
and in the paranodal loops of oligodendrocyte myelin (Trapp et al., 1988).  CNPase is also
found in PNS myelin being localized similar to that of CNS myelin.  CNPase is present within
the oligodendrocyte plasma membrane during the earliest phase of axonal ensheathment prior
to the appearance of PLP and MBP.  Gravel et al. (1996) suggested that CNPase might play a
role in the extension of oligodendrocyte cytoplasmic processes around the axons during the
early stages of myelinogenesis.  Over expression of CNPase in transgenic mice perturbed
myelin formation, resulted in a formation of intramyelenic vacuoles, aberrant expansion of
oligodendrocyte cytoplasmic processes and precocious oligodendrocyte maturation (Gravel et
al., 1996).
MAG, as a quantitatively minor constituent of myelin, represents only 1% of the total
protein found in CNS myelin and only 0.1% in PNS myelin.  MAGs are transmembrane
proteins with extracellular regions that are homologous to N-CAM and other members of the
immunoglobulin gene superfamily (Salzer et al., 1987).  Recently, MAGs have been identified
as members of sialic acid binding lectins, the sialoadhesins, which preferentially bind to neuron
cell surface sialoglycolipids (Yang et al., 1996).  In the adult rat, MAG is largely distributed
across different regions of the PNS myelin internode (Meyer-Franke and Barres, 1994; Trapp
and Quarles, 1982), whereas it is confined to the periaxonal collar of the myelin sheath in the
CNS (Trapp et al., 1989).  MAG is involved in the activation of a protein tyrosine kinase Fyn
and a member of the src family, during the initial stages of myelination (Umemori et al., 1999)
and morphological differentiation of oligodendrocytes (Osterhout et al., 1999).  Although
MAG-deficient mice develop almost normal CNS myelin, the myelin that is formed contains
cytoplasmic organelles between noncompact lamellae, no periaxonal cytoplasmic periaxonal
collar in most of the internodes, and an abnormal collar in the remainder (Li et al., 1994,
Montag et al. 1994).  Montag et al. (1994) suggested that MAG might participate in the
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formation of the periaxonal cytoplasmic collar of oligodendrocytes and be responsible for the
adhesion of oligodendrocyte processes to axons in the CNS.  Two MAG proteins have been
identified, large MAG and small MAG (Frail et al., 1985; Salzer et al., 1987), which differ not
only in terms of their molecular weight but also in regard to their function.  Pathological
abnormalities of CNS myelin, but no PNS axon or myelin degeneration, are reported in large
MAG mutant mice (Carenini et al., 1997), although full null MAG mutants (i.e. both large and
small MAGs) develop a peripheral neuropathy in addition to CNS myelin pathology (Fruttiger
et al., 1995).  These data indicate that large MAG is the critical MAG isoform in CNS myelin,
whereas small MAG is important in the PNS for the maintenance and integrity of the myelin
sheath (Fujita et al., 1998).  Consistent with this suggestion, large MAG is expressed earlier
than small MAG during CNS myelination and is the predominant isoform in adult CNS myelin,
whereas small MAG is the predominant isoform in PNS myelin in both rodents (Frail et al.,
1985; Salzer et al., 1987) and humans (Miescher et al., 1997).
MOG was first identified as the antigen responsible for the demyelination observed in
animals injected with whole CNS homogenates (Lebar et al., 1976, 1986).  Present only in
mammalian species, the MOG gene is co-localized to the human major histocompatibility
complex (MHC) on chromosome 6 in the human genome, and on chromosome 17 in mice
(Pham-Dinh et al., 1993).  MOG is located in the plasma membrane of oligodendrocytes,
especially on the cytoplasmic processes, and on the outermost lamellae of the myelin sheaths
(Brunner et al., 1989).  MOG is also a surface marker of mature (Birling et al., 1993; Coffey
and McDermott, 1997; Pham-Dinh, 1993) and myelinating (Solly et al., 1996)
oligodendrocytes.  The extracellular domain of MOG, which is a member of the
immunoglobulin superfamily, is believed to induce both a T cell-mediated inflammatory
immune reaction and a demyelinating antibody-mediated response in the experimental
autoimmune encephalomyelitis (EAE) animal model (Lassmann et al., 1988).
PMP22 is a small, hydrophobic glycoprotein most prominently expressed by Schwann
cells as a component of compact myelin of the PNS (Naef and Suter, 1998; Snipes et al., 1992).
Functionally, PMP22 is involved in myelination during the development of peripheral nerves
and in the maintenance of peripheral myelin structure (Uyemura, 1993).  Mutations affecting
the PMP22 gene include duplications, deletions, and point mutations.  Point mutations are
responsible for the most common forms of hereditary peripheral neuropathies including
25
Charcot-Marie-Tooth disease type 1A (Patel et al., 1992; Timmerman et al., 1992), hereditary
neuropathy with liability to pressure palsies and a subtype of Dejerine-Sottas syndrome (Roa et
al., 1993).
P0 glycoprotein is the major transmembrane protein of PNS myelin of mammals as well
as of fish and amphibia (Uyemura et al., 1995).  In contrast to what is seen for mammalian
oligodendrocytes, the oligodendrocytes of fish express P0 (Jeserich and Waehneldt, 1986).
Lemke and Axel (1985), Lemke et al. (1988) and Lemke (1993) suggest that P0 mediates both
the extracellular and the cytoplasmic compaction of myelin.  The extracellular domain of P0
interconnects the turning loops of Schwann cell processes to form the intraperiod line (D’Urso
et al., 1990; Filbin et al., 1990; Schneider-Schaulies et al., 1990).  PMP22 interacts with P0 to
form complexes, which probably hold adjacent Schwann cell membranes together (D’Urso et
al., 1999).  The intracellular part of P0 contains positively charged basic residues and is
believed to interact with the phospholipids and MBP in the cytoplasmic face of apposing
Schwann cell membranes, thus forming the major dense line (Kirschner and Ganser, 1980;
Ding and Brunden, 1994; Martini et al., 1995).  P0-deficient mice develop severely
compromised myelin compaction, primarily at the site of the intraperiod line, whereas the
major dense line continues to be formed by Schwann cells (Giese et al., 1992; Martini et al.,
1995).  In the absence of MBP, Schwann cells expressing P0 are still able to form the major
dense line in shiverer mice (Kirschner and Ganser, 1980; Inouye et al., 1985).  The lack of both
MBP and P0 in the double mutants results in an almost complete loss of major dense lines in
PNS myelin (Martini et al., 1995).  Therefore, the formation of the major dense line in
peripheral nerve myelin is formed by both P0 and MBP (Martini et al., 1995).
In multiple sclerosis (MS), an immune response is directed against components of CNS
myelin, including MBP (Zamvil and Steinman, 1990; Steinman, 1993, 1995) and MOG
(Kerlero de Rosbo et al., 1993).  B-cell and T-cell reactivity against PLP, CNPase and MAG
have also been observed in MS patients (Oksenberg et al., 1993; Steinman, 1995).  The MOG
gene has been identified within the major histocompatibility complex 1 region on the
chromosome 6 (Daubas et al., 1994; Pham-Dinh et al., 1993).  Steinman (1993) suggested that
MOG might display some immune function in the CNS.  MOG can be an autoantigen as it is
located on the surface of the outermost lamellae of the myelin sheath, where MOG is more
exposed to antibodies than are other myelin proteins like MBP or PLP.   Oligodendrocytes are
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found to be susceptible to lysis by complement (Compston et al., 1989).  Piddlesden and
Morgan (1993) suggested that the absence of the complement-inhibitory protein CD59 from the
oligodendrocyte membrane contributes to this susceptibility to lysis by oligodendrocytes.
There are morphological and molecular differences between CNS and PNS myelin.
Although MBP, PLP, MAG and Cx32 are expressed in both oligodendrocyte and Schwann cell
myelin, oligodendrocytes also produce MOG and CNPase, whereas Schwann cells make
PMP22 and P0 myelin proteins.  In contrast to oligodendrocytes, which typically ensheath and
myelinate multiple CNS axons, myelinating Schwann cells always have a 1:1 relationship with
PNS axons.  A myelinated axon is always associated with an adjacent Schwann cell, the
nucleus of which gives the appearance of a “signet ring”.  The cytoplasmic processes of
adjacent myelinating Schwann cells interdigitate at the node of Ranvier, in marked contrast to
the exposure of CNS axons to extracellular space at each node (Bunge, 1968).  The soma of a
Schwann cell unlike that of an oligodendrocyte is circumferentially covered by a basal lamina,
which is continuous with that of the adjacent internode, regardless of whether the Schwann cell
is myelinating or not.  This type of myelination is called peripheral or PNS-type.  Schwann cell
myelinated fibers are separated from each other by extracellular compartment, the
endoneurium, whereas the oligodendrocyte myelinated fibers are in close contact.
1.3.2 Oligodendrocytes
Rio Hortega first introduced the term oligodendroglia in 1921 describing neuroglial
cells with few processes in metallic impregnation stained brain tissue (reviewed in Baumann
and Pham-Dinh, 2001).  Although a major role of oligodendrocytes is the myelination of CNS
axons, there are also satellite oligodendrocytes, which are found perineuronally and which are
believed to regulate the microenvironment around neurons (Ludwin, 1997).  A myelinating
oligodendrocyte extends several cytoplasmic processes, each of which contacts and repeatedly
envelops a stretch of axon with subsequent condensation of multispiral myelin (Bunge et al,
1962; Bunge, 1968).  Adjacent myelin segments (i.e. internodes) on the same axon belong to
different oligodendrocytes, with each segment being separated by a node of Ranvier.  In
contrast to the PNS, the axolemma is exposed to the extracelluar milieu at the nodes of Ranvier
in the CNS (Bunge, 1968) and is in close proximity to astrocytic processes (Black and
Waxman, 1988) and to NG2 positive glial precursor cells (Butt et al., 1999).  The number of
axons that are myelinated by each oligodendrocyte varies according to the area of the CNS and
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possibly also the species, from 40 in the optic nerve of the rat (Peters et al., 1991) to 1 in the
spinal cord of the cat (Bunge et al., 1961).
Butt et al. (1995) classified myelinating oligodendrocytes into four types based on their
morphology and on the size and thickness of the myelin sheath they formed.  Type I
oligodendrocytes were small cells supporting short, thin myelin sheaths for 15-30 small
diameter axons.  Intermediate types of myelinating oligodendrocytes were classified as types II
and III.  The type IV oligodendrocytes were the largest cells, forming long, thick myelin
sheaths around 1-3 large diameter axons (Bunge, 1968).
Originating from migratory and mitotic precursors, oligodendrocyte progenitors
differentiate progressively into postmitotic myelin-producing cells as they sequentially express
developmental and then myelinating markers (Hardy and Reynolds, 1993; Pfeiffer et al., 1993).
At the early developmental stages, oligodendrocyte precursors have been characterized by their
bipolar morphology and by the expression of nestin (Gallo and Armstrong, 1995), the DM-20
isoform of PLP (Ikenaka et al., 1992; Peyron et al., 1997; Timsit et al., 1992, 1995), the PDGF-
β receptor (reviewed in Richardson et al., 2000; Spassky et al., 2000), PSA-NCAM (Grinspan
and Franceschini, 1995; Hardy and Reynolds, 1991), and CNPase.  Later, PSA-NCAM and
nestin are no longer expressed.  As the oligodendrocyte progenitors are actively proliferating
and migrating within the CNS during embryonic and fetal development, they maintain
production of PDGF-β receptor, DM-20 and CNPase and begin synthesizing the GD3
ganglioside (Hardy and Reynolds, 1991), the gangliosides recognized by the monoclonal
antibody A2B5 (Fredman et al., 1984), and the rat NG2 proteoglycan (Nishiyama et al., 1996,
1999).  These migrating oligodendrocyte progenitors eventually settle along fiber tracts of the
presumptive white matter as pro-oligodendrocytes, which are cells of the oligodendrocyte
lineage that express sulfatides and unidentified glycolipids that bind the O4 monoclonal
antibody (Bansal et al., 1989).
As the pro-oligodendrocytes differentiate into oligodendrocytes they become less motile
(Orentas and Miller, 1996), lose their mitogenic response to PDGF-β receptor (Gao et al.,
1998; Hart et al., 1989; Pringle and Richardson, 1993), and they no longer express antigenic
epitopes recognized by the A2B5, GD3 and NG2 antibodies (reviewed in Baumann and Pham-
Dinh, 2001).  These immature oligodendrocytes are identified by virtue of their expression of
Gal-C (Pfeiffer et al., 1993; Raff et al., 1978; Zalc et al., 1981), and by the expression of the
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RIP antigenic epitope (Butt et al., 1995; Friedman et al., 1989).  As the cells differentiate into
oligodendrocytes they begin to express MBP (Butt et al., 1995).  Even in the absence of
neurons, oligodendrocyte progenitors can differentiate into cells that extend myelin-like
membranes (Sarlieve et al., 1983) and express the myelin proteins PLP, MBP and MAG.  Thus,
the capacity of oligodendrocyte progenitors to differentiate into cells expressing a myelinating
phenotype is specific to the lineage (Temple and Raff, 1986).  Nevertheless, co-culture of
oligodendrocyte progenitors with neurons increases gene expression of these myelin proteins in
the oligodendrocytes (Macklin et al., 1986; Matsuda et al., 1997), similar to that observed in
vivo (Kidd et al., 1990).  When axonal contact occurs, oligodendrocytes dramatically modify
their morphology, retract cytoplasmic processes that have not made contact with an axon
(Hardy and Friedrich, 1996), downregulate DM-20 expression, and begin to express the full-
length isoform of the PLP gene (Trapp et al., 1997).  Those oligodendrocytes in white matter
that do not make axonal contact undergo programmed cell death and die, thus eliminating
unneeded cells (Barres et al., 1992).  This switch from DM-20 expression to full-length PLP
expression is believed to signal the beginning of the process of myelination (Trapp et al.,
1997).
1.3.3 Schwann cells
Professor Theodor Schwann in 1839 published his treatise on the cell theory, where he
showed that in spite of a fibrous nature peripheral nerves are made up of cells, which were later
named after him (reviewed in Gould, 1990).  Schwann cells are the myelinating glia of the
PNS.
Schwann cells develop from the neural crest (Le Douarin et al., 1991) and evolve
through three steps (Mirsky et al., 2001).  First, after the transition from the neural crest
Schwann cell precursors are typically found in rat and mouse nerves of 14-15 and 12-13 day
old embryos, respectively.  Second, precursors become immature Schwann cells that are
present in 17 day old rat embryo and 15 day old mouse embryo to around birth. Subsequently,
the immature Schwann cells differentiate along the peripheral nerves into two mature types
with myelinating Schwann cells appearing first and mature non-myelinating Schwann cells
shortly after (Mirsky and Jessen, 1996; Jessen and Mirsky, 1997, 1998).  It is not known how
glial cells originate from the neural crest, which also gives rise to other lineages including
neurons and melanocytes.  Henion and Weston (1997) suggest that while migrating to their
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final destination cells of the neural crest enter distinct lineages under the influence of
instructive signals.  For example, β-neuregulins appear to bias neural crest cell differentiation
towards the glial lineage by blocking entry of the cells into the neuronal lineage (Shah et al.,
1994), whereas transforming growth factor β (TGF-β) promotes the generation of smooth
muscle cells and bone morphogenic protein 2 stimulates development of autonomic neurons
(Shah et al., 1996).
In postnatal rodents, immature myelinating Schwann cells ensheath the large axons and
the non-myelinating cells accommodate small diameter axons in their membrane invaginations.
Driven by axonal signals, myelinating Schwann cells carry out a large amount of membrane
synthesis and ensheathment needed to form the myelin sheath (Jessen and Mirsky, 1992).
Extensive changes in gene expression occur in immature Schwann cells when they are induced
to myelinate an axon including up-regulation of myelin proteins such as P0, MBP, PMP22 and
down-regulation of NCAM, p75NGFR and GFAP (Jessen et al., 1990).  Three transcriptional
factors that are known to play an important role in Schwann cell myelination include Sox-10 a
member of the SRY-like high motility group domain family of transcription factors (Kuhlbrodt
et al., 1998; Southard-Smith et al., 1998), the POU domain factor Oct-6/SCIP/tst-1 (Arroyo et
al., 1998) and the zinc finger protein Krox-20 (Topilko et al., 1997).  In mice with transiently
arrested Oct-6/SCIP/tst-1 expression or permanently blocked Krox-20 transcription factors,
promyelinating Schwann cells appear normal; they express a basal lamina and normal levels of
MAG, MBP and P0 mRNAs.  However, Schwann cells in these transgenic animals do not form
a concentric compacted myelin sheath (Bermingham et al., 1996; Topilko et al., 1994).
Recently, the mutation of Egr-1 (Krox-20) has been identified in patients with Charcot-Marie-
Tooth disease, an inherited demyelinating neuropathy, (Warner et al., 1998, 1999; Timmerman
et al., 1999).
During embryonic development, the survival of Schwann cell precursors depends on
axonal signals (i.e. β-neuregulins), whereas mature Schwann cells can survive in the absence of
axons (Grinspan et al., 1996; Li et al., 1998; Mirskiy et al., 2001; Trachtenberg and Thompson,
1996).  This is due primarily to the presence of an autocrine growth factor loop in Schwann
cells starting in rats from embryonic day 18 onwards (Meier et al., 1999).  The most important
growth factor components of autocrine survival include insulin-like growth factor (IGF)–2,
PDGF-BB and neurotrophin-3 (Meier et al., 1999).  This ability of Schwann cells to survive in
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the absence of axons is critical in the context of peripheral nerve regeneration after injury,
when the axons must enter the distal stump and regrow into their target tissue.  Living Schwann
cells are necessary for successful peripheral nerve repair, providing essential adhesion
molecules and trophic factors (Fawcett and Keynes, 1990; Nadim et al., 1990).
Two distinct forms of Schwann cells exist in peripheral nerves in adult mammals:
myelinating and nonmyelinating Schwann cells.  Schwann cells form contacts with axons, other
Schwann cells and with the extracellular matrix.  During differentiation, myelinating Schwann
cells lose contact with all but a single axon segment, which they subsequently ensheath with
cytoplasmic processes and myelinate (Zorick and Lemke, 1996).  Axonal contacts are essential
for initiation of myelination, which induce a Schwann cell to express myelin genes, the
expression of which is influenced by extracellular matrix  (Bunge et al., 1989, Scherer et al.,
1994; Scherer, 1997).  Schwann cells are known to produce basement membrane components
including laminin, type IV collagen and fibronectin, to which they adhere via integrin
receptors, dystroglycans and N-syndecan (Bunge et al., 1989; Mirsky and Jessen, 1996;
Scherer, 1997).  Interactions with laminin are suggested to be important for Schwann cell
migration (Milner et al., 1997) and myelination (Chen et al., 2000; Fernandez-Valle et al.,
1994).  In addition, morphological arrangements of actin cytoskeleton are also critical for
Schwann cell differentiation and myelination (Fernandez-Valle et al., 1997).
1.3.4 Olfactory ensheathing cells
In vivo, OECs ensheath but do not myelinate small C fibers (i.e. the olfactory axons;
Doucette, 1984, 1990; Raisman, 1985).  Barnett et al. (1993) and Devon and Doucette (1994,
1995) have demonstrated, OECs also express a nonmyelinating phenotype when grown in
neuron-free cell cultures.  OECs express a mixture of astrocyte-specific and Schwann-cell
specific phenotypic features (Doucette, 1990, 1995; Franklin, 2002b; Franklin and Barnett,
1997; Ramon-Cueto and Avila, 1998; Ramon-Cueto and Valverde, 1995) and have been
reported to perform the roles of both astrocytes and Schwann cells (Doucette, 1990, 1993;
Doucette and Devon, 1995).  Given the fact that OECs only ensheath unmyelinated axons in
vivo (Barnett et al., 1993; Devon and Doucette, 1992, 1995), they would be expected to express
a nonmyelinating phenotype when grown in vitro.  The media shown to be effective in vitro in
promoting the growth and differentiation of neopallial and olfactory bulb oligodendrocyte
progenitor cells failed to induce OECs to express a myelinating phenotype (Barnett et al., 1993;
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Doucette and Devon, 1995).  Moreover, OECs in neuron-free cultures treated with dBcAMP
can be induced to express GAL-C but not induced to express MBP (Doucette and Devon, 1994,
1995).  In contrast, Schwann cells re-express myelin proteins (MBP and P0) when cAMP had
been added to the culture medium (Lemke and Chao, 1988; Morgan et al., 1991; Pleasure et al.,
1985).  The results of these studies indicated that the molecular mechanisms regulating the
expression of a myelinating phenotype by OECs are different from those that function in
Schwann cells.
The first evidence that OECs could assemble a myelin sheath was reported by Devon
and Doucette (1992), who co-cultured OECs obtained from the olfactory bulbs of E18 rat
embryos with dorsal root ganglion (DRG) neurons.  Co-culturing of DRG neurons with OECs
resulted in the expression of a myelinating phenotype and the assembly of a PNS-type myelin
sheath around the DRG neurites.  Devon and Doucette (1992) used fluoredeoxyuridine to
eliminate non-neuronal cells from the DRG cultures and confirmed the purity of these cultures
by microscopy before adding OECs prelabelled with a lipophilic fluorescent dye (PKH26).  In
these co-cultures, each OEC either myelinated only one neurite or ensheathed several
unmyelinated neurites at the same time.  Each OEC, whether it was myelinating single neurites
or ensheathing multiple unmyelinated axons, was also enclosed within its own basal lamina, a
situation that does not exist in vivo in the primary olfactory pathway (Doucette, 1984, 1990; see
Section 1.2.1).  Only occasionally, two or more myelinated neurites were ensheathed by the
same glial cell and were enclosed within a common basal lamina.  Immunocytochemical
stainings revealed that S100-positive OECs ensheathing single DRG neurites were also MBP-
positive.  These MBP-positive OECs assumed a bipolar morphology and formed a contiguous
series of cells along the length of each DRG neurite (Devon and Doucette, 1992, 1995).
Axonal contact is one essential prerequisite for Schwann cells to express a myelinating
phenotype (Brunden and Brown, 1990; Brunden et al., 1990), a requirement that also applies to
OECs (Barnett et al., 1993; Devon and Doucette, 1992, 1995; Doucette and Devon, 1994,
1995).   In contrast to Schwann cells, however, OECs do not require addition of L-ascorbic acid
to the growth medium for them to assemble either a basal lamina or a myelin sheath in vitro
(Doucette and Devon, 1995).
Franklin et al. (1996) used an O4-positive (+ve) clonal OEC cell line they had
generated using tissue from the newborn rodent olfactory bulb and grafted these cells into an
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EtBr/x-irradiated (see Section 1.7.1) demyelinated area of the adult rat spinal cord.  Their study
provided the first in vivo evidence of the ability of OECs to remyelinate demyelinated CNS
fibers; similar to what had been previously described in vitro (Devon and Doucette, 1992,
1995).  This clonal cell line myelinated the axons in a Schwann cell-like fashion.  Subsequent
studies by Imaizumi et al. (1998) using primary rat cell cultures of OECs not only replicated
these in vivo experiments but, most importantly, also showed that the OEC remyelination of
axons in the dorsal columns enhanced axonal conduction across the previously demyelinated
area.  The grafting of OECs obtained from human OB (Bartnett et al., 2000), human olfactory
nerve (Kato et al., 2000) or canine OB (Smith et al., 2002) into x-irradiated/EtBr-induced
demyelinated rat spinal cord resulted in Schwann-like remyelination of CNS axons within the
demyelinated lesion.  Radtke et al. (2004) utilized OECs harvested from an adult H-transferase
transgenic pig for transplantation into the nonhuman primate spinal cord and observed
remyelination of EtBr-induced demyelinated CNS axons.
Thus, OEC remyelination was demonstrated to be functionally significant.  OECs were
also found capable of remyelinating electrolytically lesioned corticospinal axons that
regenerated into and through the site of the lesion after grafting OECs into the lesion site (Li et
al., 1998).  However, the remyelinating ability of OECs was questioned when the in vitro study
of Plant et al. (2002) failed to identify any myelination of DRG neurites by co-cultured OECs,
which were obtained using the technique of Ramon-Cueto and Nieto-Sampedro (1992).
Schwann cells form more myelin sheaths in co-culture with DRG neurons than OECs in these
experiments.  Such lack of myelination in vitro by OECs, perhaps, could have been determined
by the extent of the purification procedure used by Plant et al. (2002).  p75NGFR-expressing
OECs used in the study by Plant et al. might not be a subset of OECs responsible for the
myelinating potential.  Another possible explanation is that Plant et al. use adult OECs that may
not have the same myelinating potential as embryonic OECs (Devon and Doucette, 1992,
1995).  Takami et al. (2002) compared regenerative abilities of OECs and Schwann cells in
vivo and found that Schwann cells but not OECs improved the functional recovery of adult rats
after contusive spinal cord injury.  Furthermore, OECs myelinated fewer axons than Schwann
cells. However, the authors reported that only a few OECs could be identified within spinal
cord tissue.  Either susceptible to cytotoxicity or other unidentified causes, OECs failed to stay
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around and therefore neither supported axon regeneration nor contributed to the remyelination
of the regenerated axons in experiments performed by Takami et al. (2002).
The molecular mechanisms controlling the expression of a myelinating phenotype by
OECs remain to be elucidated.  Smith et al. (2001b) initiated a study to identify which
transcription factors were expressed by OECs engaged in remyelinating spinal cord axons.
Similar to Schwann cells (Blanchard et al., 1996; Zorick et al., 1999), the expression of Oct-6
/SCIP/ tst-1, Krox-20 and desert hedgehog transcription factors was detected in an EtBr/x-
irradiated rat spinal cord lesion after OEC transplantation (Smith et al., 2001b).  However, the
authors did not present direct evidence that these transcription factors were expressed by
grafted OECs, as opposed, for example, to invading host Schwann cells.  Other studies (Barnett
et al., 1993; Devon and Doucette, 1995; Doucette and Devon, 1994, 1995) indicate that OECs
have similar, but not identical, requirements to Schwann cells for expression of a myelinating
phenotype.  So methodological differences, such as the age of animals from which the OECs
were obtained, the method of purification, etc. might have had an impact on the results rather
than the actual myelinating ability of the OECs.  Moreover, there is little known yet about
factors regulating the myelinating phenotype in OECs and whether all OECs even possess the
ability to myelinate.
Oligodendrocytes are known to synthesize significant levels of myelin-associated
molecules (i.e. Gal-C and MBP) in vitro even in the absence of axonal contact, provided the
growth medium contains insulin, hydrocortisone, and triiodothyronine (Lopes-Cardozo et al.,
1989; McMorris et al., 1986; Mozell and McMorris, 1991; Poduslo et al., 1990; Ved et al.,
1989).  When similar growth medium is used to feed neuron-free cultures of OECs, these glial
cells are not induced to express either Gal-C or MBP (Barnett et al., 1993; Doucette and Devon
1994, 1995).  These data suggest that the promoter region of the MBP gene is under different
regulatory control in oligodendrocytes and OECs (Doucette and Devon, 1994, 1995).  The
MBP promoter is also believed to be controlled differently in oligodendrocytes and Schwann
cells (Foran and Peterson, 1992; Gow et al., 1992).  Gal-C expression by OECs in neuron-free
cultures can, however, be induced by increasing the intracellular level of cAMP (Doucette and
Devon, 1994, 1995), which at the same time fails to induce these cells to express MBP
(Doucette and Devon, 1995).
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1.4 Multiple Sclerosis
MS is a relatively common and always disabling disease of the CNS primarily affecting
young adults (20 to 40 years of age) that exhibits extraordinary clinical, radiological, and
pathological heterogeneity.  The MS Society of Canada estimates that 50,000 Canadians have
MS, with this disease affecting 1-2 people per 1000 population (MS Society of Canada website;
October, 2004; http://www.mssociety.ca).
1.4.1 Neuropathology and clinical course
MS is characterized by ongoing lesion formation in the CNS and increasing cumulative
damage and is now also recognized as a disease with on-going pathological processes in most
patients most of the time.  Autopsy studies indicate that there are individuals who never
develop clinical symptoms, in spite of having neuropathologic changes typical of MS.
Although no accurate data have been collected yet to estimate subclinical disease, it has been
suggested that asymptomatic MS might account for up to 25% of all cases (Joy and Johnston,
2001).  The majority of MS patients (~85%) develop neurological signs and symptoms over a
period of several days, reach a plateau, and then show some improvement followed by a period
of clinical quiescence (i.e. remission) that is variable in length but is rarely permanent
(Wingerchuk et al., 2001).  New attacks (i.e. relapses) typically consist of one or a combination
of symptoms including optic neuritis, axial or limb parasthesias with neck flexion (Lhermitte’s
sign), weakness, gait ataxia, diplopia, and symptomatic worsening with increases in body
temperature (Uhthoff symptom).  The relapses of disabling symptoms repeat themselves over
and over, interspersed with periods of remission; these patients are referred to as having
“relapsing-remitting MS”.  As the disease progresses, the frequency and duration of the
relapses often increase while that of the remissions usually decreases until they no longer
experience any periods of remission; at this point in the progression of the disease these
patients are considered to have switched from a “relapsing-remitting” to a “secondary
progressive” form of MS (Prineas et al., 2001).
For the remaining 15% of MS patients, the disease presents first and foremost with a
gradually progressive loss of neurological function that presents with no intervening periods of
remission.  This form of MS is referred to as “primary progressive”.  The appearance of, and
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worsening of, the clinical exacerbations in all MS patients are usually accompanied by
inflammatory infiltrates and demyelination in the brain and spinal cord white matter giving rise
to the pathological hallmark of the disease, the MS plaque.  Patients with primary progressive
MS tend to be older.  Although women are twice as likely as men to develop relapsing-
remitting MS, men are as likely to develop primary progressive MS as are women.
An MS plaque is a circumscribed area of demyelination within the brain or spinal cord
within which there is a relative preservation of axons.  Although plaques may occur anywhere
within the white matter, the periventricular area of the cerebral hemispheres, optic nerve, brain
stem, cerebellum and spinal cord are among the more frequent sites (Wingerchuk et al., 2001).
Varying proportions of immune cells and immunoreactive substances (i.e. immunoglobulins)
populate plaques, which can be classified as being active, inactive or chronic.  Active plaques
contain leukocytes that have invaded the CNS from the vascular system, resident activated
macrophages/microglia, and reactive astrocytes located at the periphery of the plaque
(Gutowski et al., 1999).  Schwann cells may be present inside plaques, but if present are only
found inside the astrocyte-poor central area of the lesion (Itoyama et al., 1983).  The number of
plaques gradually increases over time as the disease progresses resulting in a gradual increase
in the number of demyelinated axons.  Demyelination and axonal pathology are important
contributors to the neurological signs and symptoms of MS (Bjartmar et al., 2001; Ferguson et
al., 1997; Nowacki et al, 2000; Peterson et al., 2001).  Although it has been assumed axons and
gray matter are spared in MS, recent observations indicate that MS is a destructive process
leading to axonal damage (Trapp et al., 1998) and brain atrophy (Jeffery et al., 2000; Sailer et
al., 2003), even in spite of current anti-inflammatory or immunosuppressive therapies.
Progressive neurological deterioration in MS patients has also been correlated with atrophy in
the spinal cord (Bot et al., 2004; Losseff et al., 1996), cerebellum (Davie et al., 1995), and
cerebral cortex (Losseff et al., 1996).  The onset of the symptoms of MS is often associated
with breakdown of the blood-brain barrier, which can be visualized by gadolinium-enhanced
lesions on magnetic resonance imaging (McFarland et al., 1992; Rudick et al., 1996; Werring
et al., 2000).
Depending on cellular composition and on the relative balance between demyelination
and remyelination, MS plaques can be divided into several different types (Lassmann et al.,
2001; Lucchinetti et al., 1996, 1999; 2000).  Type I and II lesions are characterized by the
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presence of a prominent inflammatory reaction, which is likely mediated in part by tumor
necrosis factor-α (TNF-α) and by the release of reactive oxygen species by T lymphocytes and
macrophages (Lucchinetti et al., 1996, 1999; 2000).  The deposition of antibodies and
complement is seen in Type II lesions but these are absent from lesions of Type I.  Antibodies
against various myelin proteins have been identified in cerebrospinal fluid (CSF) and in sera
obtained from MS patients, although their role in the pathogenesis is not clear.  For example,
anti-MOG antibodies have been identified both in serum and in CSF of some MS patients
(Reindl et al., 1999).  Hypoxic damage in oligodendrocytes is predominant in type III lesions
(Aboul-Enein et al., 2003; Lassmann, 2003), which are characterized by ill-defined borders,
rims of spared myelin surrounding inflamed vessels, and preferential loss of MAG.  Other
myelin proteins (PLP, MBP, CNP) are still present within active lesions.  The Type III lesion is
considered to be active because activated macrophages filled with myelin degeneration
products are present.  Marked degeneration of oligodendrocytes, a minor inflammatory reaction
and extensive tissue destruction are present at the Type IV lesion.  Similar to that of Type I and
II lesions, the perivenous and radial plaque growth and simultaneous loss of all myelin protein
are also present in Type IV lesions.  Various degrees of remyelination are seen in both Type I
and II lesions, but not in either Type III or Type IV lesions.
Depending on a number of factors such as location of lesions, disease activity,
medication and genetic susceptibility, axonal loss reaches a certain threshold and becomes
clinically obvious at various time-points.  In longstanding lesions, an increased number of
inflammatory attacks axonal injury can be substantial and results in considerable irreversible
neurological impairment and disability of MS patients.
This irreversible disability that MS patients exhibit has been attributed to axonal
dysfunction and loss (Davie et al., 1995; De Stefano et al., 1998).  Acute axonal injury has
been demonstrated in early lesion formation and is most pronounced in actively demyelinating
plaques in part due to the inflammatory edema (Bitsch et al., 2000; Ferguson et al., 1997;
Kornek et al., 2000; Trapp et al., 1998).  Axonal injury begins at disease onset and remains
clinically silent for many years.  Irreversible neurological disability develops when axonal loss
reaches its threshold and compensatory resources of the CNS tissue are exhausted.
Accumulation of axonal amyloid precursor protein (APP), a marker of axonal injury or
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dysfunction, was found in active plaques and at the border of the chronic MS lesions (Ferguson
et al., 1997).
1.4.2 Theories on etiology of MS
The primary cause of MS remains unknown.  Many investigators generally accept the
concept that the immune system contributes to the destruction in multiple sclerosis and CD4
positive T cells initiate an inflammatory cascade that leads to demyelination.  However, it has
not yet been determined what causes MS.  Therefore, researchers investigate different
hypotheses such as environmental (Agranoff and Goldberg, 1974; Bach, 2002; Kurtzke, 1980),
viral (Challoner et al., 1995; Friedman et al., 1999; Gilden, 1999; Kazmierski et al., 2004;
Lucchinetti et al., 2000), genetic (Ebers et al, 1995; Sadovnick et al, 1993; Weinshenker et al,
1998), vascular (Aboul-Enei et al., 2003; Lassman et al., 2001) and inflammatory (Bo et al,
1994; Bonetti and Raine, 1997; Dowling et al., 1996; Hofman et al., 1989; Merrill et al., 1993;
Trapp et al., 1999).  A majority of researchers believe that a viral agent directly or indirectly
triggers inflammatory and autoimmune cascades which initiate MS pathogenesis.
Epidemiological findings support an environmental hypothesis since the prevalence of
MS generally increases with distance from the equator, and thus the disease occurs
preferentially in areas that receive a relatively low amount of ultraviolet radiation from sunlight
(Agranoff and Goldberg, 1974; Kurtzke, 1980).  As a consequence, low vitamin D production
is detected in the population of these areas and especially in MS patients (Bach, 2002).  Other
environmental factors suspected in predisposing people to the development of MS include
infections (Challoner et al., 1995; Friedman et al., 1999; Gilden, 1999; Kazmierski, 2004;
Lucchinetti et al., 2000) and ecological factors (Lauer, 1997, reviewed in Wingerchuk et al.,
2001), such as climate, soil conditions, and diet.  It has been hypothesized that some infections
including human herpes virus 6 (Challoner et al., 1995; Friedman et al., 1999, Lucchinetti et
al., 2000; Knox, 2000; Goodman, 2003), Chlamydia pneumonia (Gilden, 1999; Sriram et al.,
1999), and influenza virus (Kazmierski, 2004) are causative agents of MS.  The genetic
hypothesis is based on the evidence of a higher prevalence of MS in monozygotic twins as
opposed to heterozygotic siblings (Sadovnick et al., 1993).  Many ethnic groups, including
North American Indians, showed reduced incidence of MSdespite them living in regions with a
high prevalence for this disease.  Many patients with MS were tested for human leukocyte
antigen (HLA) DR2, as a more susceptible locus on chromosome 6 (Ebers et al., 1995).
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Although HLA polymorphism is not considered to be a significant contributor, genetic factors
may still be important determinants of the disease course (Weinshenker et al., 1998).
Polymorphisms in the interleukin (IL)-1β and IL-1β receptor antagonist genes (Schrijver et al.,
1999), the apolipoprotein E gene (Evangelou et al., 1999), and immunoglobulin (Ig) G Fc
receptor genes (Myhr et al., 1999) have been also associated with MS course.  MS patients with
a combination of IL-1β and IL-1β receptor antagonist polymorphisms are found to have a
higher rate of progression on the Expanded Disability Status Scale when compared with other
possible combinations (Schrijver et al., 1999).  At the apolipoprotein E gene, the ε4 allelle is
found to be more common in MS patients with more rapid progression of disability in MS
(Evangelou et al., 1999).  Authors suggest that apolipoprotein E is not implicated in the early
pathogenesis of MS; however, patients possessing the ε4 allelle have a reduced capacity for
neuronal remodeling after relapses.  Although the frequencies of two IgG Fc receptors IIA and
IIIB do not differ between the MS patients and the controls, MS patients homozygous for the
IgG Fc receptor IIIB neutrophil antigen 1 allele have more benign course of disease than that of
patients heterozygous or homozygous for the IgG Fc receptor IIIB neutrophil antigen 2 allele
(Myhr et al., 1999).
There are an increasing number of studies reporting the role of an immunomediated
vasculitis leading to MS plaque development (Aboul-Enei et al., 2003; Lassman et al., 2001).
Activated T-cells and macrophages damage endothelial cells causing microvessel thrombosis
with secondary ischemic damage of white matter.  Activated microglia secrete nitric oxide (Bo
et al., 1994; Merrill et al., 1993) and cytokines TNF-α (Hofman et al., 1989) and lymph toxin
(Selmaj et al., 1991), which were found to selectively damage oligodendrocytes in vitro and in
some MS lesions (Bonetti and Raine, 1997; Dowling et al., 1996; Trapp et al., 1999).  Matrix
metalloproteases (MMPs), a family of proteolytic enzymes including collagenasese,
gelatinases, stromelysins, membrane-type metalloproteinases, matrilysin and metalloelastase,
are known to be involved in remodeling of extracellular matrix of many tissues (Birkedal-
Hansen et al., 1993).  They have been implicated in degradation of vascular basement
membrane thereby facilitating leukocyte migration into inflammatory sites (Yong et al., 1998).
The authors focused their attention on MMP-9 (gelatinase B) because it is known to degrade
type IV collagen and to disrupt cell-matrix contacts.  The subsequent loss of integrin signaling
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leads to oligodendrocyte apoptosis (Chandler et al., 1997).  MMP-9 has been shown to degrade
myelin basic protein of the myelin sheath (Chandler et al., 1995; Gijbels et al., 1993).
1.4.3 Host glial cell response
The MS lesions have been characterized by the composition of demyelination,
oligodendrocyte pathology, the inflammatory infiltrate, astrogliosis and axonal damage
(Kornek and Lassmann, 2003; Lassmann et al., 1998).  However, it remains unclear, which of
the processes develop primarily in response to still unknown cause and which develop
secondarily as a consequence of, or as a reaction to, an initiating event.  The pathology of MS
is associated with immunological and inflammatory processes that result in complex changes in
gene expression by astrocytes and microglia in the vicinity of the lesion, in the recruitment of a
number of cell types (e.g. leucocytes) into the lesion (Adamson et al., 1999; Al-Omaishi et al.,
1999; Asensio et al., 1999), and in the alteration of the extracellular matrix of the plaque
(Gutowski et al., 1999; Opdenakker, 1997).  Chemokines, which are expressed in response to
CNS inflammation, are known to induce a chemotactic migration of microglial cells (Badie et
al., 1999; Cross and Woodroofe, 1999; Yamagami et al., 1999).  INF-γ and TNF-α are the most
studied inflammatory cytokines and both molecules are expressed in MS lesions (Wingerchuk
et al., 2001).
Heterogeneity of pathological changes in MS plaques has been previously documented
(Lucchinetti et al., 2000).  However, one of the constant features of all plaques is the presence
of microglial and astrocytic reactivity.  A very recent study of patients with relapsing and
remitting MS, who died during or shortly after the onset of a relapse, showed extensive
oligodendrocyte apoptosis, as well as microglial and astroglial activation, in myelinated tissue
in which there were few or no lymphocytes or myelin phagocytes (Barnett, 2004).
Microglia along with T cells infiltrate injured CNS tissue and play an important role in
the development and progression of active MS lesions. Sriram and Rodrigez (1997) implicated
macrophage/microglia as principal players in the demyelination process due to activation of
these cells and release of the factors that are toxic to the oligodendrocytes and myelin.  This
model was supported by the findings of Chiang et al. (1996), who described
macrophage/microglia-mediated demyelination induced by low-level chronic secretion of IL-3.
The macrophages/microglia within active plaques are filled with myelin degradation products,
whereas inactive plaques contain far fewer cells and the macrophages/macroglia that are
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present do not normally contain myelin debris.  Demyelination is believed to be occurring at
the site of active plaques, whereas inactive plaques are most likely areas where some degree of
tissue repair either has occurred or is actively taking place.  The demyelinated lesions in
patients with chronic MS have well-demarcated areas with very few cells visualized with Luxol
Fast Blue staining, varying degrees of axonal loss, and persistent but minor inflammation; these
lesions are referred to as chronic plaques.  In recent years a harmful role of
macrophage/microglia has been questioned.  Diemel et al., (1998) and Loughlin et al., (1997)
suggested that macrophages can be beneficial for MS lesion and that they also may promote
recovery from demyelination by the phagocytosis of myelin debris and the release of trophic
factors.  Macrophages were found to stimulate myelinogenesis (Hamilton and Rome, 1994) as
well as remyelination (Cuzner et al., 1994; Loughlin et al., 1997) in cell cultures.  There are
still questions also to whether macrophages found in MS lesions are agents of destruction or
contributors to recovery.  Bartnik et al. (2000) showed that macrophages promoted myelination
in embryonic spinal cord aggregate cultures at normal and low levels of oxidative stress and on
the other hand were part of the cause of neuronal damage when the levels of oxidative stress
were higher.
A network of reactive astrocytes can be found in the majority of MS lesions.  It is
believed that astrocytes are activated by pro-inflammatory cytokines (Selmaj et al., 1990) and
such an astrocytic reaction is not specific for MS.  Although the role of astrocytic activation is
not yet clear, Rosen et al. (1989) suggested that astrocyte sclerosis might serve as a barrier for
regeneration.  Other studies showed that astrocytes may be a source of growth factors,
including vascular endothelial growth factor and fibroblast growth factor (FGF) 2, and could
therefore support regenerative processes (Horner and Palmer, 2003; Ridet et al., 1997).
Reactive astrocytes present inside chronic MS plaques produce molecules such as tenascin-R
and –C, which are believed to impede remyelination and axonal repair by contributng to the
formation of a glial scar  (Gutowski et al., 1999).
1.4.4 Current treatment
The treatment of MS patients is very complex and best accomplished with a
multidisciplinary approach involving a neurologist, ophtalmologist, psychiatrist,
urologist, gastroenterologist, nurse, physical therapist, rehabilitation specialist, and
social worker. There is no cure for MS at the present time, because its cause remains
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unknown.  Therefore, the treatment of patients with MS is very challenging and
complex.  The patients with MS often develop complications such as fatigue,
depression, sleep disorders, spasticity, pain, decubitus ulcers, speech and swallowing
disorders, mood and cognition disorders, and others.  Such complications usually
require attention of a psychiatrist, physiotherapist and rehabilitation specialist.
Clinically significant acute relapses are currently being treated with the use of
corticosteroids and plasma exchange to hasten recovery.  Although no consensus about
the optimal form, dose, route and duration of corticosteroid therapy has been accepted,
corticosteroids such as methylprednisolone and prednisone have been used to reduce the
rate of clinical relapses, delay progression of disability and reduce CNS lesion activity
as evidenced by magnetic resonance imaging (MRI; Beck, 1992, 1995).  Plasma
exchange is found to enhance recovery of relapse-related neurological deficits in MS
patients who show no response to high-dose corticosteroids (Weinshenker et al., 1999).
Phase 3 trials indicate that treatment with interferon derivatives, such as INF β-1a
(Rebif®) may delay the development of clinical and MRI evidence of a second
diagnosis-defining bout after a first episode of acute neurological syndromes suggestive
of MS (Jacobs et al., 2000).  The rate of clinical relapses, the development of new
lesions and increase in volume of existing lesions on MRI scans are also reduced by
approximately 30 percent with administration of INF β-1b (Betaseron®, Berlex
Laboratories) (Paty and Li, 1993; The IFNB Multiple Sclerosis Study Group, 1995) and
INF β-1a (Avonex®, Biogen; Rudick et al., 1997).  INF β-1a and glatiramer acetate, a
mixture of synthetic polypeptides containing glutamic acid, alanin, lysine, and tyrosine,
(Copaxone®, Teva Pharmaceutical Industries) were found to reduce the frequency of
relapse (Johnson et al., 1995; Johnson et al., 1998).  In addition, INF β-1a may also
delay the progression of disability in MS patients with minor disability and a relapsing
form of MS (Simon et al., 1998; Jacobs et al., 1996; Rudick et al., 1997).  The specific
mechanisms of action of interferons in MS are not completely understood.  These
agents are believed to exert their immunomodulating activities by reducing both the
proliferation of T cells and the production of TNF-α, by decreasing antigen
presentation, by altering cytokine production and favoring ones governed by type 2
helper T (Th) cells, by increasing the secretion of IL-10, and by reducing the passage of
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immune cells across the blood-brain barrier by means of their effects on adhesion
molecules, chemokines, and proteases (Rudick et al., 1997).  Glatiramer acetate is
found to promote the proliferation of Th2 expressed cytokines, compete with MBP for
presentation on MHC class II molecules, thereby inhibiting antigen-specific T-cell
activation, altering the function of macrophages, and inducing antigen-specific
suppressor T-cells (Bornstein et al., 1987).  An elevation of serum IL-10 levels,
suppression of the pro-inflammatory cytokine TNFα mRNA, and elevation of the anti-
inflammatory cytokines TGF-β and IL-4 mRNAs in leukocytes were observed in a 12
month study conducted by Miller et al. (1998).  They suggested that the beneficial
clinical effects of glatiramer acetate in MS patients may be attributed to changes in
activation of T cells and a shift from a Th1 to a Th2/Th3 cytokine profile, probably
leading to glatiramer acetate-driven mechanisms of bystander suppression.
1.5 Glial Cell Reaction to Injury
Following an acute insult to the CNS, a complex of morphological and metabolic
changes takes place within the nervous system with the goal to repair the damaged tissue
(Deckert-Schluter et al., 1995; Drescher et al., 1997; Griffin et al., 1992; Kreutzberg, 1996;
Raivich et al., 1996).  The injured neurons undergo crucial steps in a fight for their survival and
stimulate nearby neuroglia including microglia and astrocytes for support (Kreutzberg, 1996;
Raivich et al., 1995).  The activation of microglia (Kreutzberg, 1996) and astrocytes (Eddleston
and Mucke, 1993) has been described as a graded, stereotypic response, which is readily
observed in stroke and ischemia, in neurodegenerative diseases, after direct or indirect axonal
injury (Norenberg, 1994) or during inflammation due to infections or autoimmune disease
(Perry et al., 1995).  The production of proinflammatory cytokines, functional changes in brain
vascular endothelia and a recruitment of cells of the immune system into the damage tissue has
been also identified after acute nervous system injury.
1.5.1 Astrocytes
The astrocytes are considered to be the predominant neuroglial cell of the CNS and
exist in two typical forms stellar-fibrillary astrocytes and protoplasmatic astrocytes.  The
former cells are normally located in the white matter and bear long slender processes, which
stain with GFAP, a typical astrocyte cytoskeletal protein (Bignami et al., 1972).  The
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protoplasmic astrocytes, on the other hand, are residents of grey matter, exhibit numerous short
and highly branched processes and only a few of these astrocytes express GFAP.  Astrocytes
provide metabolically optimized nutrients to the highly energy-consuming neurons and
maintain ionic balance in the extracellular space (reviewed in Tsacopoulos and Magistretti,
1996).  In addition, astrocytes induce tight junctions on endothelial cells (Janzer and Raff,
1987; Pekny et al., 1998; Tao-Cheng et al., 1987), induce the ramified phenotype in microglia
and blood-derived monocytes (Kloss et al., 1997; Schmidtmayer et al., 1994) and provide
numerous trophic factors including PDGF (Hermanson et al., 1995), NGF, IGF-1, TGF-α for
adjacent neurons and oligodendrocytes, particularly following injury (Eddleston and Mucke,
1993; Ridet et al., 1997).
In response to an injury that occurred some distance away, astrocytes became activated
and increase of their synthesis of GFAP within 24 hours for example after facial nerve axotomy
(Tetzlaff et al., 1988).  Reactive astrocytes in the adult brain appear to recover the capacity to
express vimentin (Pixley and De Vellis, 1984; Schiffer et al., 1988; Takamiya et al., 1988),
which normally is expressed only during embryogenesis and during the first two postnatal
weeks in rodents (Pixley and De Vellis, 1984; Schnitzer et al., 1981; Voigt, 1989).  Reactive
astrocytes create a physical barrier between damaged and healthy cells.  Beginning 2 weeks
after axonal injury, the reactive astrocytes gradually replace microglia from the neuronal
surface and begin to enwrap the perikarya of injured neurons with thin, flat cytoplasmic
processes (Graeber and Kreutzberg, 1988; Guntinas-Lichius et al., 1997).  Processes of
adjacent astrocytes adhere to each other and form a multilayered stack of astrocytic lamellae,
which could act as a small glia scar surrounding the axotomized neuron.  Physical damage,
ischemia or inflammation will lead to disruption of the blood brain barrier, collateral activation
of adjacent microglia and a much stronger response of astrocytes, which will proliferate and
form a massive scar (Balasingam et al., 1994; Giulian and Lachman, 1985).  A dense network
of hypertrophic astrocytes with thick, interdigitating processes and associated extracellular
matrix compose the glial scars (Brodkey et al., 1995).  It is commonly believed that the cell
surface of astrocytes and the extracellular matrices in which they are embedded are more likely
to hinder rather than facilitate the growth of axons in vivo in the adult mammalian CNS
(Fraher, 1999; Reier et al., 1986; Reier and Houle, 1988; Ridet et al., 1997).  The components
of the extracellular matrix such as chondroitin sulfate proteoglycans (Giftochristos and David,
44
1988; Lips et al., 1995; McKeon et al., 1991), tenascin (Laywell et al., 1992; Lips et al., 1995;
McKeon et al., 1991) and collagen IV (Stichel et al., 1999) have been found to inhibit neurite
outgrowth.
However, astrocytes are not always nonpermissive for axonal growth.  In fact, there
appear to be differences in the ability of astrocytes to support axonal growth.  This can depend
on the degree of differentiation of the cells (Baehr and Bunge, 1989; Hatten et al., 1991; Lucius
et al., 1996), on whether the astrocytes have formed a two- or three-dimensional substratum for
the growing axons (Fawcett et al., 1989), on the region of the CNS that is injured (Alonso and
Privat, 1993a, 1993b; Chauvet et al., 1998; Prieto et al., 2000), and on the presence or absence
of macrophages (David et al., 1990), Schwann cells (Berry et al., 1992; Dezawa et al., 1999) or
OECs (Li et al., 1997, 1998; Ramon-Cueto et al., 1998, 2000).
1.5.2 Microglia
Microglia are thought to be derived from infiltrating hematopoietic or mesodermal cells
during the early development of the CNS (Eglitis and Mezey, 1997; Hickey and Kimura, 1988;
Hickey et al., 1991, 1992; Kurz and Christ, 1998; Ling and Wong, 1993).  The normal, resting
microglia have long, ramified processes oriented parallel to the nerve fibers in the white matter,
and display a stellate morphology in the gray matter (Compston et al., 1997).  Microglia appear
to participate in the immune surveillance of the nervous system.  During embryonic and early
postnatal (up to postnatal day 21) rat development, microglia express the complement type 3
receptor and the MHC class 1 antigen, which can be recognized by monoclonal antibodies OX-
42 and OX-18, respectively (Domaradzka-Pytel et al., 1999).  After P21, microglia within the
normal CNS no longer express the MHC class 1 antigen but remain OX-42 positive.  However,
microglia will re-express complement type 3 receptor in response to neural damage (Graeber et
al., 1988).
Microglia respond to neural damage by undergoing characteristic changes, which
involve cellular and morphological events, such as increased cell size and number of activated
cells, as well as the expression of cell surface molecules (i.e. MHC class 1 antigen; Graeber et
al., 1988), cytokines (i.e. IL-1β, TNF-α; Bartholdi and Schwab, 1997) and growth factors (i.e.
NGF, neurotrophin-3, ciliary neurotrophic factor; Eddleston and Mucke, 1993; Elkabes et al.,
1996; Mallat et al., 1989).  Following axotomy of the facial nerve, resting microglia become
activated and then proliferate and tightly ensheath injured motoneurons with enlarged
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cytoplasmic processes (Blinzinger and Kreutzberg, 1968).  If an injured neuron survives and re-
grows its axon, reactive microglia may revert back to the resting form.  If neurons die,
microglia change their form from process bearing to rounded (ameboid) macrophages, which
remove the dead cells (Streit and Kreutzberg, 1988).  Activated microglia develop enlarged cell
processes, which give the cells a bushy appearance.  Cellular hypertrophy is concomitant with
upregulation of complement type 3 receptor expression (Graeber et al., 1988) and both are
apparent by 24 hours after injury.  Microglia begin to proliferate 2-3 days after injury and their
numbers reach maximum levels after 4-7 days.  Following an epidural application of kainic
acid over the rat cerebral hemispheres, Kaur and Ling (1992) observed extensive neuronal
degeneration, which elicited an increased expression of the complement type 3 receptor
(marked by OX-42) and induced MHC 1 expression (marked by OX-18) in microglia.  The
elevated expression of the former receptor may be related to the phagocytic activity of these
reactive microglia, whereas re-expression of the latter antigen was suggested to facilitate the
activated microglial cells interaction with T lymphocytes as part of an immune response.
Streit et al. (1999) suggest that activation of microglia shortly after injury may serve to
limit secondary damage to neurons, whereas chronically activated microglia may take an active
role in neuron destruction.  Microglial activation after acute CNS injury is described as a
transient and self-limited event and it usually subsides within about one month after either
traumatic or ischemic insults (Gehrmann et al., 1991; Morioka et al., 1991; Koshinaga and
Whittemore, 1995).  An increasing number of studies have focused on the expression of
microglia-derived cytokines and growth factors following CNS injury.  The mRNA levels of
microglia-derived cytokines and growth factors fluctuate depending on the injury type.  The
expression of proinflammatory cytokines, such as IL-1β and TNF-α, is minimally upregulated
following axotomy of the facial nerve (Streit et al., 1998), whereas a sharp increase in the
expression of these cytokines is seen immediately after spinal cord injury (Bartholdi and
Schwab, 1997).  The upregulation of proinflammatory cytokine mRNAs is observed for a very
short duration, with the levels returning to baseline levels one or two days after injury
(Bartholdi and Schwab, 1997; Buttini et al., 1994; Streit et al., 1998; Taupin et al., 1993;
Woodroofe et al., 1991).  Streit et al. (1999) suggested that this transient increase in IL-1β and
TNF-α expression is tightly controlled and these cytokines may function in triggering
secondary events, including the production of neurotrophins, which may be beneficial to the
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subsequent repair and regeneration process (Fagan and Gage, 1990; Lindholm et al., 1987).  In
contrast, prolonged increases in the production of proinflammatory cytokines (i.e. TNF-α;
Probert and Akassoglou, 2001) such as occurs in chronic conditions such as MS may be
detrimental to neural repair and cause secondary, irreversible damage to nervous tissue.
1.5.3 Inflammation
Reactive gliosis is a universal event after CNS injury and is a prominent pathological
feature in MS where reactive astrocytes constitute the major cell type in demyelinating plaques
(Raine, 1984).  After injury and/or during inflammation, TNF-α and IL-6 (Selmaj et al., 1990)
induce rapid proliferation and hypertrophy of astrocytes, which in turn secrete numerous
humeral factors (e.g. TNF-α, prostaglandins, and TGF-β; Hatten et al., 1991; Nieto-Sampedro
et al., 1983; Reier and Houle, 1988).  Therefore, secreted products of activated inflammatory
cells contribute to the reactive gliosis found in white matter diseases of the CNS.
MS lesions are commonly characterized by the presence of inflammatory infiltrates
consisting of lymphocytes and macrophages/microglia.  Oligodendrocytes and the myelin
sheaths they produce can be destroyed by different immunological mechanisms, such as direct
interaction with cytotoxic T-cells and T-cell cytokines (Selmaj et al., 1990), demyelinating
antibodies (Linington et al., 1988; Raine, 1984), and cytotoxic cytokines (i.e. TNF-α; Probert
and Akassoglou, 2001).  It has been suggested that inflammation in MS is induced by the
migration of activated T cells through the blood-brain barrier (Conlon et al., 1999).  INF-γ and
TNF-α, which are released as part of the inflammatory response, induce the capillary
endothelial cells to express vascular cell adhesion molecule (V-CAM) and class II molecules of
the MHC (Cannella and Raine, 1995).  Activated T cells express integrins, particularly alpha-4
integrin, and CD4, a member of the immunoglobulin supergene family, which bind to V-CAM
and MHC class II molecules, respectively.  T cells express very late antigen (VLA)-4, which
enables them to penetrate the endothelium.  VLA-4 was found on T cells that collected around
veins and capillaries and formed perivascular lymphocyte cuffs in acute MS lesions.  The
blockade of VLA-4 with cyclic peptides resulted in a reversion of clinical paralysis in EAE
animals (Dutta et al., 2000).  Once outside the blood vessels, the activated lymphocytes
expressed alpha 1 integrin, which binds to collagen type IV in the extracellular matrix.  T cells
here began to secrete enzymes such as MMPs, some of which, MMP-2 and MMP-9, also called
gelatinase A and B, specifically degrade collagen type IV (Brosnan and Raine, 1996; Conlon et
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al., 1999; Gijbels et al., 1994).  In this way activated lymphocytes gain access to the CNS
where they then induce an inflammatory reaction in the white matter, creating a situation that is
potentially very detrimental to CNS myelin and oligodendrocytes.
In the neuropil, activated Th1 cells may stimulate local microglia and hematopoetic
macrophages, through the secretion of cytokines such as TNF-α, INF-γ, lymphotoxin-α (also
known as TNF-β) and IL-12.  These in turn damage myelin and cause a further release of
potential antigens.  These cytokines are expressed in actively demyelinating MS lesions and
elevated levels of TNF-α correlate with disease activity and blood-brain barrier damage (Bitsch
et al., 2000).  However, TNF-α was recently shown to also protect neurons (Akassoglou et al.,
1997; Liu et al., 1998; Probert et al., 1995), to promote proliferation of oligodendrocyte
progenitors and to facilitate their remyelination of CNS axons (Arnett et al., 2001).
Lymphotoxin-α and TNF-α then stimulate macrophages, microglia and astrocytes to produce
nitric oxide and osteopontin (Steinman, 2001).  Merrill et al. (1993) suggested that nitric oxide,
one of the free radicals that in combination with antibodies, complement and TNF-α (Selmaj et
al., 1991) mediate damage to oligodendrocytes by macroglia, plays a role in lesion formation in
MS.  Osteopontin, an extracellular glycosylated bone phosphoprotein, further induces Th1
cytokine production, including INF-γ and IL-12, while downregulating Th2 cytokines such as
IL-10.  Th1 cytokines are found during MS exacerbation whereas Th2 cytokines may reduce
the size of MS lesions (Bielekova et al., 2000; Chabas et al., 2001; Kappos et al, 2000;
Steinman, 2001).
CD4+ helper cells are present mainly in perivascular areas of the CNS of MS patients,
whereas CD8+ cells are more prominent within the MS plaques and, therefore, are thought to
be more directly involved in the tissue destruction than are the CD4+ cell population (Babbe et
al., 2000; McCallum et al., 1987; Steinman, 2001; Woodroofe et al., 1986).  The number of
CD8+ cells also correlates better with the extent of acute axonal injury than does the number of
CD4+ cells (Bitsch et al., 2000).
A number of pro- and anti-inflammatory cytokines have been identified in the serum
and CSF of MS patients.  The expression of some of these markers, such as TNF-α (Bertolotto
et al., 1999; Rieckmann et al., 1998), as well as molecules like adhesion molecules (Kraus et
al., 2002; Rieckmann et al., 1998), MMPs (Waubant et al., 1999), chemokine receptors (Strunk
et al., 2000) and macrophage-related protein (e.g. MRP8/14; Bogumil et al., 1998), was shown
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to correlate with clinical course and lesion activity identified with MRI.  However, none of
these markers are specific for MS and the results of different studies remain controversial and
have not been adopted for use yet in clinical practice (Bertolotto et al., 1999, Bitsch et al.,
1998, Carrieri et al., 1998; Strunk et al., 2000; van Oosten et al., 1998).
1.5.4 Degeneration
The primary injury caused by direct mechanical trauma to the brain or spinal cord
encompasses the focal destruction of neural tissue.  The initial insult usually also results in a
progressive wave of secondary injury, which via a complex of harmful pathophysiological
mechanisms exacerbates the injury to CNS tissue and causes both necrosis and apoptosis.
Following either brain or spinal cord injury, the extracellular glutamate concentration rises
continuously leading, especially in an hypoxic environment (Choi, 1993), to overstimulation of
ionotropic α-amino-3hydroxy-5-methyl-4-isoxazoleppropionic acid (AMPA)/kainate receptors
and triggering excitotoxic cell death (Doble, 1999).  Precisely what factors expressed by dying
neurons trigger activation of microglia remains poorly characterized.  Damaged axons may
release adenosine triphophate (ATP), which could activate microglial cells via purinoreceptors.
The increase of ATP in culture medium was found to induce microglia membrane currents and
transmembrane Ca2+ fluxes (Haas et al., 1996; Illes et al., 1996; Kettenmann et al., 1993; Walz
et al., 1993).  High levels of extracellular potassium could also be responsible for mediating
certain aspects of glial cell activation.  Gehrmann et al. (1993) described a transient potassium
chloride-induced microglial activation, which was accompanied by short-lasting hypertrophy
and increased OX-42 expression, but not proliferation of microglia.
In both the acute and the chronic phases of MS, demyelination and axonal degeneration
have both been correlated with the severity of disabilities such as paralysis and the inability to
walk (Losseff et al., 1996; Trapp et al., 1998).  During the inflammatory reaction in both MS
and in EAE, lymphocytes, microglia and macrophages produce excessive amounts of
glutamate, which in turn activates AMPA/kainate receptors present on oligodendrocytes and
neurons (reviewed in Steinman et al., 2002).  Glutamate via its receptors induces calcium
influx and causes necrotic damage to oligodendrocytes and axons.  In the EAE animal model,
blocking the AMPA/kainate with quinoixalin derivatives (NBQX and MBQX) provided some
protection to the oligodendrocytes and axons from immune-mediated damage, although the
immune response to myelin antigens was not altered (Pitt et al., 2000; Smith et al., 2000).  It
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has been suggested that cytotoxic CD8+ T cells might mediate axonal damage in inflammatory
lesions of MS tissue (Babbe et al., 2000), in EAE mice (Huseby et al., 2001), and in vitro
(Medana et al., 2001).  Within MS plaques, axons are particularly vulnerable to degeneration
when exposed to nitric oxide (Smith et al., 2001a).  In addition, inflammatory edema increases
extracellular pressure contributing to axonal damage especially in CNS anatomical locations
such as the spinal cord where room for tissue expansion is limited (Shi and Blight, 1996).
Wujek et al., (2002) noted there was a 9% increase in the volume of the spinal cord during the
first attack in mice with relapse-remitting EAE.
1.6 Animal Models for Studying Demyelination and Remyelination
Many animal models have been developed to study the biology and pathology of
demyelination and remyelination in the CNS (Steinman, 1999), since it is not feasible to
perform experimental manipulations in humans.  These animal experiments provide
investigators with the opportunity to study the morphological, cellular and molecular
mechanisms involved in CNS demyelination and remyelination and are designed to mimic
some, but not all, of the pathological and neurological sequelae of MS.  The available animal
models fall into the following categories: (1) neurotoxicant-induced demyelination, including
EtBr (Yajima and Suzuki, 1979), lysolecithin (Hall, 1972) and cuprizone; (Blakemore, 1973),
(2) autoimmune-induced demyelination, including EAE (Raine and Traugott, 1984); and (3)
viral-induced demyelination, including corona-virus (Herndon et al., 1977) and Theiler’s
murine encephalomyelitis virus (TMEV) (Rodriguez et al., 1988).
1.6.1 Ethidium bromide
EtBr is a nucleic acid-binding neurotoxicant that has often been used to induce
demyelination because of its effectiveness in killing CNS glial cells, but not axons, when
injected into white matter.  This nucleic acid chelating agent reacts with the nuclei of those
cells residing in the vicinity of the injection (Blakemore, 1984; Yajima and Suzuki, 1979).
When injected in the dorsal column of the spinal cord, EtBr demyelinates axons of the dorsal
column sensory pathways by killing all the glial cells, including the oligodendrocytes,
astrocytes and microglia, in the vicinity of the injection.  However, axons are spared from the
toxic effects because their cell bodies lie elsewhere, specifically within the dorsal root ganglia
situated some distance from the site of EtBr injection.  Within three days, the EtBr-induced
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demyelinating lesion is composed of naked, demyelinated axons, and a total absence of glial
cells.  During lesion repair, invading macrophages scatter among the demyelinated axons and
around blood vessels, and cluster around disintegrating myelin sheaths to clean up the debris. In
addition, oligodendrocyte progenitor cells, astrocytes and Schwann cells all migrate into the
lesion site from the surrounding tissue to assist in neural repair.  The oligodendrocytes
contribute to the remyelination of the demyelinated axons in the central part of such EtBr
lesions, while Schwann cells remyelinate axons in the subpial areas and astrocyte-free regions
(Felts and Smith, 1996; Yajima and Suzuki, 1979).  Blakemore and Patterson (1978) were the
first to expose the animal’s spinal cord to x-irradiation prior to injection of EtBr, using 40
Grays of x-irradiation to suppress the spontaneous repair of the lesion by host glial progenitor
cells.  Such a lesion provides an excellent environment in which the myelinogenic properties of
grafted myelin-forming cells can be tested (Akiyama et al., 2001, 2002a, 2002b; Blakemore
and Crang, 1985; Franceschini and Barnett, 1996; Franklin et al., 1996; Groves et al., 1993).
1.6.2 Lysolecithin
Another neurotoxicant-induced animal model of demyelination is one using lysolecithin
(lysophosphatidyl choline), which was first used by Hall and Gregson (1971) for tissue in the
PNS.  Numerous investigators have subsequently injected lysolecithin into the CNS to
permeabilize the plasma membranes of cells (Blakemore et al., 1977; Blakemore, 1978;
Waxman et al., 1979). Due to its permeabilizing property lysolecithin affects oligodendrocytes,
thus resulting in demyelination in the immediate vicinity of the injection site (Blakemore,
1978).
Woodruff and Franklin (1999) compared lesions induced by either EtBr or lysolecithin
and found that a significant proportion of axons remained demyelinated for a longer time after
an EtBr injection than after a lysolecithin-induced demyelination.  Although, EtBr-induced
demyelinated lesions remyelinated more slowly than after lysolecithin injection, exposure to
the latter toxin did cause axonal damage.
1.6.3 Cuprizone
The neurotoxicant cuprizone, bis–cyclohexanone-oxaldihydrazone, is a copper chelator,
causes copper deficiency resulting in liver and brain tissue damage (Blakemore, 1972, 1973;
Ludwin, 1978; Suzuki and Kikkawa, 1969).  Rats, guinea pigs, and hamsters acquired a severe
spongiform encephalopathy after being on an 8 week cuprizone (0.2%) diet (Carey and
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Freeman, 1983).  In Wister male rats, only oligodendrocyte perturbation and intramyelinic
edema were observed (Love, 1988).  However, after a short 4 or 6 week exposure to a diet
containing cuprizone C57BL mice developed acute demyelination.  This occurred as a result of
the apoptotic death and depletion of mature oligodendrocytes within the corpus callosum
(Armstrong et al., 2002; Arnett et al., 2001; Hiremath et al., 1998; Mason et al., 2000, 2001;
Morell et al., 1998) and the superior cerebellar peduncle (Komoly et al., 1987; Stidworthy et
al., 2003).  Cuprizone treatment has been also used as a model for investigating the damage to
oligodendrocytes in Swiss, CD1, and ICI mice (Bakker and Ludwin, 1987; Blakemore, 1974,
Ludwin, 1978).  Oligodendrocytes are considered to be the main CNS target of cuprizone
because copper is required in high levels for proper mitochondrial function and
oligodendrocytes are much more metabolically active (Hiremath et al., 1998; Morell et al.,
1998) than other cell types in the central nervous system (Blakemore, 1973; Cammer and
Zhang, 1993).  When cuprizone was used in SJL mice before inducing EAE by PLP peptide
administration, it was found to inhibit both T-cell activation and function and to attenuate the
severity of the EAE (Emerson et al., 2001).
The cuprizone-induced demyelination is presumably mediated by
microglia/macrophages (Hiremath et al., 1998) since the blood-brain barrier remains intact and
there is no lymphocyte-induced inflammatory reaction (Bakker and Ludwin, 1987; Kondo et
al., 1987; McMahon et al., 2002).  After cuprizone removal from the diet, oligodendrocyte
progenitors start to proliferate and migrate from the subventricular zone.  They accumulate
within the demyelinating lesions and differentiate into mature oligodendrocytes, which in turn
remyelinate the demyelinated axons (Mason et al., 2000).  However, prolonged maintenance of
C57BL mice on the cuprizone diet resulted in the failure of remyelination (Mason et al., 2004).
Newly regenerated mature oligodendrocytes along with the resident progenitors become
progressively depleted within the chronically demyelinated corpus callosum.
1.6.4 Experimental autoimmune encephalomyelitis
The basis for the development of models of acute EAE emerged from “paralytic
accidents”, which were noted by Stuart and Krikorian (1928), Rivers et al. (1935), Kabat et al.
(1947) after rabies immunizations in which spinal cord inflammation led to clinical paralysis
(reviewed by Steinman, 1999).  An animal model of acute disseminated EAE by Rivers (1935)
was developed in monkeys once immunization against brain tissue was identified as the cause
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of the demyelination and paralysis (reviewed by Steinman, 1999).  A mixture of brain material
with complete Freund’s adjuvant, an emulsion made from killed mycobacteria tuberculosis,
was used by Kabat et al. (1947) to produce highly reproducible white matter inflammation,
demyelination and acute paralysis (reviewed by Steinman, 1999).
Although the actual mechanisms responsible for the extensive CNS demyelination in
MS remain to be elucidated, it is believed the pathology is related to autoimmunological
phenomena induced by viral infection or by exposure to an unknown allergen (see Section
1.5.2).  Once sensitized to an antigen present on CNS (but not PNS) myelin, lymphocytes enter
the neuropil and induce macrophages to engulf CNS myelin.  Myelin breakdown products
further stimulate the immune response in the form of a positive feedback loop.
The presence of autoimmune antibodies against myelin components in the sera of MS
patients lends support to the use of EAE as an animal model for MS (Raine et al., 1974, 1977;
Steinman, 1999).  Experimental animals can be immunized with MBP (Raine et al., 1974,
1977), or with a synthetic peptide analog of MBP that contains only the essential amino acids
(Fallis et al., 1989), with PLP, or with MOG (Steinman, 1999).  Then, adoptive transfer of T-
cells sensitized to myelin antigens is required to induce demyelination in the CNS.  When
induced in the guinea pig (Raine et al., 1974, 1977; Stone and Lerner, 1965; Traugott et al.,
1982) or mouse (Brown and McFarlin, 1981; Lublin et al., 1981), EAE presents the
neurological features of chronic CNS demyelination.  Experimental animals with EAE display
neurological signs such as weight loss, mouth wetting, some urinary and fecal incontinence,
and mild hindlimb paraparesis.  Incomplete recovery and progressive worsening follow after
each relapse of demyelination until the animals often eventually develop quadriparesis or
spastic paraparesis (Raine and Traugott, 1983).
These clinical features are the result of plaques of chronic demyelination scattered
throughout the white matter.  T cells, immunoglobulin, and complement play a role in the
demyelinating pathogenesis in EAE.  T cells reactive to myelin and antibodies to MBP, MOG,
and PLP can be detected in the CSF and in demyelinated areas from brains of animals with
EAE (Steinman, 1996).  Adhesion molecules, cytokines, chemokines, HLA molecules, and
metalloproteases are also critical participants in the development of inflammatory lesions
(Steinman, 1999).  Treatment with antibodies to α-integrin, CD4+ve T cells reactive to myelin
proteins, and to the cytokines IL-6 and TNF-α have been found to reverse paralysis in EAE
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(Conlon et al., 1999).  Targeting of these molecules is now in use in clinical trials on MS
patients (Steinman, 1999).  As a consequence of these studies, Copaxone, a synthetic polymer
analog of MBP (Arnon, 1996) and INF-β (Ruuls et al., 1996) were found to be effective in
reducing the relapse rate in MS.  On the other hand, INF-γ, also a critical cytokine tested in
clinical trials, was found to exacerbate disease, and a monoclonal antibody to TNF-α and a
soluble TNF-α receptor also the worsened clinical symptoms in MS patients (Steinman, 1999).
Although the EAE animal model gives rise to clinical signs comparable to those seen in
MS, such as demyelination and a sparing of astrocytes and microglia, EAE-induced lesions are
numerous and scattered all over the CNS with no experimental control over their location and
size.  In order to control where and how big the demyelinated lesions are, it is preferable to
inject a single dose of EtBr, which results in the demyelination of the axons without inducing
Wallerian degeneration.
1.6.5 Theiler’s virus
Theiler’s murine encephalomyelitis virus is a single-stranded RNA virus that belongs to
the Piconaviride family and was first described by Theiler in 1937 (reviewed in Oleszak et al.,
1995).  This virus has been reported to cause neurological and enteric diseases in susceptible
strains of mice, such as SJL (Dal Canto et al., 1996; Lipton and Jelachich, 1997; Monteyne et
al., 1997; Oleszak et al., 1995; Tsunoda and Fujinami, 1996).  After intracranial inoculation
with the Theiler’s virus DA strain, these mice develop a biphasic disease.  Acute disease occurs
within 3 to 12 days postinfection followed by late chronic demyelinating disease developing at
30 to 40 days postinfection.  Later, the animals die being unable to completely clear the virus
from their bodies (reviewed by Dal Canto et al., 1996; Monteyne et al., 1997; Oleszak et al.,
1995; Tsunoda and Fujinami, 1996).  In contrast, in resistant strains of mice, such as C57BL/6,
the animals develop only the early acute phase of the disease without progression into late
chronic demyelinating disease and these mice also clear the virus completely from their bodies
by about 3 weeks postinfection (Lipton, 1975; Lorch et al., 1981).
Both susceptible and resistant strains of mice develop acute polioencephalitis with
destruction of neurons to a variable degree, extensive mononuclear cell and lymphocyte
infiltration in the CNS (reviewed by Begolka et al., 1998; Drescher et al., 1997; Oleszak et al.,
1995; Rodriguez et al., 1988).  Variably intense and multifocal demyelinating lesions of the
cerebral hemisphere and spinal cord white/grey matter, mononuclear cell infiltrates in the
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spinal cord, progressive spinal cord atrophy and axonal loss were observed in DA-induced
susceptible mice 30 to 40 days after inoculation.  The inflammatory areas were concentrated in
the regions of the diencephalon, the hippocampus, the basal ganglia, the anterior horn of the
spinal cord and leptomeninges with sparing of the white matter during the early acute phase of
the disease.  The monocytes and T lymphocytes infiltrated small and medium-sized
parenchymal blood vessels forming perivascular cuffings and foci of ischemic-type coagulative
necrosis.  During the late chronic stage, myelin loss, myelin-laden phagocytic macrophages,
axonal swellings, perivascular and leptomeningeal infiltrates were detected within the
demyelinating lesions, which involved the spinal cord anterior, lateral, and dorsal columns with
preferential susceptibility of the thoracic segments.
1.7 Cell Transplantation: A Potential Therapeutic Approach to Treating Multiple
Sclerosis
Remyelination by transplanted myelin-forming cells has been explored extensively in
animal experiments as a possible approach for achieving repair in demyelinating diseases.
There are several different cell types for such transplantation, including oligodendrocytes and
their progenitors, Schwann cells, OECs, bone marrow cells, neuronal stem cells, tanycytes and
enteric glia.  Franklin and Barnett (2000) reviewed the properties of the ideal cell for
transplantation including an ability to remyelinate CNS axons, availability of cell source,
migratory and survival capabilities, compatibilities with astrocytes, and potential vulnerability
of the myelin produced by the cell candidate.
Oligodendrocytes are normally responsible for CNS myelination and are the cells that
are typically targeted by the different approaches being used to induce demyelination in animal
models.  Therefore, the ability of oligodendrocytes in these animal models to sufficiently
respond to demyelination is severely compromised.  This leaves oligodendrocyte progenitor
cells and stem cells as the main glial contributors of the CNS to the remyelination of the axons.
There is a wealth of experimental evidence demonstrating the production of new myelin in
animals after transplantation of oligodendrocyte lineage cells (Barnett et al., 1993; Duncan et
al., 1992; Franklin and Blakemore, 1997; Groves et al., 1993; Warrington et al., 1993).  Human
oligodendrocyte progenitors have also been shown to myelinate congenitally dysmyelinated
axons in the mouse brain (Windrem et al., 2004).  Remyelination by transplanted cells was also
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accompanied by both improved conduction (Utzschneider et al., 1994) and functional recovery
(Jeffery et al., 1999).  Therefore, oligodendrocyte progenitors would be the most suitable for
cell transplantation in MS.  However, the isolation of oligodendrocytes from neural tissue is a
complex process, which not only yields low cell numbers but also lacks broad ethical approval.
Although Penderis et al. (2003) found no depletion of oligodendrocyte progenitors after
repeated episodes of focal EtBr-induced demyelination in the rat caudal cerebellar peduncle,
several authors have suggested that repeated demyelination in MS results in the depletion of
oligodendrocyte progenitors (Niehaus el al., 2000; Wolswijk, 2002).  Furthermore, the ongoing
immunological process directed against myelin and oligodendrocytes might attack the
transplanted cells.
Schwann cells normally myelinate only PNS axons; however, it has been known for
many years that in some conditions these cells can and will remyelinate axons within the
confines of the CNS (Blakemore and Crang, 1985, 1989; Blakemore et al., 1995).  In addition
to experimental data, Schwann cells contribute to the spontaneous remyelination in MS
(Ghatak et al., 1973; Itoyama et al., 1983, 1985).  Although Schwann cells myelinate only a
single axon in contrast to oligodendrocytes, it has been shown that transplantation of Schwann
cells into demyelinated spinal cord can restore normal conduction properties of CNS axons
(Honmou et al., 1996).  In order for these cells to contribute to remyelination, unlike mature
oligodendrocytes, the Schwann cells must migrate from the PNS towards the demyelinated area
or be grafted into the lesion.  The Schwann cell migration towards the demyelinated area was
observed only when astrocytes were absent from a lysolecithin-induced lesion in irradiated rat
spinal cord (Harrison, 1985).  Similar to what is found in animal models, Schwann cells can
sometimes be identified inside the astrocyte-poor central area of MS plaques (Itoyama et al.,
1983).  Unlike oligodendrocytes, human Schwann cells are readily accessible from the sciatic
nerve, where peripheral myelin is intact in MS patients.  Schwann cells can be expanded in
vitro (Rutkowski et al., 1995; Van den Berg et al., 1995) and used after cryopreservation
(Kohama et al., 2001).  Therefore autologous Schwann cells could be harvested from an MS
patient, expanded under appropriate conditions in vitro and injected directly into demyelinated
lesions.  The advantages of using Schwann cells are the accessibility of these myelinating cells,
the possibility of autologous transplantation without the need of subsequent immunosupression,
and the potential for avoidance of immune attacks against CNS myelin in MS.  However,
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Schwann cells are not a normal cellular component of the undamaged CNS.  These cells
migrate into areas of the damaged CNS, where they remyelinate axons only in astrocyte
depleted areas of the CNS (Blakemore, 1975).  Another potential problem for the use of
Schwann cells is the inhibitory effect of astrocytes on Schwann cell remyelination of CNS
axons (Franklin and Blakemore, 1993; Harrison, 1985; Woodruff and Franklin, 1999).  In
addition, MS plaques are disseminated throughout the CNS neuropil, thus Schwann cells would
be required to migrate to many lesions.  These cells have shown limited migratory ability when
injected into an animal’s spinal cord in the presence of a toxin-induced demyelinated lesion
(see Section 1.8.2).
 Bone marrow cells (BMCs) have recently also been considered as a potential candidate
for transplantation as part of a therapeutic approach in the treatment of demyelinating diseases.
BMCs are known to be a source of circulating erythrocytes, platelets, monocytes, granulocytes,
and lymphocytes (Phinney et al., 1999).  BMCs can be obtained from an individual’s bone
marrow and, therefore, they have been under the scope of researchers as a potential candidate
for autologous cell therapies.  Several studies have used BMCs isolated from rat femoral bones
for transplantation into the demyelinated (x-irradiation/EtBr) spinal cord of adult rats (Akiyama
et al., 2002a; Sasaki et al., 2001).  Sasaki et al. (2001) observed predominantly a peripheral
pattern of myelination, reminiscent of that of Schwann cells, after BMC transplantation,
whereas Akiyama et al. (2002a) reported both peripheral and central types of remyelination of
CNS axons, with a concomitant improvement in conduction velocity.  Although x-
irradiation/EtBr-induced demyelination has been reported to lead to delayed endogenous
remyelination (Blakemore and Crang, 1985; Honmou et al., 1996), there is a possibility that
host Schwann cells were recruited from outside the lesion area as a result of performing the
injection procedure of BMCs.  Thus, host Schwann cells could have produced the peripheral
type of remyelination seen in rats that received BMC transplant.  This interpretation would be
consistent with BMCs secreting various growth factors that could have created an environment
suitable for Schwann cell migration and remyelination.  Admittedly, BMCs have been also
reported to differentiate into non-hematopoietic and non-lymphopoietic cells (Caplan, 1991;
Owen, 1988; Prockop, 1997) and recently also to produce neurons and astrocytes when grown
in cell culture (Woodbury et al., 2000).  In vivo experiments have shown that BMCs possess the
capacity to differentiate into astrocytes when transplanted into normal (Azizi et al., 1998) and
57
ischemic (Eglitis et al., 1999) brain or lead to neuronal differentiation when injected
intravenously (Brazelton et al., 2000; Mezey and Chandross, 2000).  Therefore, the fate of
transplanted BMCs requires further study to investigate further possible lineages these cells
might take in their response to a new environment.
Tanycytes present in the mediobasal hypothalamus and pituicytes from the
neurohypophysis were found to express a distinctive set of immunological markers in common
with OECs and nonmyelinating Schwann cells, namely p75NTR, O4 antigen, estrogen
receptor-α type, and IGF-1 (Gudino-Cabrera and Nieto-Sampedro, 2000).  Gudino-Cabrera and
Nieto-Sampedro (2000) suggested that OECs, tanycytes, and pituicytes share a common
phenotype and are three members of a family of Schwann-like macroglia of the CNS.  They
referred to these three glial cells as aldynoglia, a term derived from a Greek word meaning “to
make grow”.  It appears that tanycytes and pituicytes, like OECs, provide a more hospitable
microenvironment for growing axons in the CNS, thus making them ideal candidates for glial
cell transplantation into areas of CNS injury.  Tanycytes have been shown to myelinate DRG
neurites in vitro (Gudino-Cabrera and Nieto-Sampedro, 2000), and also promote the growth of
CNS axons after grafting into the CNS of adult rats (Prieto et al., 2000).  Although tanycytes
and pituicytes have been shown to promote axonal regeneration and myelination of DRG
neurites, the harvesting procedure of these cells in humans is complicated and would require a
challenging neurosurgical manipulation.
Dogiel (1899) was the first to describe the glial cells of the enteric nervous system
(Brehmer et al., 1999).  Enteric glia (EG) have been shown to facilitate the regeneration of
dorsal root axons through the normally non-permissive environment of the dorsal root entry
zone (DREZ) into the spinal cord and as well as an incomplete functional recovery of the
cutaneous trunci muscle reflex after injury (Jiang et al., 2003).  However, EG can only be
obtained by means of an abdominal surgical procedure, which can lead to unnecessary
postsurgical complications.
Neuronal stem cells (NSCs) are multipotent cells, which have been identified in the
developing and adult CNS (Gage et al., 1995; Johe et al., 1996; Lois and Alvarez-Buylla, 1993;
Palmer et al., 1997; Reynolds and Weiss, 1992).  Grafts of normal mouse clonal NSCs injected
into the brain ventricles on newborn shiverer mice have been shown to effectively reverse the
pathology and improve some symptoms of the mutant strain (Yandava et al., 1999).  The
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researchers found that most of the transplanted cells migrated through the brain and
differentiated into oligodendrocytes.  The injection of NSCs derived from wild type mouse
either intravenously or into the cerebral ventricles of C57/BL mice with MOG-induced EAE
resulted in a marked increase in the numbers of oligodendrocyte progenitors within
demyelinated areas, a decreased extent of demyelination and axonal loss, and functional
recovery of the mice receiving such transplants (Pluchino et al., 2003).  Transplantation of
human NSCs into demyelinated rat spinal cord resulted in axonal remyelination similar to that
of Schwann cells (i.e. PNS-type myelin) and improvement of conduction velocities of the
remyelinated axons (Akiyama et al., 2001).
NSCs can be isolated from the adult human brain only during a neurosurgical
procedure, such as collection of a biopsy (Kukekov et al., 1999).  Addition of growth factors
such as EGF and basic fibroblast growth factor (bFGF) to culture medium is required to expand
these cells in vitro (Cattaneo and McKay, 1990; Gensburger et al., 1987; Hammang et al.,
1997; Kalyani et al., 1997; Svendsen et al., 1996).  Mouse NSCs have been shown to
differentiate into both neurons (Brustle et al., 1995; Stemple and Anderson, 1992; Svendsen et
al., 1996) and oligodendrocytes (Hammang et al., 1997; Milward et al., 1997) when
transplanted into the embryonic and neonatal CNS but only into astrocytes when grafted into
the adult CNS (Lundberg and Bjorklund, 1996).  Therefore, these cells differentiate along the
different cell lineage depending on environmental signals.  Fetal tissue is considered to be the
best current tissue source for human neural stem cells; however, unresolved ethical issues are a
major concern in future clinical applications.  The other important issue is that stem cells are
highly proliferative and thus also bear the risk of tumor formation (Bjorklund et al., 2002).
Although stem cell research has a lot of questions to be answered, the potential of such an
approach should not be neglected.
OECs are the glial cells that ensheath the olfactory axons of the first cranial nerve
(Doucette, 1984, 1990, 1995; Ramon-Cueto and Avila, 1998; Ramon-Cueto and Valverde,
1995).  Although in vivo OECs express only a nonmyelinating phenotype, Devon and Doucette
(1992, 1995) demonstrated their myelinating ability in vitro, which was independently
confirmed in vivo by several other research groups (Franklin et al., 1996; Imaizumi et al., 1998;
Li et al., 1997, 1998; Lakatos et al., 2003).  The regenerative effort of most types of axons
within the CNS fails to support more than a minimal amount of growth (Kiernan, 1979; Reier
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and Houle, 1988; Fawcett, 1998), but olfactory axons are usually, in the absence of
experimental intervention, successful at reinnervating the olfactory bulb (Graziadei and Monti
Graziadei, 1979; Barber and Lindsay, 1982; Doucette et al., 1983; Doucette, 1990).  It appears
the growth of olfactory and non-olfactory axons is favored by a permissive OEC environment
(Doucette, 1990, 1995; Ramon-Cueto and Valverde, 1995; Franklin and Barnett, 1997;
Fawcett, 1998; Ramon-Cueto and Avila, 1998).
A number of studies over the past several years have demonstrated the ability of OECs
to support the growth of non-olfactory CNS axons in vivo (Lustgarten et al., 1991; Ramon-
Cueto and Nieto-Sampedro, 1994; Smale et al., 1996; Li et al., 1997, 1998; Perez-Bouza et al.,
1998; Ramon-Cueto et al., 1998; Navarro et al., 1999).  OECs were shown to facilitate the
regeneration of primary afferent axons after rhizotomy across the DREZ of the spinal cord
(Ramon-Cueto and Nieto-Sampedro, 1994; Navaro et al., 1999), cholinergic fibers of the
fimbria/fornix pathway across a cavity formed after aspiration of a large portion of the fiber
pathway (Smale et al., 1996), lesioned corticospinal tract axons (Li et al., 1997, 1998; Nash et
al., 2002) and after spinal cord transection injury (Ramon-Cueto et al., 1998, 2000).  Therefore,
OECs have been receiving increased attention as possible candidates for neural repair through
the grafting of myelinating glia.
Cellular interactions within demyelinating CNS lesions are complex and ultimately
determine whether oligodendrocytes or Schwann cells will assume primary responsibility for
remyelinating the axons.  Astrocytes are one of the key players in determining which glial cell
type will remyelinate axons in each demyelinated area of the CNS (Blakemore et al., 2003).
Cells of the oligodendrocyte lineage are given such preference in the presence of astrocytes.
However, it is unlikely that any one glial cell type can correct all of the problems in injured
CNS tissue.  A cell that can adopt several different roles is needed.  OECs were demonstrated
to possess this feature, being able to switch their phenotype from that resembling an astrocyte
to one more like that of a myelinating Schwann cell (Devon and Doucette, 1992, 1995;
Doucette, 1995).  Due to their highly malleable phenotype, OECs will very likely be able to
combine the roles of astrocytes and Schwann cells when transplanted into a lesion cavity
(Doucette, 1995).  Even if OECs may not promote axonal growth better than Schwann cells, or
any other potential candidate, OECs might differ from Schwann cells in restoring the glia
limitans and blood brain barrier and allowing maximal re-entry of axons into the host tissue.
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Schwann cells fail to integrate into the CNS, which in part is due to astrocytic
perturbation of the neuron-Schwann cell interaction and a consequent lack of ensheathment and
myelination (Blakemore and Crang, 1989; Franklin et al., 1992; Guenard et al., 1994).  The
migratory ability of Schwann cells within the CNS parenchyma is also limited, being mostly
confined to the vicinity of the graft when they are transplanted into the cerebral hemisphere
even of newborn shiverer mice (Baron-Van Evercooren et al., 1992).  Eventually, grafted
Schwann cells are usually extruded from the CNS, even after remyelinating axons in the spinal
cord of mice are exposed to an intracisternal injection of cholera toxin B (Jasmin et al., 2000).
Several authors suggested that astrocytes inhibit the migration of Schwann cells within the
parenchyma of the CNS (Fawcett and Asher, 1999; Franklin and Blakemore, 1993).  Schwann
cells and astrocytes have been shown to avoid one another when they are co-cultured in the
same culture dish.  Astrocytes either grown together with Schwann cells in vitro (Lakatos et al.,
2000) or after transplantation of the latter cells into the adult rat spinal cord were induced to
increase the expression of axon growth inhibitory chondroitin sulfate proteoglycans (Lakatos et
al., 2003).
The repair of the CNS damage in patients with demyelinating disorders remains a major
challenge for physicians and neuroscientists.  Therapeutic cell transplantation has shown
potential in promoting CNS repair.  However, what cell or combination of different cells is the
best for transplantation?  The cell candidate should be of a nature that avoids the need for
immunosupression and this can be achieved if the cells were obtained from the patient.  Other
important issues are the cell source, the approach for cell harvesting with minimal damage to
the patient, the efficiency of both the harvesting technique and the tissue processing to yield a
large enough number of cells.  The chosen cell has to have the ability to form a myelin sheath
around demyelinated axons, even in the presence of activated host cells (i.e. astrocytes and
microglia) and even within an inflammatory environment.  In addition, the transplanted cells
will be required to migrate to multiple demyelinated areas as seen in MS and remyelinate axons
at least in those located in the vitally important parts of the CNS like brainstem.
1.8 Migration of Myelinating Glia Within Central Nervous System
If glial cell transplantation is to be considered a realistic therapy for the repair of
demyelinated CNS lesions in disorders such as MS, a number of important questions have to be
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resolved, among which is the ability of each glial candidate to migrate following implantation
into the CNS.  This is a very important issue in MS since transplanted cells will be required not
only to grow and myelinate within the extent of a single demyelinated area but also to migrate
between at least several plaques so that a minimal number of cell injections will be needed to
repair multiple lesions.
1.8.1 Oligodendrocyte Migration
The migratory abilities of oligodendrocytes and their progenitors have been studied
extensively both in vitro (Armstrong et al., 1990; Milner et al., 1997) and in vivo (Fruttiger et
al., 1999; Milner and Ffrench -Constant, 1994; Milner, 1997; Niehaus et al., 1999; Osterhout et
al., 1999).  The oligodendrocyte progenitors have been shown to be highly motile (Gansmuller
et al., 1991; Small et al., 1987).  Growth factors such as PDGF (Armstrong et al., 1990;
Fruttiger et al., 1999; Osterhout et al., 1999) and bFGF (Milner et al., 1997) promote
oligodendrocyte progenitor migration either in vitro (Armstrong et al., 1990; Milner et al.,
1997) or in vivo (Fruttiger et al., 1999; Osterhout et al., 1999).  In contrast to oligodendrocyte
progenitors, more mature oligodendrocytes bear multiple processes, which probably impede the
migratory capabilities of these cells.  Oligodendrocyte maturation correlates with down-
regulation of integrin expression (i.e. α v β 1, α v β 3, α v β 5 and α v β 8) by
oligodendrocytes, receptors known to play an important role in cell migration (Milner and
ffrench-Constant, 1994; Milner, 1997).  Endogenous oligodendrocytes have been observed
migrating from the subventricular zone toward the lysolecithin-induced lesion in the corpus
callosum of adult rat (Nait-Oumesmar et al., 1999).
Transplantation of cells of the oligodendrocyte lineage has also shown that progenitor
cells migrate further in vivo than do the more mature cells (Warrington et al., 1993; Archer et
al., 1997).  When grafted into uninjured CNS tissue, oligodendrocyte progenitor cells migrated
for up to 3-4 mm in the rostral-caudal direction from the injection site in the spinal cord of the
myelin deficient newborn rat (Tontsch et al., 1994) and for 20 mm along the dorsal columns of
Shiverer rat pups (Archer et al., 1997).  When CG4 cells (oligodendrocyte progenitor cell line)
were transplanted into the normal rat spinal cord, their migration and survival was found to be
limited to areas of the injection site (Franklin et al., 1996).  In contrast, following
transplantation into the x-irradiated spinal cord of adult rats, CG4 cells migrated from the
grafting site (i.e. ventral funiculi) through both white and grey matter towards the x-
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irradiation/EtBr-induced demyelinated lesion in the dorsal funiculi (Franklin et al., 1996).
Baron-Van Evercooren et al. (1996) observed migration of transplanted oligodendrocyte
progenitors from the grafting site towards a lysolecithin-induced demyelinated lesion in adult
wild type and Shiverer mouse spinal cords.  Migrating cells were identified along the meninges,
perivascular space, as well as the outer surface of myelin sheaths in CNS wild type and
Shiverer mouse white matter.  In summary, it has been shown that the more immature cells of
the oligodendrocyte lineage migrate the best within the CNS are.
1.8.2 Schwann Cell Migration
Schwann cells have been reported to migrate into the CNS and myelinate CNS axons in
a number of developmental and pathological studies (reviewed in Franklin and Blakemore,
1993).  Blakemore (1975) observed Schwann cells migrating along perivascular spaces and
reaching demyelinated axons after an injection of lysolecithin into the spinal cord of adult rats
and after the consequential destruction of the glia limitans in this area of the CNS.  The
migratory ability of Schwann cells grafted into the cerebral hemisphere of newborn Shiverer
mice is mostly confined to the vicinity of the graft (Baron-Van Evercooren et al., 1992).
Schwann cells from an immortalized cell line (MSC80) but not Schwann cells that were
obtained from the sciatic nerves of newborn rats migrated towards a focal lysolecithin-induced
demyelinated lesion of the Shiverer mouse spinal cord (Baron-Van Evercooren et al., 1992,
1993).  The migrating MSC80 cells used the ependyma, meninges, and blood vessels as the
main migratory routes rather than white matter tracts.  Limited migration of Schwann cells
along perivascular routes and intrafascicularly within the fimbria was also noted after grafting
primary Schwann cells into the hippocampus (Brook et al., 1993; Raisman et al., 1993).  These
Schwann cells extended long fiber-like cytoplasmic processes that extended singly amongst
and parallel to the orientation of the host glial cells and the axons in the fimbria (Raisman et al.,
1993).  Although the transplanted Schwann cells induced a transient but marked hypertrophy of
host fimbrial astrocytes, the migration of the donor Schwann cells did not appear to be
impeded.  In other studies describing Schwann cell migration, blood vessels (and the glia
limitans) were also found to be favored routes of migration (Blakemore, 1984; Blakemore et
al., 1986; Langford and Owens, 1990).  Laminin, a glycoprotein constituent of blood vessel
basal lamina, has been reported to facilitate migration of Schwann cells in vitro (McCarthy et
al., 1983).  Iwashita and Blakemore (2000) created areas of persistent demyelination in the
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dorsal funiculus of the rat thoracolumbar spinal cord by injecting EtBr into white matter
exposed to x-irradiation.  Their results indicated that significant numbers of transplanted
Schwann cells were not attracted to migrate through normal tissue towards the demyelinated
area (Iwashita and Blakemore, 2000).  Schwann cells also show poor long-term survival after
transplantation into either normal or x-irradiated adult white matter (Iwashita et al., 2000).
Fawcett and Asher (1999) suggest that astrocytes inhibit the migration of Schwann cells via the
secretion of chondroitin sulphate proteoglycans.
1.8.3 Olfactory ensheathing cell migration
Several studies have reported that OECs have the ability to migrate within the
microenvironment of the injured spinal cord when Hoechst prelabelled cells were grafted very
close to the site of injury (Navarro et al., 1999; Ramon-Cueto and Nieto-Sampedro, 1994;
Ramon-Cueto et al., 1998, 2000).  Transplanted neonatal OECs expressing β-Galactosidase (β-
Gal) were found to migrate from the DREZ into the dorsal horn and adjacent dorsal funiculus
(Riddell et al., 2004).  However, other reports presented evidence for little migration of virally-
infected OECs that were grafted directly into the cystic cavity of a spinal cord contusion injury
(Boyd et al., 2004; Plant et al., 2003).  These data may indicate that OECs migrate best within
the injured CNS when grafted close to, but not within, the area of tissue injury.  OECs may also
prefer to stay within the lesion site when grafted directly into it and help the host tissue
facilitate a more hospitable environment for axon regeneration.  Takami et al. (2002) grafted
virally infected OECs into the cystic cavity of the compression injury of the spinal cord in the
adult rat but after 12 weeks found no β-Gal+ve OECs within or around the damaged area;
therefore, this study raises the question as to whether the OECs actually survived being grafted
into the lesion cavity.  When mouse OECs derived from the lamina propria of the olfactory
mucosa were grafted into the DRG of adult rats they migrated towards the DREZ of the spinal
cord but did not cross into the CNS and also failed to promote the regeneration of dorsal root
axons across the DREZ (Ramer et al., 2004).
In contrast to the limited migration of OECs observed in spinal cord injury, these cells
have been reported to migrate within the large demyelinated (x-irradiation/EtBr) area induced
in the dorsal funiculi of the adult rat spinal cord (Imaizumi et al., 1998).  OECs grafted into a
focal electrolytically induced lesion of the corticospinal tract at the upper cervical segment of
the rat spinal cord not only infiltrated the lesion area but also extended beyond it for at least 2-3
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mm in the caudal direction (Li et al., 1997, 1998).  Interestingly, when cat OECs were
transplanted into the medial longitudinal fasciculus of adult cats immediately caudal to a
transection, Gudino-Cabrera et al. (2000) found the cells migrated retrogradely towards the
abducens nucleus but failed to find any anatomical or functional evidence for the regeneration
of the axonal projection from the abducens nucleus towards the oculomotor nucleus.
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2. MATERIALS AND METHODS
2.1 Olfactory Ensheathing Cell Cultures
2.1.1 Dissection of embryos
Breeding colonies of adult Wistar rats were kept over one night in an animal room with a
12/12 hour light/dark cycle (Doucette, 1993). The next morning the females were checked for the
presence of a vaginal plug; if present, this day was designated embryonic day 1 (E1). The
pregnant rats were placed in a chamber filled with 5% CO2 for 5 -10 min and then cervically
dislocated.  Using sterile techniques, the uterine horns of pregnant rats (E18) were exposed by
transabdominal cesarean section, fetuses dissected from the surrounding tissue, and immersed in
a room temperature bath of Hank's balanced salt solution (HBSS).  To reduce developmental
variation, only embryos at Theiler stage 23 (Theiler, 1972) of development were used for these
experiments.  Immediately after dissection, embryos were observed under a dissecting
microscope in order to determine their developmental stage and separate the embryos at Theiler
stage 23 from those of younger or older stages (1-2 embryos per litter).  Four phenotypic features
were used to identify embryos at Theiler stage 23 of development.  The first feature was the
presence of hair follicles over all the skin of the embryos and a second feature was the complete
separation and divergence of the digits in both the forelimbs and the hind limbs.  A third feature
was an ear pinna that covered more than half of the external auditory meatus and the fourth
feature was the presence of an umbilical hernia.  The Theiler stage 23 embryos were decapitated,
their heads transferred to a 1:1 mixture Dulbecco's Modified Eagle's Medium (DMEM; 4.5 g/L
of glucose; Sigma-Aldrich Canada Ltd.) and F12 containing 10% fetal bovine serum (FBS;
Hyclone, Logan, UT) and then split in half along the sagittal midline.
2.1.2 Disaggregation of tissue and setting up cell culture
The olfactory bulbs were dissected from embryo heads as described in Doucette (1993,
2001).  Each head was transferred into a 60 mm Petri dish containing growth medium
(DMEM/F12/10% FBS).  Under a dissecting microscope, the heads were fixed upright with a
pair of Dumont Forceps inserted into the tissue lying to either side of the nose.  The skin,
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subcutaneous tissue, and fibrous tissue of the cranium were cut between the presumptive cerebral
hemispheres and cerebellum and then between the right and left cerebral hemispheres along the
midline, beginning posteriorly and continuing as far forward as the presumptive nasal bones of
the skull.  The prongs of the Dumont Forceps were placed between the cerebral hemispheres and
the cerebellum to fix the embryo's head while cutting it with the scalpel in the sagittal plane, thus
completely separating each head into a right and left half.  Using a pair of spring scissors, the
olfactory nerves were cut along the ventral surface of the bulb.  The exposed olfactory bulbs
were dissected out of their position in the anterior cranial fossa by cutting the olfactory peduncle.
The bulbs were collected in a 60 mm Petri dish, while the rest of the embryo's head was
discarded.  This dissection procedure for obtaining the olfactory bulbs was repeated for each
fetus.
The ONL was dissected from each olfactory bulb as follows.  The prongs of one pair of
forceps were placed inside the bulb's cut end that previously had been attached to the olfactory
peduncle.  The free edge of the outer ONL was grasped with a second pair of forceps and gently
peeled off the deeper layers of the bulb primordium.  The ONLs were collected in a growth
medium (DMEM/F12/10% FBS).  This peeling procedure removed almost all of the ONL from
the entire circumference of the bulb, with the exception of an occasional small tag of olfactory
bulb tissue.  The dissected ONLs were gently forced through a Nitex mesh (75 µm pore size) to
disaggregate the cells mechanically.  The resulting cell suspension was diluted to a final volume
of 40 ml in DMEM/F12/10% FBS.  Five milliliters of the cell suspension were plated inside each
of eight 25 cm2 Falcon flasks. For immunostaining, 2 ml of the cell suspension were placed into
each of ten 35 mm Falcon dishes with glass coverslips inside and 5 ml of the remaining cell
suspension were plated inside each of four 25 cm2 Falcon flasks.  All cultures were incubated at
37°C in a humidified atmosphere of 5% CO2 in air.
2.1.3 Purification and expansion of cell culture
Beginning with the first feed after 3-4 days in vitro (DIV), twice a week (for 2 weeks) the
cultures were fed with a modification of the G5 medium (mG5) of Bottenstein (1985). The mG5
medium consisted of DMEM (4.5 g/l of glucose) as the basal medium, to which insulin (5
mg/ml), transferrin (50 mg/ml), selenium (5.2 ng/ml), hydrocortisone (3.63 ng/ml), and biotin
(10 ng/ml) were added.  Any meningeal fibroblasts contaminating the sparse primary cell
cultures did not grow very well in this serum-free condition.  In comparison to the G5 medium,
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the mG5 medium contained neither epidermal growth factor nor fibroblast growth factor, which
were found not to be mitogenic for fetal OECs (Doucette and Devon, 1995).  After 10-14 days in
mG5, the medium was changed to DMEM/F12/10% FBS and the cultures were fed with this
medium until they approached confluency.
2.1.4 Harvesting cells and long-term storage of cells
Cell cultures were rinsed three times with Puck's balanced salt solution (PBSS) to remove
all traces of serum.  The cultures were then incubated in 0.025% trypsin/0.01%
ethylenediaminetetraacetic acid (EDTA)/PBSS for 5 min at room temperature.  Using the
phase contrast microscope to monitor the progress of the trypsinization, the flasks were lightly
tapped on the countertop several times.  The trypsin solution was then triturated to assist in
dislodging the cells.  The resulting cell suspension was centrifuged at the relative centrifugal
force of 160 G (800 RPM, for 10 min) and then resuspended in DMEM/F12/10% FBS.  In order
to determine the number of viable cells, 400 µl of the cell suspension was stained with 0.3%
Nigrosin dye.  Dead or dying cells were stained purple-black by the Nigrosin dye, whereas living
(i.e. viable) cells remained unstained.  The number of viable (i.e. Nigrosin-excluding) cells were
counted in four corners of an Improved Neubauer Levy Hemacytometer (Hausser Scientific
Partnership, Horsham, PA, 19044). The number of viable cells per ml was calculated using the
following formula:
 Total count x 10 x 1000 x 5 = number of viable cells/ml.
             4                                4
Using this count, the cell suspension was diluted in DMEM/F12/10% FBS to the desired cell
concentration and 1 ml of the resulting cell suspension was placed into each of several Nalgene
cryovials (≈1x106 cells per 1 ml of medium).  To each vial, 110 µl of dimethyl sulfoxide
(DMSO) was added prior to sealing the cryovials and placing them into a NALGENE Cryo 1°C
Freezing Container (Nalge Company, Rochester, N. Y., USA) containing isopropyl alcohol. The
NALGENE Cryo Container was stored overnight in a -70°C freezer. The following morning, the
cryovials were transferred to the vapor phase of liquid nitrogen in a Locator (JR Plus, Cryo
Biological Storage System) for long-term storage.
2.1.5 Prelabelling cells with DiI
When the cell cultures approached confluency the cells were ready to be labelled by DiI.
The cell cultures were first trypsinized, as described in Section 2.1.4, after which the resulting
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cell suspension was incubated in DMEM/F12/10% FBS containing 40 µg/ml of DiI for 1 hour at
37°C in a 5% CO2 atmosphere.  At the end of the 1 hour incubation the cell suspension was
centrifuged at 160 G (for 10 min) and resuspended in DMEM/F12/10% FBS.  Following a
second centrifugation and resuspension in DMEM/F12/10% FBS, a cell count was performed to
determine the number of viable cells (see Section 2.1.4) and the DiI-prelabelled OECs were
frozen in aliquots of ~1x106 cells per 1 ml, as described in Section 2.1.4.
2.2 Immunofluorescent Staining of Cell Cultures
Some OEC cultures initiated at the time of the initial dissection were plated into 35 mm
dishes containing uncoated glass coverslips to assess the phenotype of the cells in the primary
cultures. In addition, when some of the OEC primary cell cultures were close to being confluent
(e.g. ~80%) they were trypsinized (see Section 2.1.4) and a cell suspension of OECs was plated
into 35 mm dishes at a density of 5x104 cells per ml to examine the immunocytochemical
phenotype of the cells.  All cultures were incubated at 37°C in a humidified atmosphere of 5%
CO2 in air.  The primary cultures were fed with mG5 medium for 14 days followed by
DMEM/F12/10% FBS for an additional 14-21 DIV and harvested after a total of 28-35 DIV.
The secondary cultures were fed with DMEM/F12/10% FBS for the entire 10-14 DIV prior to
harvesting the cultures for staining.
2.2.1 Intracellular antigens
Immediately after the coverslips were removed from the dishes, the cells were fixed in
either Zamboni's fix, consisting of 0.2% picric acid and 4% paraformaldehyde in 0.2 M
phosphate buffer (pH 7.4), or in a mixture of 0.2% picric acid/4% paraformaldehyde/0.05%
glutaraldehyde (PPG) in 0.2 M phosphate buffer solution (PBS, pH 7.4) for 15 min at room
temperature. The Zamboni's fixative was used when the cell culture was to be stained with
mouse anti-nestin; the PPG fixative was used when staining the cultures with the rabbit anti-
S100β antibody.  After fixation, the cell cultures were rinsed twice in 0.03M PBS (30 sec each at
room temperature), followed by a third PBS wash for 30 min at 4°C and a fourth PBS rinse for 1
min at room temperature.  The cells were then incubated for 5 min in a solution of 0.2% Triton
X-100 (TX-100) in order to permeabilize the cell membrane and were then washed in PBS for 10
min.  A 10 min blocking in 2% skim milk powder (SMP) was followed by a 30 min incubation at
room temperature in a 1:1 mixture of the following antibodies: mouse anti-nestin (1:100) and
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rabbit anti-S100β (1:200). These antibodies were diluted in 1% SMP/0.2% TX-100 in 0.03 M
PBS.  The control sections were incubated in diluent only.
The cell cultures were rinsed in 0.03 M PBS for 10 min.  Appropriate FITC and Texas
Red-conjugated secondary antisera were then applied in a 1:1 mixture on the cell cultures for a
30 min incubation at room temperature.  The secondary antibodies included: swine anti-rabbit
IgG FITC conjugated (1:100, Dimention Labs, Dako A/S, Denmark) and goat anti-mouse IgG
Texas Red conjugated (1:100, Bio/Can Scientific, Mississauga, ON, Canada).
The cells were washed in PBS for 5 min before incubation in a Hoechst solution (diluted
1:50) for 15 min at room temperature.  The cells were then given a final rinse in PBS for 5 min.
The coverslips were mounted onto slides using Citifluor (Marivac Ltd, Halifax, NS, Canada)
medium (a Glycerol/PBS solution).  After excess Citifluor was removed from around the edges,
the coverslips were sealed with clear nail polish.
2.2.2 Live method
The coverslips were removed from the culture dishes and incubated in DMEM medium
containing 5% horse serum (HS) and 15 mM N-2-Hydroxyethylpiperazine-Ní-2-ethanesulfonic
acid (HEPES) for 5 min at room temperature.  The cells were then incubated for one hour in
rabbit anti-mouse p75NGFR (1:100) diluted in DMEM/5% HS/15 mM HEPES.  The control
sections were incubated in diluent only.
The coverslips were washed four times (5 min each at 4oC) with Dulbecco’s phosphate
buffered saline (DPBS).  This solution contained 2.68 mM potassium chloride, 1.47 mM
potassium dihydrophosphate, 0.14 M sodium chloride, 8.1 mM di-sodium hydrophosphate, 0.49
mM magnesium chloride and 1.19 mM calcium chloride dissolved in distilled water.  Then the
cells were fixed by immersion in Zamboni’s fixative (pH 7.4) for 15 min at room temperature.
The cells were washed twice in DPBS (30 sec each at room temperature), followed by a third
wash in DPBS for 30 min at 4°C and a fourth DPBS rinse for 1 min at room temperature.
The swine anti-rabbit FITC-conjugated secondary antiserum (1:100) was then applied to the cell
cultures for a 30 min incubation at room temperature. The cell cultures were then washed with
four changes of DPBS for 5 min each at 4°C before incubation in a Hoechst solution (see Section
2.2.1). The cells were then given 4 final rinses in DPBS for 5 min each, after which the
coverslips were mounted onto slides using Citifluor medium (see Section 2.2.1).
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2.2.3 Live method in combination with intracellular antigens
After being removed from the culture dishes, the coverslips were incubated in DMEM
medium containing 5% HS and 15 mM HEPES for 5 min at room temperature.  The cells were
then incubated for one hour in rabbit anti-mouse p75NGFR (1:100) diluted in DMEM/5% HS/15
mM HEPES.  The control sections were incubated in diluent only.
The coverslips were washed with four changes in DPBS for 5 min each at 4°C and then
fixed by immersion in Zamboni’s fixative (pH 7.4) for 15 min at room temperature.  The cells
were washed twice in DPBS (30 sec each at room temperature), followed by a third wash in
DPBS for 30 min at 4°C and a fourth DPBS rinse for 1 min at room temperature. The cultures
were then incubated for 15 min in a solution of 0.2% TX-100, 5% HS and 0.1% BSA in 0.03 M
PBS (pH 7.4).
These cell cultures were fixed with Zamboni's fixative for immunostaining with mouse
anti-nestin.  Following a 15 min fixation at room temperature, the cells were washed twice in
DPBS (30 sec each at room temperature), followed by a third wash in DPBS for 30 min at 4°C
and a fourth DPBS rinse for 1 min at room temperature.  The coverslips were incubated for 15
min in a solution of 0.2% TX-100, 5% HS and 0.1% bovine serum albumen (BSA) in 0.03 M
PBS (pH 7.4).  Preincubation in TX-100 was required to permeabilize the cell membranes.  A 30
min incubation in the mouse anti-nestin (1:100) antibody followed immediately after the TX-100
incubation.
The cell cultures were rinsed in DPBS four times for 5 min each.  Appropriate FITC and
Texas Red-conjugated secondary antisera (see Section 2.2.1) were then applied to the cell
cultures for a 30 min incubation at room temperature.  Swine anti-rabbit IgG FITC conjugated
secondary antiserum (1:100) was used in a 1:1 mixture with a goat anti-mouse IgG Texas Red
conjugated secondary antiserum (1:100).
The cell cultures were washed with four changes of DPBS for 5 min each at 4°C before
incubation in a Hoechst solution (see Section 2.2.1). The cells were then given 4 final rinses in
DPBS for 5 min each. The coverslips were mounted onto slides using Citifluor medium (see
Section 2.2.1).
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2.3 Retroviral Infection
All procedures involving handling of the retroviral supernatant and cells infected with the
retrovirus (RV) were performed in accordance with requirements and standards of the Biosafety
Code of the University of Saskatchewan (endorsed by the Board of Governors on March 29,
2001), the Laboratory Biosafety Guidelines (Laboratory Center for Disease Control, Health
Protection Branch, Health Canada, Second Edition, 1996), as well as the Policies of the
Department of Health, Safety and Environment and the Biosafety Advisory Committe of the
University of Saskatchewan.  Use of the RV in these experiments was covered under Biosafety
Permit #ANA-02.  All of the in vitro work done with the RV was done in a Biosafety Level 2
hood in a designated Biohazard room.
2.3.1 Production and collection of retrovirus
The BAG replication-deficient RV was constructed by Price et al. (1987).  They cloned
the Escherichia coli Lac-Z gene, which produces an indelible and innocuous marker enzyme
called β-galactosidase, into a vector (pDOL) that was derived from the Moloney murine
leukemia virus (Mo-MuLV).  In the pDOL vector, the wildtype Mo-MuLV LTR provides the
promoter to drive stable expression of the Lac-Z gene in infected cells. Downstream from the
Lac-Z gene they cloned the simian virus 40 (SV 40) early promoter and the Tn5 neo gene to
provide a selectable marker for removing uninfected cells from cell cultures infected with the
BAG replication-deficient RV.
The ψ (PSI) 2 BAG alpha cells, the packaging cell line for this replication-deficient RV,
were purchased from the American Type Culture Collection company (Catalog # CRL 9560, Lot
# 206280, ATCC, Manassas, VA, USA) and were used to produce supernatant containing a high
titer of RV.  The ψ 2 BAG alpha packaging system, which was developed from the NIH/3T3 cell
line, provides viral envelopes to package the BAG replication-deficient RV so it can be used to
infect other cells (e.g., the OECs).  Once the BAG RV has infected an OEC it is unable to spread
to adjacent non-infected cells due to the absence of the genetic machinery in the OEC genome
that is required to make a viral envelope.
Vials of frozen ψ 2 BAG alpha cells were thawed in a 37°C water bath.  The cells were
transferred into a DMEM medium containing 10% bovine calf serum (BCS) and 1% antibiotic-
antimycotic (Sigma-Aldrich Canada Ltd, Oakville, ON).  After the cell suspension was
centrifuged at 160 G for 10 min, the cell pellet was resuspended in a desired volume of
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DMEM/10% BCS/1% antibiotic-antimycotic.  The resulting cell suspension was plated into 25
cm2 flasks, which were gassed with 5% CO2 for approximately 1 min and then tightly closed
with sealed caps.  Cultures of ψ 2 BAG alpha cells were fed with DMEM/10% BCS/1%
antibiotic-antimycotic medium twice a week.  When the cell cultures became confluent, the
growth medium was removed and discarded and fresh DMEM/10% BCS/1% antibiotic-
antimycotic medium was added to each flask.  Within 2-3 days the medium in the flasks had
turned yellow reflecting the high density and metabolic activity of the cells, which in turn
indicated a high titer of RV was present in the medium.  This yellow-colored medium was
collected from the cell cultures every 2-3 days, stored in sterile 50 ml plastic centrifuge tubes at
4oC, and filtered through a 0.45 µm low protein binding filter.  Aliquots of filtered RV-
containing medium were either used right away or frozen and stored at -80°C until needed.  
2.3.2 Titration of retrovirus
NIH 3T3 cells were used to determine the viral titer in the ψ 2 BAG α conditioned
medium.  The NIH 3T3 cells were purchased from the American Type Culture Collection
(ATCC Catalog # CRL-1658).  Vials of frozen NIH 3T3 cells were thawed in a 37°C water bath
and then the cells were transferred into a DMEM/10% BCS/1% antibiotic-antimycotic medium.
After the cell suspension was centrifuged at 800 RPM for 10 min, the cell pellet was resuspended
in the desired volume of DMEM/10% BCS/1% antibiotic-antimycotic medium. The resulting
cell suspension was plated into 60 mm dishes at a density of 5 x 104 cells/ml.  The day after the
cells were plated, the growth medium was replaced with DMEM/10% BCS/1% antibiotic-
antimycotic medium to which was added one of several different volumes of RV supernatant and
8 µg/ml polybrene; the cell cultures were placed in the incubator at 37°C for 2.5 hours.  The NIH
3T3 cells were infected with logarithmic dilutions (10-1 through 10-5) of retroviral supernatant.
In order to ensure an even distribution of the virus over the surface of the cell culture, the dishes
were agitated every 30 min throughout the 2.5 hour incubation period.  After 2.5 hours of
incubation, a sufficient volume of DMEM/10% BCS was added to each dish to dilute the
concentration of polybrene in the growth medium to 2µg/ml.  The infection of NIH 3T3 cells
with RV containing supernatant was repeated daily for an additional two days.  These NIH 3T3
cell cultures were trypsinized (see Section 2.1.4) immediately upon finishing the infection.  Cell
suspensions were collected separately from each dish, centrifuged and resuspended in
DMEM/10% BCS.  The resulting cell suspensions, derived from infections with logarithmic
73
dilutions of RV supernatant, were diluted 1:20 in DMEM/10%BCS containing 400 µg/ml
geneticin (G 418 sulfate, Life Technologies, Gibco BRL); each cell suspension was plated into
three 60 mm dishes.  The cell cultures were fed with fresh DMEM/10% BCS containing 400
µg/ml geneticin twice a week for the next 10-14 days. At the end of the culture period, the
growth medium was removed from the dishes and the cells were fixed in methanol for 15 min at
room temperature.  The fixed cells were allowed to air dry, after which they were stained with
0.45% Coomassie brilliant blue (color index = 42660) dissolved in Methanol/acetic acid for 1
min at RT and rinsed with distilled water.  The average number of virus-expressing Geneticin-
resistant colonies was determined using the following formula:
number of colonies  x  dilution factor  =  number of colony forming units/ml
                           volume of RV supernatant
2.3.3 Infection of olfactory ensheathing cells
The OEC cultures were initiated as described in Section 2.1 and grown in 25 cm2 Falcon
flasks.  The cell cultures were fed with mG5 medium as described in Section 2.1.3.  Infection
with RV began on the day the cell cultures were switched from mG5 medium to serum-
containing medium.  One control flask from each set of cell cultures was fed with the
DMEM/F12/10% FBS medium containing no RV.  One ml of the retroviral supernatant in
DMEM/10% BCS medium containing 8 µg/ml polybrene was added to each 25 cm2 Falcon flask
designated for RV infection and the cell cultures were incubated for 2.5 hours at 37°C.  At the
end of this time 3 ml of DMEM/F12/10% FBS were added to each flask after which the flasks
were returned to the incubator for 21.5 hours.  Fresh RV/polybrene solution was added daily, as
just described, for 2 weeks.  The control flask was treated identically on a daily basis, but
received no exposure to RV.
2.3.4 Geneticin selection of infected cells
After the 2 week period of daily exposure to RV containing medium, the RV-infected and
uninfected cell cultures were fed twice a week with DMEM/F12/10% FBS medium containing
geneticin (400 µg/ml); control (uninfected) cell cultures were fed in an identical manner.  Close
monitoring of control cultures determined when all uninfected cells were killed, which usually
occurred within 4-5 days of being first exposed to the geneticin.  The RV-infected OEC cultures
were then expanded with DMEM/F12/10%FBS medium that contained no geneticin, until they
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approached confluence.  Prior to harvesting, 400 µg/ml of geneticin was added to the growth
medium for the last 3-4 days.
2.3.5 x-Gal staining of OEC cultures
Some RV-infected OEC cultures were stained with x-Gal solution to confirm that the
cells were expressing β-galactosidase.  The following steps were performed in the Biohazard
hood.  The growth medium was aspirated from the dishes prior to rinsing them 3 times with
0.03M PBS at room temperature.  The cell cultures were then fixed for 5 min at room
temperature with a 0.2% glutaraldehyde solution (in 0.03M PBS) and washed 3 more times with
0.03M PBS (room temperature).  Once the cells were fixed, the following steps could be carried
out in the general lab.  The OEC cultures were incubated with a solution containing 0.1% x-Gal
(5-bromo-4-chloro-3-indolyl-β-d-galactoside; Gibco BRL, Grand Island, N.Y. 14072 USA) in 20
mM potassium ferricyanide, 20 mM potassium ferrocyanide, and 2 mM MgCl dissolved in
0.03M PBS for 4 hours at 37°C.  These cultures were then rinsed 3 times with 0.03M PBS
and stained for 2 min at room temperature with a solution containing 3.7 mM Nuclear Fast
Red (5-chloro-2-methoxybenzenediazonium chloride hemi (zinc chloride) salt; Sigma-
Aldrich, Oakville, ON) and 75 mM aluminum sulfate dissolved in distilled water.  After a
final wash with distilled water, the OEC cultures were dehydrated in an ascending series of
ethanols (70%, 95%, 100%), cleared in xylene for 2 min and then mounted on slides using
Shandon xylene substitute mountant.
2.4 Surgery
All surgical procedures were performed under sterile conditions. Animal care was
provided in accordance with the requirements of the Canadian Council on Animal Care, and the
experimental protocols were evaluated and approved by the Protocol Review Committee, which
is a Subcommittee of the University Committee on Animal Care and Supply (University of
Saskatchewan).  Animals had free access to food and water throughout the period of study.
2.4.1 Anesthesia and analgesia
Thirty six adult (3-4 months old) female Wistar rats weighing 210-280 grams (U of S
Laboratory Animal Service Unit) were anesthetized intraperitoneally (i.p.) with sodium
pentobarbital (Somnotol; MTC Pharmaceuticals, Cambridge, Ontario, Canada) at a dose of 55
mg per kg body weight (Groups 1-4; see Table 4-1).  In addition, Buprenex (Buprenorphine
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hydrochloride, Reckitt & Colman Products Limited, Hull, England), an opioid analgesic, was
administered intramuscularly before surgery was started at a dose of 0.05 mg per kg body
weight.
An additional 21 rats were anaesthetized by inhalation of Halothane (MTC
Pharmaceuticals, Ontario, Canada) (Groups 5-8; see Table 1).  The induction of anesthesia was
achieved by a mixture of 3% Halothane in 100% oxygen using a Boyle anaesthetic machine
(Ohmeda, Mississauga, ON).  After 5-10 min, the animals were immobile and unresponsive to a
pinch test on their hind paws (pedal reflex).   A single intramuscular injection of Buprenex (0.05
mg per kg body weight) was then administered prior to making the skin incision.  The
concentration of 3% Halothane was maintained during the initial parts of the surgery until it was
time to begin the laminectomy.  Beginning with the laminectomy, and continuing through the
EtBr and cell grafting, the Halothane concentration was kept at 2-2.5%; closure of the wound
was done using 1-1.5% Halothane.
During the course of the entire surgery, each animal was closely monitored (every 3-5
min) for their respiration, heart rate, selected reflexes, and the color of their paws.  For all of the
rats in Groups 1-8 they continued to breath at a normal rate, their heart rate seemed appropriate
(as judged by palpation), pedal and tail pinch reflexes were absent, and the paws remained pink
in color throughout the duration of each operation.
2.4.2 Laminectomy
An operation field was designated on the midline of the back.  The rats were placed onto
a reusable heating pad (Safe and Warm Incorporated, Seattle WA, USA) to maintain normal
body temperature.  The shaved operating field was washed with a 1:1 mixture of Betadine
antiseptic solution (10% povidone-iodine topical solution UPS) and 70% ethanol. Using a #23
Almedic stainless steel scalpel blade, a 3-5 cm longitudinal incision was made through the skin
and the superficial fascia along the posterior midline, immediately superficial to the spines of the
lower thoracic vertebrae.  In the surgical area, the muscles located on the dorsal surface of the
spine were cut and moved laterally.  A laminectomy was performed of the designated thoracic
vertebra, after the appropriate spinous process had been removed using bone rongeurs.  The dura
mater was cut longitudinally within the hole created by the laminectomy.
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2.4.3 Injection of ethidium bromide
A 32 Gauge Hamilton needle was connected to a 5 µl Hamilton syringe, which was then
mounted onto a rodent stereotaxic apparatus using the syringe holder of a KD Scientific Syringe
Pump (KDS 310).  A previously prepared stock solution of 0.03% EtBr dissolved in distilled
water was loaded into the 5 µl Hamilton syringe.  The 32 Gauge needle was lowered so it just
touched the spinal cord surface, as seen through a Nikon SMZ-1B stereoscopic dissecting
microscope.  After zeroing the XYZ coordinates of the stereotaxic apparatus, the needle was
slowly lowered into the right dorsal funiculus to a depth of 1 mm, approximately 1 mm to the
right of the dorsal spinal artery.  The needle was left in place for 1 to 2 min after being inserted
into the cord, prior to initiating the injection of EtBr.  Using the KDS 310 syringe pump, 1µl of
0.03% EtBr was injected over 10 min using a flowrate of 0.10 µl/min.  After completion of the
injection, the needle was left in the spinal cord for 1-2 min prior to being slowly withdrawn. The
syringe with attached needle was immediately rinsed with dH2O, followed by a couple of rinses
with acetone and then a few final rinses with dH2O.
2.4.4 Grafting DiI-labelled olfactory ensheathing cells
Immediately before surgery, cryovials were withdrawn from the locator and thawed in a
bath of lukewarm water for approximately 1 min.  The cell suspension was then slowly added to
medium in a Falcon centrifuge tube to dilute the DMSO, followed by centrifugation at 160 G
(for 10 min) and resuspension in medium (x2). After the last wash in medium, the total number
of viable cells was determined as described in Section 2.1.4.  The cell viability averaged 73%
(see Table 2.1).
The cell pellet was resuspended in a grafting solution containing 1 µg/ml of CaCl2, 1
µg/ml of MgCl2, 0.1% Glucose in 0.1M PBS; the final cell concentration was 50,000 cells per µl.
This cell suspension was stored at 4°C for no longer than 1 hour prior to grafting. This cell
suspension was loaded into the 5 µl Hamilton syringe, as just described for the EtBr. The
injection of cells into the dorsal funiculus was done using the same flowrate setting, as
previously described for EtBr (see Section 2.4.3).  A 1 µl volume of cell suspension, containing
50,000 DiI-labelled OECs, was injected over a period of 10 min.  After completion of the
injection, the needle was left in the spinal cord for 1-2 min prior to being slowly withdrawn. The
syringe with attached needle was immediately rinsed with dH2O, followed by a couple of rinses
with acetone and then a few final rinses with dH2O.
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Table 2.1 Cell counts of viable OECs before and after being frozen in liquid
nitrogen
The cell culture
number
Total number of
viable cells frozen
Total number of
viable cells when
thawed
% Viability
K 427 ONL 1,152,600 703,125 61%
K 428 ONL 881,400 687,500 78%
K 429 ONL 863,000 725,000 84%
K431 ONL 1,001,600 781,250 78%
K 447 ONL 1,218,750 775,000 71%
K 462 ONL 1,127,300 721,500 64%
Mean number: 739,375 73%
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2.4.5 Grafting retroviral-infected olfactory ensheathing cells
The procedure for grafting of RV-infected OECs into the dorsal funiculus of the rat spinal
cord (n=1) was identical to that described for DiI-labelled OECs in Section 2.4.4.
In order to graft RV-infected OECs onto the pial surface of the rat spinal cord (n=3), the
Anesthesia and Analgesia (Section 2.4.1) and Laminectomy (Section 2.4.2) parts of the surgical
procedure were the same as previously described.  The cell suspension was prepared for
transplantation and loaded into the 5 µl Hamilton syringe similar to that described in Section
2.4.4.  The 30 Gauge 90° needle was lowered so it just touched the spinal cord surface, as seen
through a Nikon SMZ-1B stereoscopic dissecting microscope.  The stereotaxic apparatus was
zeroed, so the needle tip was inserted into the slit in the dura and touched the dorsal surface of
the spinal cord under visual observation.  The needle was slowly moved 1 mm to the right of the
dorsal spinal artery so the right lip of slit in the dura surrounded the needle’s tip without the
needle being injected into the right dorsal funiculus.  A 1 µl volume of cell suspension,
containing 50,000 RV-infected OECs, was injected over a period of 10 min at the same flowrate
setting described for EtBr (see Section 2.4.3).  After completion of the grafting, the needle was
left in position adjacent to the dorsal surface of the spinal cord for 1-2 min prior to being slowly
withdrawn.
2.4.6 Wound closure and postoperative care   
The needle was slowly withdrawn 1 to 2 min after either the cell grafting or EtBr
injection had been completed. The muscles along the spine were sutured with Ethicon 4-0
surgical silk, and washed with a 3% solution of hydrogen peroxide (diluted in dH2O) for
antiseptic purposes.  The skin wound was closed with 3-4 silk sutures, washed with Betadine
antiseptic solution diluted 1:1 with 70% ethanol, and painted with a 2% Xylocaine local
anaesthetic gel (Lidocaine Hydrochloride Jelly, USP Sterile Topical Anesthetic, Astra Pharma
Inc., ON, Canada).
Each animal was monitored every 5 to 10 min during the first hour of the postoperative
period for their respiration rate and for the color of their paws.  The Group 1-4 rats were kept on
a heating pad for 2-3 hours either until the pad had reached room temperature or until the rat had
started to move around in the cage, whichever came first.  Any bedding was kept away from the
animal's face to avoid inhalation of small particles.  The rats were observed each hour
postsurgically for the next three hours and also the following morning to ensure they were
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drinking water and eating food.  On the first postoperative day the rats were transferred back to
the animal facility room.  Postoperative monitoring was done once a day until the rats were
killed by an overdose of Somnotol and perfused for necropsy (see Section 2.5).  During this
monitoring, particular attention was directed towards the sutures and the healing of the wound.
No problems were observed with the sutures on any of the rats.  Postoperative wounds healed
with no complications and were replaced by soft white linear scars after 2-3 weeks.  By this time,
the sutures were no longer observed and the new fur grew enough to cover the postoperative
scar.  On a daily basis, the rats were also checked for their mobility, alertness, food and water
consumption, and the condition of their fur. The surgical manipulations did not cause noticeable
mobility problems in any of the rats included in the Groups listed in Table 4-1.
With the exception of several animals, all rats were drinking water, eating food, and
actively moving around in the cage during the postoperative period.  Their activity, general
appearance and behavior appeared to be normal.  There were only three rats after somnotol
anesthesia noticed lying in the cage for more than 30 min after surgery; these rats were barely
moving but were breathing normally.  These animals received 5 ml injections of saline i.p. one
time each and their condition improved over the next two hours.  Another three rats suddenly
stopped breathing either during the last steps of the surgery or shortly after the operation, which
might have been due to Halothane side effects, myocardial and respiratory depression, or the
animal's individual sensitivity to Halothane.  These animals were cervically dislocated and are
not included in the animal numbers listed in Table 4-1.  There were two additional rats whose
entire body jerked when the needle was inserted into the dorsal funiculus of the spinal cord.
Such a whole body reaction was likely due to the needle reaching the corticospinal tract located
at the depths of the dorsal funiculus.  During the postoperative period, it was noted that the right
hind limb of these rats was paralyzed.  Following necropsy, the lesion occupied the entire dorsal
funiculus including the corticospinal tract.  The tissue sections of these rats were excluded from
analysis and the rats are not included in the animal numbers listed in Table 4-1.
2.4.7 Minocycline treatment
Six rats injected with EtBr at T10 and OECs at T12 (Group 6; see Table 4-1) and six
additional rats that were injected with EtBr at both T10 and T12 and OECs at T12 (Group 7; see
Table 4-1) received a 0.5 ml i.p. injection of either minocycline (45 mg/Kg in 0.9% saline; n=3
for each of Groups 6 and 7; Sigma-Aldrich, Oakville, ON) or vehicle (i.e. 0.9% saline; n=3 for
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each of Groups 6 and 7) daily at approximately 24 hour intervals for the first 4 weeks after EtBr
injection.  The abdomen of all rats was examined each day prior to giving these daily injections
for evidence of tenderness or other adverse reactions to either the minocycline or saline
injections. To minimize the discomfort of daily injections, a new sterile needle was used for each
injection.  The minocycline and vehicle treated rats (Groups 6 and 7) were kept in the animal
facility for an additional four weeks after the last minocycline or vehicle injection. A 4 week
treatment time frame was chosen to ensure the anti-inflammatory property of minocycline was
active for a sufficiently long period of time.
2.5 Necropsy of Tissue
2.5.1 Perfusion of the rats
Between 2 to 8 weeks after the last operation (i.e. Grafting DiI-labelled OECs) the rats
were deeply anaesthetized with an i.p. injection of 0.35 c.c. Somnotol (~90 mg/kg body weight).
The rat's chest cavity was opened transabdominally to expose the heart, after which the apex of
the left ventricle was cut off with scissors. A needle, which was connected to the tubing of a
Variable Flow Tubing Pump (VWP Scientific Products, VWR Canlab), was inserted into the left
ventricle and pushed up into the ascending aorta.  Blood exited the cardiovascular system via an
additional incision in the wall of the right atrium; this incision was made immediately after the
perfusion had begun.  Approximately 300 ml of a 1% solution of sodium nitrite dissolved in 0.03
M PBS (pH 7.4) was passed through the vascular system to flush out the blood. The rat was then
perfused with approximately 250 ml of a freshly made cold solution of 4% paraformaldehyde
(PF) in 0.03 M PBS (pH 7.4) over a period of 30-40 min.
2.5.2 Dissection of spinal cord
When the perfusion was done, the skin and muscles were cut longitudinally along the
posterior midline from the skull to the tail base.  The exposed spinous processes and vertebral
laminae were removed using bone rongeurs through the whole length of the spinal column. The
spinal cord with its short rootlets were gently dissected out, immersed in fresh fixative (4% PF)
and stored overnight at 4°C.  After approximately 18-20 hours fixation, the spinal cords were
immersed in a 30% solution of sucrose dissolved in 0.03 M PBS (pH 7.4) for 2-3 days at 4°C.
The spinal cords were then ready for sectioning on a sliding microtome.
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2.5.3 Cutting and storage of tissue sections
The rat thoracic spinal cord segments (T8-T12) were identified by counting the short
rootlets left after dissection, beginning in the cervical area and proceeding caudally.  These
segments were individually separated using a scalpel blade. The specimen holder of a sliding
microtome (American Optical Company, Scientific Instrument Division, Buffalo, New York,
USA) was frozen in dry ice prior to application of Tissue-Tek O.C.T. 4583 compound (Sacura
Finetek U.S.A., Inc., Torrance, CA 90504 USA) onto its surface. One spinal cord segment at a
time was placed onto the prepared specimen holder, covered with O.C.T. medium, and frozen by
means of dry ice.  The sliding microtome was used to cut coronal sections of 40 µm thickness.
Serial coronal sections were collected and placed in a 96 well storage plate filled with
cryoprotectant (a solution of 0.11 M sodium phosphate monobasic and 0.38 M sodium phosphate
dibasic in distilled water, containing 3% Glycerin and 3% Ethylene Glycol). Free floating
sections were stored in this cryoprotectant at -20°C until they were mounted onto subbed slides
for cell counts or for immunohistochemical staining.
2.5.4 Immunohistochemical staining
The 40 µm thick sections of spinal cord were removed from cryoprotectant and washed
three times in 0.03 M PBS (30 sec each at room temperature), followed by a fourth PBS rinse for
30 min at 4°C. The sections were then incubated for 30 min in a solution of 3% SMP and 0.1%
TX-100 in 0.03 M PBS (pH 7.4); preincubation in SMP/TX-100 was required to block non-
specific binding sites and to permeabilize the cell membranes.
Incubation in primary antibodies was done overnight at 4°C. The following antibodies
were used: rabbit anti-mouse p75NGFR (1:9000, Chemicon International Inc., Temecula, CA
92590, USA), rabbit anti-cow GFAP (1:11000, Dimension Labs, Dako A/S Denmark),  mouse
anti-rat MHC Class I (Clone OX-18, 1:9600, Secotec Product Datasheet, Kidlington, Oxford,
England), mouse anti-CD11b (Clone MRC OX-42, 1:3200, Serotec Product Datasheet,
Kidlington, Oxford, England), and mouse anti-Vimentin (Clone V9, 1:1000, Sigma Immuno
Chemicals, St. Louis, MO 63178, USA). The primary antibodies were diluted in 0.03 M PBS.
The control sections were incubated in diluent only.
The following day, the sections were washed with two changes of 0.03 M PBS and then
blocked again in a solution of 3% SMP/0.1% TX-100 in 0.03M PBS for 30 min.  Appropriate
biotinylated secondary antisera were then applied to the sections for a 30 min incubation at room
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temperature. The biotinylated secondary antibodies included: goat anti-rabbit IgG (1:200,
Vectors Labs, Burlingame, CA 94010 USA) and horse anti-mouse IgG (1:150, Vectors Labs,
Burlingame, CA 94010 USA).
The sections were then incubated for 15 min in a 1% solution of hydrogen peroxide
(H2O2) in 30% methanol to quench the enzymatic activity of endogenous peroxidase.  An
additional wash in two changes of 0.03 M PBS (pH 7.4) was followed by incubation in a 3%
solution of SMP in 0.03 M PBS (pH 7.4) (30 min).  The Vectastain Elite ABC kit (Vector
Laboratories, Inc., Burlingame, CA 94010 USA) was used to make the Avidin DH (reagent A)/
biotinylated horseradish peroxidase H (reagent B) cocktail; 8µl of each reagent per ml were
diluted in 0.03 M PBS (pH 7.4) 30 min prior to being used. The sections were incubated in this
solution for one hour at room temperature.
After two washes in 0.03 M PBS (pH 7.4), the sections were rinsed in 0.175 M sodium
acetate (pH 6.8) for 10 min. A solution of 0.0185 M diaminobenzidine tetrahydrochloride (DAB)
and 0.1586 M nickel sulfate (NiSO4) in 0.175 M sodium acetate (pH 6.8) was made one hour
prior to use and kept in the dark. Immediately after adding 85 µl of a 30% solution of hydrogen
peroxide to each 100ml of DAB/NiSO4 solution, the sections were immersed in
DAB/NiSO4/H2O2 for 5 min in the dark.
The sections were then rinsed once (for 10 min) in 0.175 M sodium acetate (pH 6.8),
given a final rinse in 0.03 M PBS  (pH 7.4) for 10 min, and mounted onto subbed (1% gelatine,
0.1% chrome alum) slides. The sections were left to air dry for approximately 18-20 hours, after
which they were dehydrated in an ascending series of ethanols (70%, 95%, 100%). The sections
were cleared in xylene for 2 min and then coverslipped using Shandon xylene substitute
mountant (Shandon, Pittsburgh, PA 15275, USA).
2.5.5 Data collection and statistical analysis
Four sections were randomly chosen from each of the caudal, middle, and rostral
portions of each spinal cord segment (i.e T8-T12), mounted onto a microscope slide, and
coverslipped using Citifluor antiquenching mounting medium.  All tissue sections to be
used for cell counting were stained with Hoescht dye (1:50 dilution) prior to mounting to
ensure that the only DiI+ve profiles counted were those associated with a nucleus.  Each
tissue section was examined to determine whether it contained any DiI+ve cells, to
identify the specific location in which the cells were found, and to count the total number
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of labelled cells within the dorsal funiculus.  For statistical analysis the mean cell count
for each group of 4 sections was computed.  The initial data analysis showed no
differences between the data collected from the rostral, middle and caudal portions of
each spinal cord segment for each Group.  Therefore, these data were combined and
plotted as one bar for each spinal cord segment and for the statistical analysis of the data.
The data collected from Groups 1-5 (see Table 4.1) were statistically compared using a
one-way analysis of variance (Prism program).  The independent variable was the
presence and location of one or two EtBr-induced demyelinated lesions (i.e. the
experimental groups).  The data on cell counts obtained from each spinal cord segment
(i.e. T8-T11) and for each survival time (2, 4 or 8 weeks) were compared separately for
statistical significance.  The significance level was set at p < 0.05.  Multiple post hoc
comparisons between the different Groups (see Table 4.1) were performed with
Bonferonni’s multiple comparison post-test (Prism program) with the significance level
being set at p < 0.05.  The data collected from Groups 6 and 7 (see Table 4.1) were
statistically compared using the Mann-Whitney U test (Prism program) and a significance
level set at p < 0.05.
2.5.6 Luxol fast blue staining of tissue sections
The 40 µm thick spinal cord sections were removed from cryoprotectant and washed in
0.03M PBS for 10-20 min.  The sections were then mounted onto gelatine-chrome alum subbed
coverslips and were left to air dry for approximately two hours.  Tissue sections were washed in
0.03M PBS for 10 min and then in distilled water for 10 min.  The sections were dehydrated in
70% and 95% ethanol for 2 min each.  Tissue sections were then incubated in a solution
containing 1.05% Luxol Fast Blue (sulfonated copper phthalcyanine; Sigma-Aldrich, Oakville,
ON), 90% ethanol and 10% acetic acid for 16 hours at 37°C.  After washing in distilled water
twice, the sections were incubated in a 0.05% lithium carbonate solution in distilled water for
20 sec, followed by 70% ethanol and another rinse in distilled water.  This was then followed
by quick rinses in 70% ethanol and then 90% ethanol, followed by two changes of isopropyl
alcohol for 3 and 2 min, respectively.  The tissue sections were quickly rinsed in a 1:1
mixture of xylene and absolute alcohol.  The sections were cleared with three changes in
xylene and then mounted on slides using Shandon xylene substitute mountant.
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2.5.7 x-Gal staining of tissue sections
The 40 µm thick sections of the brain, olfactory bulbs, cerebellum, brain stem, cervical
and thoracic spinal cord of Group 8 rats were stained with x-Gal solution to determine the β-
galactosidase expression in OECs after either intraspinal implantation or pial surface grafting.
Tissue sections were removed from cryoprotectant and washed in 0.03M PBS for 10-20 min.
The sections were then mounted onto gelatine-chrome alum subbed coverslips and were left to
air dry for approximately two hours.  Tissue sections were incubated in a 0.1% x-Gal solution for
48 hours at 37°C.  The sections were rinsed 3 times with 0.03M PBS and then stained for 2
min at room temperature with a 0.1% Nuclear Fast Red solution in distilled water also
containing 5% ammonium sulfate.  After a final wash with distilled water, tissue sections
were dehydrated in an ascending series of ethanols (70%, 95%, 100%).  The sections were
cleared in xylene for 2 min and then mounted on slides using Shandon xylene substitute
mountant.
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3. SPECIFIC AIMS
Multifocal demyelinated lesions in white matter are the main characteristic pathologic
features of MS, which is the most common CNS demyelinating disease in humans.  Although
the pathology of MS is believed to be related to immunological phenomena induced by viral
infection or exposure to unknown allergens (Agranoff and Goldberg, 1974; Bach, 2002;
Challoner et al, 1995; Friedman et al, 1999; Gilden, 1999; Kazmierski et al., 2004; Kurtzke,
1980; Lucchinetti et al., 2000), the mechanisms responsible for the extensive CNS
demyelination and controlling whether remyelination occurs remain to be elucidated. In order
to enhance remyelination in the adult mammalian CNS, several approaches involving the
transplantation of myelinating glia have been considered (Barnett et al., 1993; Blakemore and
Crang, 1985, 1989; Blakemore et al, 1995; Duncan et al., 1992; Franklin and Blakemore, 1997;
Groves et al., 1993; Warrington et al., 1993).  The cells of choice have been oligodendrocytes,
Schwann cells and OECs (see Section 1.7).  Although in vivo OECs provide ensheathment for
the unmyelinated axons of the first cranial nerve, these glial cells can be induced to express a
myelinating phenotype both in vitro (Devon and Doucette, 1992, 1995) and after grafting into
demyelinated areas of the adult mammalian spinal cord (Franklin et al., 1996; Imaizumi et al.,
1998; Li et al., 1997, 1998; Lakatos et al., 2003).  It was the neurite-promoting and
remyelinating abilities of the OECs that first attracted investigators to graft these cells into
damaged CNS tissue (Lustgarten et al., 1991; Ramon-Cueto and Nieto-Sampedro, 1994; Smale
et al., 1996; Li et al., 1997, 1998; Perez-Bouza et al., 1998; Ramon-Cueto et al., 1998; Navarro
et al., 1999).
The demyelinated lesions in MS are scattered throughout the white matter of the CNS,
making it impractical to graft myelin-forming cells into each demyelinated area as part of a
therapeutic approach to remyelinating the axons.  A more sensible approach would entail
grafting the cells into a smaller number of sites and having the glial cells migrate towards each
of several demyelinated areas.  The purpose of my Ph.D. research project was to examine the
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migratory ability of one type of myelin-forming cell, namely the OECs, after they were grafted
into the spinal cord of adult rats and to identify the conditions under which they would be
induced to migrate towards a focal area of demyelination.  For these experiments the
ensheathing cells were prelabelled with a fluorescent dye (i.e. DiI) prior to grafting so the cells
could be identified for cell counting after they had mingled with host cells in spinal cord
segments rostral to the graft.  The specific aims of my research project were:
Specific Aim # 1 To determine whether OECs will be induced to migrate towards a focal
area of demyelination in the spinal cord of adult rats when the cells are
grafted into normal CNS white matter.
Specific Aim # 2 To determine whether the grafted OECs migrate away from a
demyelinated area of spinal cord into normal CNS tissue.
Specific Aim # 3 To determine whether the grafted OECs migrate away from a
demyelinated area of spinal cord towards a second demyelinated area.
Specific Aim # 4 To determine whether microglial reactivity contributes to the migratory
signal inducing OECs to migrate towards a focal demyelination of CNS
white matter.
Specific Aim # 5 To determine whether OECs grafted onto the pial surface of the spinal
cord will migrate into the neuropil in the absence of demyelination.
87
4. RESULTS
4.1 Olfactory Ensheathing Cell Cultures
At 3 DIV sparsely distributed flat and fusiform cells, either singly or in groups
of a few cells, comprised the cell cultures initiated from the tissue obtained from the
ONL of the E18 rat olfactory bulb.  Over the next 10 DIV, as the cell cultures were fed
twice a week with the mG5 serum-free medium, the morphology of the cells comprising
the culture changed to predominantly a fusiform, bipolar or tripolar morphology.  The
bipolar and tripolar cells were small phase bright cells, whereas the somata of the
fusiform cells were flatter (Fig. 4.1a).  A very small number of large, flat cells, which
were most likely meningeal fibroblasts, were present in the cell cultures when the
growth medium was first changed from one containing serum to the mG5 medium; the
mG5 medium supported an increase in the number of fusiform, bipolar and tripolar cells
at the expense of the larger, flatter cells, which were usually almost completely absent
from the cell cultures after 2 weeks (i.e. after ~10 days in mG5).  The growth medium
for the cell cultures was then switched back to DMEM/F12/10% FBS, which was used
to expand the cell cultures over the next 20 to 30 DIV until they approached confluency.
In the serum-containing medium the cells acquired a flatter multipolar and fusiform
morphology (Fig. 4.1b).
To assess the purity of the cell cultures they were double immunostained with a
monoclonal antibody to nestin in combination with either polyclonal antisera to p75 or
to S100. Almost all of the cells in these cultures were both S100+ve (Fig. 4.1e) and
nestin+ve (Fig. 4.1f).  Likewise, the majority of the cells in these cultures co-expressed
the p75 NGF receptor on their cell surface, including the somata as well as the
cytoplasmic processes (Fig. 4.1c), and the intermediate filament protein nestin (Fig.
4.1d).  There were only a small number of cells not expressing any of these markers
(indicated by arrows in Fig. 4.1c-f).
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 FIGURE 4.1: Morphology and Phenotype of OECs in vitro.
Phase contrast micrographs showing OECs in serum-free medium (a) and in serum
containing medium (b). Double immunostaining of OECs showing their co-expression
of p75NGFR (c) and nestin (d), and of S-100 (e) and nestin (f). Cells that expressed
none of these markers (the white arrows) were rare in any of the cell cultures used for
this thesis. Bar = 100 µm
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4.2 The Animal Model For Studying OEC Migration
4.2.1 The Ethidium Bromide Lesion
The 0.03% EtBr solution used in this research project created a demyelinated
lesion that remained confined to the right dorsal funiculus of the spinal cord  with no
detectable involvement of the contralateral funiculus.  Practically the entire right dorsal
funiculus was demyelinated at the epicenter of the EtBr injection, with the rostral-
caudal extent of the damage extending for approximately 1 mm; this length
corresponded to approximately 20% of the length of a spinal cord segment.  Previous
studies have used x-irradiation to impede host glial cells in their repair of demyelinated
area of white matter (see Section 1.6.1) but in the model used here the cell migration of
OECs was allowed to occur in conjunction with the host glial cells being allowed to
contribute to the neural repair.  With this concentration of EtBr, demyelination was still
evident at 2 weeks after injury (Fig. 4.2e) but by 8 weeks this region of white matter
had been almost entirely remyelinated (Fig. 4.2f).
The monoclonal antibody OX42 recognizes the CR3 complement receptor on
the surface of resting and phagocytic microglia while the monoclonal antibody OX18
recognizes the rat class 1 major histocompatibility complex antigen on the surface of
phagocytic microglia.  Both of these antibodies were used in this research project to
reveal the extent of the microglial reactivity to the cell graft.  The spinal cord tissue was
also stained with a monoclonal antibody to vimentin because astrocytes in the adult
mammalian CNS do not normally express detectable levels of vimentin, unless they are
induced to do so in response to brain or spinal cord injury.  At 2 weeks after injury in a
cross-section through the segment of injury, OX-18+ve reactive microglia (Fig. 4.2g)
and vimentin+ve reactive astrocytes (Fig. 4.2h) were confined primarily to the
demyelinated lesion within the right dorsal funiculus, with only an occasional reactive
glial cell being found in the left dorsal funiculus or in the medial part of the right dorsal
horn.  Since this 0.03% EtBr concentration created an acceptably small, demyelinated
lesion that was confined to one-half of the dorsal funiculus, this concentration was used
in all subsequent experiments. 
91
 FIGURE 4.2:  A small, focal EtBr-induced demyelinated lesion.
A schematic diagram (a) and a Luxol Fast Blue stained coronal section (b) of the
normal adult rat spinal cord. c) A schematic diagram of an EtBr-induced demyelinated
lesion at T10 (yellow circle). d) A micrograph showing the needle for injecting EtBr
inserted into the right dorsal funiculus at T10. Luxol Fast Blue stained coronal sections
of the T10 spinal cord segment two (e) and eight (f) weeks after injecting EtBr into this
white matter. The OX-18+ve microglial (g) and vimentin+ve astrocytic (h) reactivity at
the lesion site at two weeks after EtBr injection. Asterisks in c-h) denote the location of
the EtBr-induced lesion. The white arrows indicate the astrocytic (g) and microglial (h)
reactivity along the medial border of the EtBr-induced lesion. Bar = 400 µm applies to
all figures except a) and c).
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4.2.2 The Cell Graft
One µl of cell suspension containing 50,000 DiI-labelled OECs was
stereotactically injected into the right dorsal funiculus of the T12 spinal cord segment
(Fig. 4.3a & b). The needle was inserted immediately lateral to the dorsal spinal artery
and was lowered into the right dorsal funiculus to a depth of 1 mm.  Macroscopically,
the grafting site could be identified on the pial surface of the cord by a pink
discoloration of approximately 1-1.5 mm in diameter that covered the surface of the
right dorsal funiculus of the T12 spinal cord segment.  Once the T12 spinal cord
segment was cut in the coronal plane into 40 µm thick sections, a similar pink
discoloration was also seen to be present throughout much of the depth of the right
dorsal funiculus.  When these coronal sections were examined with a dissecting
microscope (~ 10x magnification) twenty to twenty-five of the sections (i.e. a length of
800-1000 µm) through the midportion of T12 were seen to contain this pink
discoloration of the right dorsal funiculus.  The remainder of the coronal sections cut
from the T12 spinal cord segment, both rostrally and caudally to the grafting site, did
not contain visible discoloration of the dorsal funiculi.  Microscopically, a compact
mass of DiI+ve OECs could be seen with the fluorescent microscope; this DiI+ve OEC
cell mass was seen within the right dorsal funiculus of each coronal section through the
midportion of the graft (Fig. 4.3b).  In addition to this compact mass, single as well as
small groups of DiI+ve OECs were found within both dorsal funiculi and both dorsal
horns of T12 (Fig. 4.3c).
Two weeks after grafting DiI+ve OECs into the right dorsal funiculus at the
midpoint of the T12 spinal cord segment, OX-18+ve reactive microglia (Fig. 4.3e) and
vimentin+ve reactive astrocytes (Fig. 4.3f) were detected within and around the location
of the cell graft.  These reactive microglia and astrocytes were localized predominantly
within the right dorsal funiculus between the midline septum and the right dorsal horn
and extending from the pial surface down to about the level of the corticospinal tract.
No OX-18+ve microglial cells were seen in the dorsal funiculus of the T12 spinal cord
segment in control animals, which received neither EtBr injection nor OEC graft
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 FIGURE 4.3:DiI+ve OECs grafted into the dorsal funiculus of T12.
a) A schematic diagram representing a graft of OECs (purple oval) in the dorsal
funiculus of the T12 spinal cord segment. b-d) DiI+ve OECs in the right dorsal
funiculus of T12 showing the graft at low power (b) and single cells at high power (c,
d). For quantitation of cell migration, these sections were stained with Hoechst dye and
each DiI-labelled OEC with a red fluorescent cell body and cytoplasmic processes
(white arrowhead) and a blue Hoechst-stained nucleus (white arrow) was counted.
Most of the cells with blue Hoechst-stained nuclei (grey arrow) were DiI-ve and were
considered to be host cells. OX-18+ve reactive microglia (e) and vimentin+ve reactive
astrocytes (f) at the site of an OEC graft at the level of T12 two weeks after grafting.
OX-18 (g) and vimentin (h) immunostaining of the T12 spinal cord segment of an adult
rat that received no cell graft or EtBr injection. Bar in ‘d’ = 100 µm and applies to
figures c) and d). Bar in ‘h’ = 100 µm and applies to figures b) and e-h).
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(Fig. 4.3g).  Vimentin staining revealed occasional activated astrocytes in the neuropil
only adjacent to pia matter (Fig. 4.3h).
4.2.3 Using DiI to Identify Grafted Cells
After grafting, the DiI-prelabelled OECs were identified for counting in the
tissue sections of the spinal cord by virtue of the red fluorescence of their cell bodies
and cytoplasmic processes (Fig. 4.3c & 4.3d).  All of the spinal cord tissue sections that
were to be used for generating cell counts of DiI+ve cells were stained with Hoechst
dye, which stains all of the nuclei in the sections and can be visualized using a DAPI
filter which shows the blue fluorescent nuclei.  For the red fluorescence to be counted as
a DiI+ve cell it had to be associated with a Hoechst+ve nucleus, as illustrated by the
arrows in Fig. 4.3c and 4.3d.  For the purposes of the cell counts, DiI-
negative/Hoechst+ve nuclei were assumed to belong to cells of the host animal.  The
majority of the DiI fluorescence was confined to fusiform- and spindle-shaped cells (see
Fig. 4.3c & 4.3d), and these were the ones that were counted in the experiments of
Sections 4.3 to 4.6.  Occasionally, red fluorescent particles were found scattered
throughout the dorsal funiculi of the tissue sections, being present for the most part
within and around the cell graft.  These fluorescent particles might have been the
remains of dead or dying cells that had been grafted into the spinal cord or the
phagocytosed remnants of these cells within the microglia or macrophages that
responded to the insertion of the needle into the spinal cord.  There was no indication of
any other possible leakage of DiI into the intercellular space; for example, there was no
DiI staining of the axons of DRG neurons or the corticospinal tract, both of which are
located within the dorsal funiculi at the grafting site.
4.3 OEC Migration In The Absence Of Demyelination
OECs were grafted into the right dorsal funiculus of the T12 segment of a
control group of rats (Group 1; see Table 4.1), which received only an OEC graft (Table
4.1; Fig. 4.4a & 4.4.b).  The rats were killed 2, 4, or 8 weeks after grafting, the spinal
cords were sectioned in the coronal plane (40 µm thick), and the tissue sections stained
with Hoechst dye to label the nuclei, as described in Section 2.5.5 and 2.5.6.
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Table 4.1 The experimental groups used to address each Specific Aim
Experimental Groups: Number
of
Animals
Used
Thesis
section where
results can be
found
Type of
Anesthesia
Group 1 rats
(OEC at T12) 9 4.3 Somnotol
Group 2 rats
(EtBr at T10 – OECs at T12) 9 4.4 Somnotol
Group 3 rats
(EtBr at T8 – OECs at T12) 9 4.4 Somnotol
Group 4 rats
(EtBr at T12 – OECs at T12) 9 4.5 Somnotol
Group 5 rats
(EtBr at T10+12 – OECs at T12) 9 4.5 Halothane
Group 6 rats
(EtBr at T10 – OECs at T12)
- minocycline treatment
- saline treatment
3
3
4.6 Halothane
Group 7 rats
(EtBr at T10+12 – OECs at T12)
- minocycline treatment
- saline treatment
3
3
4.6 Halothane
Group 8 rats
RV-labelled OECs at T12 pial surface 3 4.7 Halothane
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 FIGURE 4.4:Schematic diagrams summarizing the experimental groups.
a) The brain and spinal cord of an adult female Wistar rat; b) A schematic diagram
representing a graft of OECs (purple oval) in the dorsal funiculus of the T12 spinal cord
segment (OECs at T12; see Table 4.1). c) and d) Schematic diagrams representing an
EtBr injection (yellow circle) at either T10 (c; EtBr at T10/OECs atT12; see Table 4.1)
or T8 (d; EtBr at T8/OECs atT12; see Table 4.1) and the grafting of OECs into the T12
spinal cord segment (purple oval). e) and f) Schematic diagrams representing an OEC
graft (purple oval) directly into an EtBr-induced demyelination at T12 (yellow oval) in
the absence (e; EtBr at T12/OECs atT12; see Table 4.1) or the presence (f; EtBr at T10,
T12/OECs atT12; see Table 4.1) of a second EtBr lesion located at T10 (yellow circle).
g) and h) Schematic diagrams representing the experimental design for EtBr injection
(yellow circle and yellow oval) and OEC cell graft (purple oval) used to test the effect
of minocycline treatment on OEC migration.
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4.3.1 The Cell Graft
The cell grafts were easily identified by virtue of their blue, Hoechst-stained
nuclei and red, DiI+ve cell bodies and cytoplasmic processes (Fig. 4.3c).   More than
200 DiI+ve OECs were present in the dorsal funiculus of each coronal spinal cord
section through the midpoint of the rostral-caudal extent of the graft.  These DiI+ve
cells were so closely packed together that it was impossible to obtain an accurate count
of the number of cells.  At all survival times a very small number of DiI+ve cells were
also found scattered throughout the dorsal funiculus of the T12 spinal cord segment.
4.3.2 Host Glial Cell Reactivity
Both reactive microglia and astrocytes were present in the dorsal funiculus of
the T12 segment of the spinal cord, presumably in response to the placement of the cell
graft (Fig. 4.3e & 4.3f).  The vimentin+ve reactive astrocytes possessed an intensely
stained cell body and several long cytoplasmic processes, whereas the OX-18+ve cells
had small round somata and a few short, branched cytoplasmic processes.  In more
rostral segments of the spinal cord in these control rats, the microglial and astrocytic
reactivity was less and less apparent in segments further away from the graft and with
increasing survival times, but was always confined to the ipsilateral dorsal funiculus.
Thus, OX-18+ve reactive microglia and vimentin+ve reactive astrocytes were found
within the right dorsal funiculus of T12 at two weeks after grafting (Fig. 4.3e & f).
Four (Fig. 4.5a, c, e &g) and eight (Fig. 4.5 b, d, f & h) weeks after cell grafting at T12,
OX-42- (Fig. 4.5 a & b) and OX-18-expressing (Fig. 4.5 c & d) microglia as well as
GFAP+ve (Fig. 4.5 e & f) and vimentin+ve (Fig. 4.5 g & h) astrocytes were also seen
within the right dorsal funiculus of T11, occupying the area between the pial surface
and the corticospinal tract.
4.3.3 DiI+ve Cells Rostral to Cell Graft
Tissue sections from the rostral, middle and caudal thirds of each spinal cord
segment rostral to T12 (i.e. T11, T10, T9 and T8) were randomly chosen for fluorescent
microscopy.  Four sections from each third of the segment (twelve per segment) were
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 FIGURE 4.5:  Microglial and astrocytic reactivity in the dorsal funiculus of T11 in
Group 1 rats.
OX-42+ve (a, b) and OX-18+ve (c, d) microglia, and GFAP+ve (e, f) and vimentin+ve
(g, h) astrocytes in the dorsal funiculus of T11 at 4 (a, c, e, g) and 8 weeks (b, d, f, h)
after grafting OECs at T12 in Group 1 rats. Minimal microglial and astrocytic reactivity
is seen at T11 when the only experimental manipulation was grafting OECs one spinal
cord segment caudally. Bar = 400 µm
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used for cell counts.  DiI+ve OECs were present within the dorsal funiculus of each
spinal cord segment from T11 to T8 (the most rostral segment examined in this study).
The average number of these cells within the dorsal funiculus of T11 varied from 17.1
per 40 µm tissue section at 2 weeks survival (Fig. 4.6a), to 30.9 after 4 weeks (Fig.
4.6b) and to 7.6 per tissue section at 8 weeks after grafting (Fig. 4.6c).  In more rostral
spinal cord segments (i.e. T8-T10) the numbers of DiI+ve OECs in the Group 1 rats
always averaged less than 8 per 40 µm tissue section regardless of survival time, except
for the average cell counts at T10 at the 4 week time point where an average of 12.1
cells per tissue section were counted (Fig. 4.7 - 4.9). The small numbers of migrating
DiI+ve OECs that were seen in each spinal cord segment rostral to the cell graft were
found on the pial surface and along the septi that lay between the fiber tracts comprising
the dorsal funiculi (Fig. 4.10a & b).
4.4 Inducing OECs To Migrate Towards A Focal Demyelination
To address specific aim #1, a gliotoxin-induced demyelination of axons was
accomplished by stereotactically injecting 1 µl of a 0.03% solution of EtBr into the right
dorsal funiculus of either the T10 (Group 2 rats) or T8 (Group 3 rats) spinal cord
segment of separate groups of adult rats (see Table 4.1).  Three days after the EtBr
injection, DiI+ve OECs were grafted into the right dorsal funiculus of the T12 spinal
cord segment of each rat (Fig. 4.4c & d).
4.4.1 The Cell Graft   
In Groups 2 and 3 rats the cell grafts had a similar appearance to that described
in Section 4.3.1 for the control group (i.e. Group 1 rats) that had received only a cell
graft (data not shown).  This cell graft consisted of a closely packed DiI+ve collection
of OECs.  Although there were more than 200 DiI+ve OECs present in each coronal
spinal cord section through the midpoint of the rostral-caudal extent of the graft, no
attempt was made to obtain an accurate quantitation since it was impossible to
distinguish individual cells throughout much of the compact mass.  DiI+ve OECs were
also found scattered within the plane of the section in the neural tissue outside of the
main body of the graft.
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 FIGURE 4.6:   Number of DiI+ve OECs in the dorsal funiculus of T11 in Groups
1-3 rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T11 spinal cord segment of control rats (OECs@T12; Group 1)
or rats injected with EtBr at either T8 (EtBr@T8/OECs@T12; Group 3) or T10
(EtBr@T10/OECs@T12; Group 2) at 2 (a), 4 (b) or 8 weeks (c) after grafting of OECs
at T12 (n = 3 for each Group at each survival time).  A one-way analysis of variance
was applied to the data with the data for each survival time being analyzed separately
for statistical significance.  The resulting value of F (6.56) was statistically significant
only at the 8 weeks (c) time point (p < 0.05).  Multiple post hoc comparisons between
Groups 1-3 at the 8 week time point were performed with Bonferonni’s multiple
comparison post-test revealing a significant difference between Groups 1 and 2 (p <
0.05; 1 asterisk).
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FIGURE 4.7:  Number of DiI+ve OECs in the dorsal funiculus of T10 in Groups 1-
3 rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T10 spinal cord segment of control rats (OECs@T12; Group 1)
or rats injected with EtBr at either T8 (EtBr@T8/OECs@T12; Group 3) or T10
(EtBr@T10/OECs@T12; Group 2) at 2 (a), 4 (b) or 8 weeks (c) after grafting of OECs
at T12 (n = 3 for each Group at each survival time).  A one-way analysis of variance
was applied to the data with the data for each survival time being analyzed separately
for statistical significance.  The resulting values of F were not significant at any time
point (p > 0.05).
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FIGURE 4.8: Number of DiI+ve OECs in the dorsal funiculus of T9 in Groups 1-3
rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T9 spinal cord segment of control rats (OECs@T12; Group 1) or
rats injected with EtBr at either T8 (EtBr@T8/OECs@T12; Group 3) or T10
(EtBr@T10/OECs@T12; Group 2) at 2 (a), 4 (b) or 8 weeks (c) after grafting of OECs
at T12 (n = 3 for each Group at each survival time).  A one-way analysis of variance
was applied to the data with the data for each survival time being analyzed separately
for statistical significance.  The resulting values of F (8.182) were statistically
significant only at the 8 weeks time points (p < 0.02).  Multiple post hoc comparisons
between Groups 1-3 were performed with Bonferonni’s multiple comparison post-test
revealing a significant difference between Groups 1 and 2 at 8 weeks survival (p < 0.05;
1 asterisk).
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FIGURE 4.9: Number of DiI+ve OECs in the dorsal funiculus of T8 in Groups 1-3
rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T8 spinal cord segment of control rats (OECs@T12; Group 1) or
rats injected with EtBr at either T8 (EtBr@T8/OECs@T12; Group 3) or T10
(EtBr@T10/OECs@T12; Group 2) at 2 (a), 4 (b) or 8 weeks (c) after grafting of OECs
at T12 (n = 3 for each Group at each survival time).  A one-way analysis of variance
was applied to the data with the data for each survival time being analyzed separately
for statistical significance.  The resulting values of F (18.43) were statistically
significant only at the 8 week time point (p < 0.003).  Multiple post hoc comparisons
between Groups 1-3 were performed with Bonferonni’s multiple comparison post-test
revealing a significant difference between Groups 1 and 2 (p < 0.05; 1 asterisk) and
between Groups 1 and 3 (p < 0.01; 2 asterisks) at 8 weeks survival.  However, the
numerical difference in cell counts was so small as to make it questionable whether the
observed differences were therapeutically of any interest.
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FIGURE 4.10:  DiI+ve cells in the dorsal funiculus of T11 and T9 in Groups 1-3
rats.
Fluorescent images of the dorsal funiculus of the T11 and T9 spinal cord segments of
control rats (Group 1) and of rats injected with EtBr at either T10 (Group 2) or T8
(Group 3). All rats survived for 8 weeks after grafting.  a & b) In control rats, DiI+ve
OECs (white arrow) were seen along the septa at T11 (a) and T9 (b).  c & d) In rats
injected with EtBr at T10, DiI+ve OECs (white arrows) were seen not only along the
septa but also within the neuropil at both T11 (c) and T9 (d).  e & f) In rats injected with
EtBr at T8, DiI+ve OECs (white arrow) were also found along the septa and in neuropil
at both T11 (e) and T9 (f), although they were much fewer in number than those in
Group 2 rats. Bar = 100 µm.
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4.4.2 The Ethidium Bromide Lesion.
After injecting EtBr into the right dorsal funiculus, the area of the injection
acquired yellow discoloration due to host tissue reaction to needle insertion and
injection of the EtBr.  Macroscopically, the EtBr lesion was identified by the yellow
discoloration (see Section 4.2.1) of the dorsal funiculus immediately to the right of the
dorsal spinal artery in tissue sections cut through the middle of either the tenth (T10) or
the eighth (T8) spinal cord segments in Groups 2 and 3 rats, respectively.  In the rats
used in this study, the EtBr lesion was fusiform in shape and about 1 mm long, with the
yellow discoloration being most intense at 2 weeks of survival.  At 4 and 8 weeks after
cell grafting, the intensity of yellow discoloration was less intense and harder to
identify.  The spinal cord segments with an EtBr injection were identified by comparing
the location of the EtBr injection with the location of the laminectomy at the time of
spinal cord dissection and spinal rootlet count prior spinal cord segment sectioning.  For
an entire spinal cord segment (e.g. T10), up to twenty 40 µm coronal tissue sections
contained the demyelinated lesion, which was confined to the right dorsal funiculus
without involvement of the corticospinal tract (Fig. 4.2e).   By 8 weeks of survival, the
right dorsal funiculus of T10 (Group 2 rats) and T8 (Group 3 rats) was close to being
fully remyelinated, at least in terms of the histological appearance as seen in tissue
sections stained with Luxol Fast Blue (Fig. 4.2f).
4.4.3 Host Glial Cell Reactivity.
Similar to what was seen in the T12 segment of the spinal cord in Group 1 rats,
reactive microglia and reactive astrocytes were present in and around the cell graft in
the right dorsal funiculus.  Microglial and astrocytic reactivity was also observed within
the ipsilateral dorsal funiculus of the T11 spinal cord segment and at the site of EtBr
injection at T8 (Group 3 rats) and T10 (Group 2 rats).   In the rats injected with EtBr at
T10 and killed 4 weeks after receiving an OEC graft, the intensity of OX-42 (Fig.
4.11a) and OX-18 (Fig. 4.11c) expressed by microglia within the right dorsal funiculus
of the T11 spinal cord segment was slightly higher than that of the opposite funiculus or
adjacent right dorsal horn.  At the same survival time, the level of GFAP expression by
astrocytes within the right dorsal funiculus was also close to that of the
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 FIGURE 4.11:  Microglial and astrocytic reactivity in the dorsal funiculus of T11
in Group 2 rats.
OX-42+ve (a, b) and OX-18+ve (c, d) microglia, and GFAP+ve (e, f) and vimentin+ve
(g, h) astrocytes in the dorsal funiculus of T11 at 4 (a, c, e, g) and 8 weeks (b, d, f, h)
after grafting OECs at T12 in Group 2 rats. Minimal microglial and astrocytic reactivity
is seen ipsilaterally at T11 by 4 weeks (a, c, e & g) after grafting, but the reactivity as
evidenced by OX-18 (d) and vimentin (h) immunostaining is much more intense by 8
weeks.  Insets in b, d, f and h show the morphology of reactive microglia (b, d) and
astrocytes (f, h).  Bar in h = 400 µm and applies to a-h.  Bar in inset in h = 20 µm and
applies to all insets.
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other parts of the section (Fig. 4.11e).  Only vimentin expression by astrocytes localized
within the right dorsal funiculus looked more intense in comparison with level of its
expression by astrocytes in the left funiculus (Fig. 4.11g).  Interestingly, the expression
of OX-18 by reactive microglia  (Fig. 4.11d) and vimentin by reactive astrocytes (Fig.
4.11h) was noticeably more intense in the rats surviving for 8 weeks to those at shorter
survival time.  Numerous intensely stained microglia and astrocytes were found
throughout much of the extent of the right dorsal funiculus reaching but sparing the
right corticospinal tract, left dorsal funiculus and right dorsal horn.  Although, microglia
and astrocytes expressed OX-42 (Fig. 4.11b) and GFAP (Fig. 4.11f), respectively, at 8
week survival time at more intense, these expressions were not as prominent as that of
OX-18 (Fig. 4.11d) and vimentin (Fig. 4.11h).
In the rats that received an EtBr injection at T8, OX-42- (Fig. 4.12a & b) and
OX-18-expressing (Fig. 4.12c & d) microglia grouped predominantly within the right
dorsal funiculus at both 4 and 8 weeks after grafting cells.  GFAP+ve astrocytes (Fig.
4.12e & f) were seen in groups also throughout the extent of the right dorsal funiculus.
Single OX-42- and OX-18-positive microglia as well as GFAP-expressing astrocytes
lined along the numerous septi of both dorsal funiculi and scattered throughout dorsal
horns.  However, vimentin+ve astrocytes (Fig. 4.12g & h) were more prominent in the
right dorsal funiculus than in adjacent structures at both 4 and 8 week survival period.
4.4.4 DiI+ve Cells Rostral to Cell Graft   
DiI+ve OECs were present within the dorsal funiculus of T11, with the numbers
of these migrating cells being quite similar in the experimental and control groups at
two (Fig. 4.6a) and four (Fig. 4.6b) weeks after grafting. However, by 8 weeks after
grafting there were several fold more DiI+ve OECs in the dorsal funiculus of T11 (Fig.
4.6c) and T9 (Fig. 4.8c) in those rats that had received an EtBr injection at T10, in
comparison to that seen in either of the other two groups of rats.  In contrast to that seen
in control rats, the migrating DiI+ve OECs in rats in which EtBr had been injected at
T10 were found not only along the septi of both dorsal funiculi but also within the
neuropil of both right and left dorsal funiculi of T11 (Fig. 4.10c) and T9 (Fig. 4.10d).
Although, the mean numbers of DiI+ve OECs in the dorsal funiculus of T8 at the 8
118
FIGURE 4.12:  Microglial and astrocytic reactivity in the dorsal funiculus of T11
in Group 3 rats.
OX-42+ve (a, b) and OX-18+ve (c, d) microglia, and GFAP+ve (e, f) and vimentin+ve
(g, h) astrocytes in the dorsal funiculus of T11 at 4 (a, c, e, g) and 8 weeks (b, d, f, h)
after grafting OECs at T12 in Group 3 rats. Minimal microglial reactivity is seen
ipsilaterally at T11 regardless of survival time (a-d). There was also no detectable
difference in GFAP (e, f) or vimentin (g, h) immunostaining between the 4 and 8 week
survival. In contrast to GFAP immunostaining, however, the vimentin immunostaining
suggested there was astrocytic reactivity ipsilaterally at T11 at least as early as 4 weeks.
Bar = 400 µm
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week time point after grafting in Group 2 and 3 rats were both significantly higher than
that of the control group (Fig. 4.9), the numerical difference in cell counts was so small
it is questionable whether the difference is therapeutically of any interest.
4.5 Inducing OECs To Migrate Away From A Focal Demyelination
To address specific aim #2, DiI+ve OECs were stereotactically injected into the
right dorsal funiculus of the T12 spinal cord segment of 9 rats (Group 4 rats; see Table
4.1) three days after an injection of 1µl of a 0.03% solution of EtBr into right dorsal
funiculus of T12 (Fig. 4.4e).  In order to address specific aim #3, an additional nine rats
received injections of 1µl of a 0.03% solution of EtBr into right dorsal funiculus of both
T10 and T12 (Group 5 rats; see Table 4.1).  Three days later, these latter nine rats were
also stereotactically injected with DiI+ve OECs into the right dorsal funiculus of the
T12 spinal cord segment (Fig. 4.4f).
4.5.1 The Ethidium Bromide Lesions
The EtBr lesion was identified by a yellow-pink discoloration at the middle of
the T12 spinal cord segment and on the right side immediately lateral to the dorsal
spinal artery.  The size of the discoloration was slightly bigger due to additional
injection of DiI-labelled OECs but it never exceeded 1-1.2 mm in rostral-caudal extent.
Approximately 30 spinal cord sections of the middle portion of T12 contained the lesion
and occupied the entire right dorsal funiculus with minimal extension into adjacent
structures.  The EtBr lesion at T10 of the Group 5 rats was similar in its location and
extent to that described in Section 4.4.2.
4.5.2 The Cell Graft.
DiI+ve OECs were grafted into a three day old EtBr lesion within the
midportion of the T12 spinal cord segment.  Similar to that previously described in
Section 4.3.1 with respect to the appearance of the cell graft within undamaged CNS
tissue, compact groups of 20 to 30 DiI+ve OECs were seen throughout the right dorsal
funiculus, with the total number of grafted cells per tissue section averaging more than
200 at the rostral-caudal midpoint of the graft.  However, due to grafting the OECs into
an EtBr-induced demyelinated lesion, the OECs were scattered throughout the whole
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right dorsal funiculus and within the entire area encompassed by the yellow-pink
discoloration of the lesion.
4.5.3 Host Glial Cell Reactivity.
As expected, reactive microglia and reactive astrocytes were both found
throughout the whole right dorsal funiculus of the T12 spinal cord segment where OECs
had been grafted into an EtBr-induced demyelinated lesion in both Group 4 and 5 rats
(data not shown).  OX-18-expressing microglia and vimentin+ve astrocytes were also
seen occupying the entire right dorsal funiculus of the T10 spinal cord segment in
Group 5 rats, which had received a second EtBr injection at T10.
In the T11 spinal cord segment, microglia expressing OX-42 (Fig. 4.13a, c, e &
g) and OX-18 (Fig. 4.13b, d, f & h) were single cells with small round cell bodies and
elongated, branched processes evenly distributed throughout the dorsal horns and dorsal
funiculi.  However, OX-42+ve/OX-18+ve microglia with round cell bodies and short or
no processes grouped together within the right dorsal funiculus of T11 regardless of the
survival time (i.e. 2 or 8 weeks) and presence of one (Group 4 rats) or two (Group 5
rats) EtBr lesions.  Astrocytes expressing GFAP (Fig. 4.14a, c, e &g) and vimentin (Fig.
4.14b, d, f & h) were less abundant than microglia in T11 spinal cord sections, but when
present they were located mostly in the white matter adjacent to the pial surface.
Although GFAP+ve astrocytes grouped together within the right dorsal funiculus of the
T11 spinal cord segment of Group 4 and 5 rats after 2 and 8 weeks, the level of GFAP
expression was more prominent in rats of both groups that survived 8 weeks.  The level
of vimentin expression was always high in astrocytes and it accumulated mostly along
the septa/blood vessels within the T11 right dorsal funiculus of Group 4 and 5 rats.
4.5.4 DiI+ve Cells Rostral to Cell Graft.
In the rats with only a single EtBr lesion (Group 4) DiI+ve OECs were present
in the dorsal funiculus of T11 (Fig. 4.15a, c & e), T9 (data not shown) and as
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FIGURE 4.13:  Microglial reactivity in the dorsal funiculus of T11 in Group 4 and
5 rats.
OX-42+ve (a, c, e & g) and OX-18+ve (b, d, f & h) microglia in the dorsal funiculus of
T11 at 2 (a-d) and 8 weeks (e-h) after grafting OECs at T12 in Group 4 (a, b, e & f) and
5 (c, d, g, & h) rats. Microglial reactivity in the ipsilateral dorsal funiculus of T11 as
evidenced by OX-42 immunostaining was noticeably greater in the double-lesioned
Group 5 rats at both 2 (c) and 8 (g) weeks after OEC grafting as compared to that seen
in Group 4 rats (a, e). The OX-18 immunostaining suggested a greater microglial
reactivity at 8 weeks (f, h) in both groups as compared to the 2 week survival (b, d). Bar
= 400 µm
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FIGURE 4.14:  Astrocytic reactivity in the dorsal funiculus of T11 in Group 4 and
5 rats.
GFAP+ve (a, c, e & g) and vimentin+ve (b, d, f & h) astrocytes in the dorsal funiculus
of T11 at 2 (a-d) and 8 weeks (e-h) after grafting OECs at T12 in Group 4 (a, b, e & f)
and 5 (c, d, g, & h) rats. Astrocytic reactivity in the ipsilateral dorsal funiculus of T11 as
evidenced by GFAP immunostaining was noticeably greater at 8 weeks survival in both
Group 4 (a, e) and 5 (c, g) rats as compared to that seen at 2 weeks. In the double-
lesioned Group 5 rats the vimentin immunostaining suggested a more intense astrocytic
reactivity at 2 weeks (d) after grafting as compared to 8 weeks (h) and was also more
intense than that seen in Group 4 rats (b) at 2 weeks survival. However, the astrocytic
reactivity in Group 4 and 5 rats was comparable at 8 weeks survival as evidenced by
vimentin immunostaining (f, h). Bar = 400 µm
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FIGURE 4.15: DiI+ve cells in the dorsal funiculus of T11 in Group 4 and 5 rats.
Fluorescent images of the dorsal funiculus of the T11 spinal cord segment of rats that
were injected with EtBr at either T12 (Group 4) or at both T10 and T12 (Group 5) and
three days later received an OEC graft into the lesion at T12. The rats survived for 2 (a,
b), 4 (c, d) and 8 (e, f) weeks after grafting. Consistently at each survival time there
were several fold more DiI+ve cells (white arrows) in the dorsal funiculus of T11 in
Group 5 rats (b, d, &f) as compared to that seen in Group 4 rats (a, c & e). Bar = 100
µm.
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far rostrally as T8 (data not shown), which was the most rostral spinal cord segment
examined.  In the single lesioned rats (Group 4), however, the DiI+ve OECs had
migrated singly or at most as pairs of cells.  The number of such cells at the levels of
T11 and T10 was consistently lower at two (Fig. 4.16a & 4.17a) and four (Fig. 4.16b &
4.17b) weeks postoperatively than had been observed in Groups 2 and 3 rats at
equivalent survival times (1.7 – 6.8 fold fewer cells) and was similar to that seen in the
latter two groups of rats at the T9 (Fig. 4.18) and T8 (Fig. 4.19) spinal cord segments at
two and four weeks after grafting.   Even by 8 weeks postoperatively, the average
number of DiI+ve OECs in the dorsal funiculus of T11 (Fig. 4.16) to T8 (Fig. 4.19)
remained relatively low.
However, the numbers of DiI+ve OECs were significantly higher in the spinal
cord segments of rats with two EtBr lesions (i.e., at both T12 and T10) (Fig. 4.15b, d &
f).  The average number of DiI+ve OECs in the T11 spinal cord segment of Group 5 rats
was 71.8 cells per tissue section as soon as 2 weeks after grafting (Fig. 4.16a).  Mean
numbers of DiI+ve OECs remained high in Group 5 rats even up to 8 weeks (50.4 cells)
after grafting (Fig. 4.16c).  These numbers were significantly higher than those rats that
had received only a single EtBr injection at T12 (i.e. Group 4 rats) regardless of
survival time (2, 4, or 8 weeks) and in comparison to those in control rats at both 2 and
8 weeks survival.  Proceeding rostrally, there were also significantly more DiI+ve OECs
in the dorsal funiculus of T10 at 4 (39.7 DiI+ve OECs) and 8 (20.9 DiI+ve cells) weeks
after grafting in Group 5 rats as compared to Group 4 rats (Fig. 4.17).  The average
number of DiI+ve cells at T9 (5.5 – 12.8; Fig. 4.18) and at T8 (4.9 – 6.4; Fig. 4.19) in
Group 5 rats was not significantly different from that of the other groups regardless of
survival time, except for the cell counts at T8 for the 2 week time point (Fig. 4.19).
However, the actual numerical difference between the cell counts for Groups 4 and 5 at
T8 was so small it is questionable whether they are of any therapeutic interest.  Either
singly or in small groups the DiI+ve OECs were found along the septi of both dorsal
funiculi and also within the neuropil of the right dorsal funiculus of T11-T10 in both
Groups 4 and 5 rats.
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FIGURE 4.16:  Number of DiI+ve OECs in the dorsal funiculus of T11 in Groups
1, 4 and 5 rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T11 spinal cord segment of control rats (OECs@T12; Group 1)
or rats injected with EtBr at either T12 (EtBr@T12/OECs@T12; Group 4) or T10 and
T12 (EtBr@T10, T12/OECs@T12; Group 5) 2 (a), 4 (b) or 8 weeks (c) after grafting of
OECs at T12 (n = 3 for each Group at each survival time).  A one-way analysis of
variance was applied to the data with the data for each survival time being analyzed
separately for statistical significance.  The resulting values of F were statistically
significant at the 2 (F = 12.51; p < 0.0075), 4 (F = 11.98; 0.0085) and 8 (F = 14.17; p <
0.006) weeks time points.  Multiple post hoc comparisons between Groups 1, 4 and 5 at
each time point were performed with Bonferonni’s multiple comparison post-test
revealing a significant difference between Groups 4 and 5 at all survival times and
Groups 1 and 5 at 2 and 8 weeks survival times. 1 asterisk = p < 0.05; 2 asterisks = p <
0.01.
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FIGURE 4.17:  Number of DiI+ve OECs in the dorsal funiculus of T10 in Groups
1, 4 and 5 rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T10 spinal cord segment of control rats (OECs@T12; Group 1)
or rats injected with EtBr at either T12 (EtBr@T12/OECs@T12; Group 4) or T10 and
T12 (EtBr@T10, T12/OECs@T12; Group 5) 2 (a), 4 (b) or 8 weeks (c) after grafting of
OECs at T12 (n = 3 for each Group at each survival time).  A one-way analysis of
variance was applied to the data with the data for each survival time being analyzed
separately for statistical significance.  The resulting values of F were statistically
significant at the 4 (F = 6.025; p < 0.04) and 8 (F = 22.02; p < 0.002) weeks time points.
Multiple post hoc comparisons between Groups 1, 4 and 5 were performed with
Bonferonni’s multiple comparison post-test revealing a significant difference between
Groups 4 and 5 at 4 and 8 weeks survival times, as well as between Groups 1 and 5 at
only the 2 week time point. 1 asterisk = p < 0.05; 2 asterisks = p < 0.01.
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FIGURE 4.18:  Number of DiI+ve OECs in the dorsal funiculus of T9 in Groups 1,
4 and 5 rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T9 spinal cord segment of control rats (OECs@T12; Group 1) or
rats injected with EtBr at either T12 (EtBr@T12/OECs@T12; Group 4) or T10 and T12
(EtBr@T10, T12/OECs@T12; Group 5) 2 (a), 4 (b) or 8 weeks (c) after grafting of
OECs at T12 (n = 3 for each Group at each survival time).  A one-way analysis of
variance was applied to the data with the data for each survival time being analyzed
separately for statistical significance.  The resulting values of F were not significantly
different at any survival time.
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FIGURE 4.19:  Number of DiI+ve OECs in the dorsal funiculus of T8 in Groups 1,
4 and 5 rats.
Histograms depicting the mean number (+/- SEM) of DiI+ve Cells (Y-axis) in the
dorsal funiculus of the T8 spinal cord segment of control rats (OECs@T12; Group 1) or
rats injected with EtBr at either T12 (EtBr@T12/OECs@T12; Group 4) or T10 and T12
(EtBr@T10, T12/OECs@T12; Group 5) 2 (a), 4 (b) or 8 weeks (c) after grafting of
OECs at T12 (n = 3 for each Group at each survival time).  A one-way analysis of
variance was applied to the data with the data for each survival time being analyzed
separately for statistical significance.  The resulting values of F (8.429) were
statistically significant (p < 0.02) only at the 2 week time point.  Multiple post hoc
comparisons between Groups 1, 4 and 5 at the 2 week time point were performed with
Bonferonni’s multiple comparison post-test revealing a significant difference between
Groups 4 and 5 (p < 0.05; 1 asterisk).  However, the numerical difference in cell counts
was so small as to make it questionable whether the observed differences were
therapeutically of any interest.
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 4.6 Microglial Reactivity Contributes To The Migratory Signal
To address specific aim #4, systemically administered minocycline was used to
reduce the activation of microglia both at the demyelinating lesion(s) and along the
white matter extending throughout the ipsilateral dorsal funiculus of T11.  Six rats
(Group 6; see Table 4.1) received an injection of 1 µl of 0.03% EtBr in the right dorsal
funiculus of the T10 spinal cord, followed three days later by an injection of DiI-
labelled OECs into the right dorsal funiculus of the T12 spinal cord segment (Fig. 4.4g).
An additional six rats (Group 7; see Table 4.1) received an injection of 1 µl of 0.03%
EtBr in the dorsal funiculus of both the T10 and the T12 spinal cord segments, followed
three days later by an injection of DiI-+ve OECs into the right dorsal funiculus of the
T12 spinal cord segment (Fig. 4.4h).  Half of the rats in each group received daily
intraperitoneal injections of minocycline while the remainder rats received vehicle (see
Section 2.4.7) for the first four weeks after grafting the cells.  This four week treatment
schedule was chosen to ensure the anti-inflammatory actions of minocycline would be
active for at least the first four weeks since it was during this time that the first signs of
lesion-induced migration of OECs was seen in the experiment of Section 4.4.  All rats
in both Groups 6 and 7 were killed 8 weeks after receiving an OEC graft.
4.6.1 Ethidium Bromide Lesion at T10 (Group 6 rats)
 The spinal cord tissues of Group 6 rats were stained with antibodies that
identified reactive microglia (OX42 and OX18 monoclonal antibodies) and reactive
astrocytes (anti-GFAP and anti-vimentin antisera) to confirm that the minocycline
treatment had been effective in preventing the activation of microglia and in assessing
the treatment’s effect on astrogliosis.  In the saline-treated, OX-42 (Fig 4.20a) and OX-
18-expressing (Fig. 4.20c) microglia were located in groups occupying the entire right
dorsal funiculus of T11.  Visibly fewer OX-42+ve (Fig. 4.20b) and small OX-18+ve
(Fig. 4.20d) microglia with short processes were identified within the T11 right dorsal
funiculus of Group 6 rats treated with minocycline.  No cell counts of microglia or other
tests to determine the level of OX-42 and OX-18 expression were performed on spinal
cord tissue of Group 6 rats treated with either saline or
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 FIGURE 4.20:  Microglial and astrocytic reactivity in the dorsal funiculus of T11
in Group 6 rats.
OX-42+ve (a, b) and OX-18+ve (c, d) microglia, and vimentin+ve (e, f) astrocytes in
the dorsal funiculus of T11 at 8 weeks after grafting OECs at T12 in Group 6 rats
receiving minocycline (b, d & f) or vehicle (a, c & e) for the first 4 weeks after EtBr
injection at T10. The minocycline treatment reduced the microglial reactivity as
evidenced by both OX-42 (b) and OX-18 (d) immunostaining as compared to vehicle
controls (a, c). There was no noticeable difference in the density of vimentin+ve
astrocytes between the vehicle and minocycline treated groups, although the medial-
lateral extent of the astrocytic reactivity was smaller after minocycline treatment. Bar =
400 µm
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minocycline.  Vimentin+ve astrocytes were primarily identified in the spinal cord tissue
adjacent to the pial surface and within the right dorsal funiculus of the Group 6 rats
regardless of treatment with saline (Fig. 4.20e) or minocycline (Fig. 4.20f).
Tissue sections from the T11 spinal cord segment of each Group 6 rat were
selected from the rostral, middle and caudal thirds of the segment and examined to
count the number of DiI+ve cells.  In Group 6 rats treated with saline, the numbers of
DiI+ve OECs found within the T11 dorsal funiculus averaged 49.3 per 40 µm tissue
section (Fig. 4.21a), values that were similar to those of Group 2 rats that survived for 8
weeks.  However, the average number of DiI+ve OECs found in the same location in
Group 6 rats treated with minocycline for the first 4 weeks after EtBr injection was only
6.8 per 40 µm tissue section, which was more than 7 fold less than that observed in the
vehicle control rats.  Mostly single DiI+ve OECs were localized to septi/blood vessels
of the right dorsal funiculus of Group 6 rats after minocycline treatment (Fig. 4.21b).
Similar to that described for Group 2 rats, single and small groups of DiI+ve OECs
were found throughout the neuropil as well as along the septi predominantly of the right
dorsal funiculus of the saline-treated rats of Group 6 (Fig. 4.21c).
4.6.2 Ethidium Bromide Lesions at T10 and T12  (Group 7 rats)
Tissue sections from the rostral, middle and caudal thirds of T11 in Group 7 rats were
examined for the presence and the location of reactive microglia and reactive astrocytes.
Similar to that seen in Group 2 and 6 rats after 8 week survival, OX-42-expressing
microglia scattered throughout the grey and white matter as single cells with small
round cell body and short, branched processes (Fig. 4.22a & b).  Under light
microscopy, there were visibly more OX-42 (Fig. 4.22a) and OX-18+ve (Fig. 4.22c)
microglia present within the right dorsal funiculus of Group 7 rats treated with saline
than that observed in corresponding spinal cord area of Group 7 rats treated with
minocycline (Fig. 4.22b &d).  Neither cell counts of microglia nor other tests to
determine the level of OX-42 and OX-18 expression were performed on spinal cord
tissue of Group 7 rats treated with either saline or minocycline.  GFAP+ve astrocytes
were distributed throughout the grey and white matter of T11 spinal cord sections with
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FIGURE 4.21: DiI+ve OECs in the dorsal funiculus of T11 in Group 6 rats.
a) A histogram depicting the mean number (+/- SEM) of DiI+ve cells (Y-axis) in the
dorsal funiculus of the T11 spinal cord segment of rats injected with EtBr at T10
(EtBr@T10/OECs@T12; Group 6) and OECs at T12 and treated with either saline or
with minocycline for the first 4 weeks after EtBr injection (n = 3 for each Group).  The
Mann-Whitney U test was applied to the data. The resulting value of U (9.0) was
statistically significant (p < 0.05; 1 asterisk) thus supporting the hypothesis of the
importance of the microglial reactivity in contributing to the strength of the migratory
signal(s).  b & c) Fluorescent images of the dorsal funiculus of the T11 spinal cord
segment of Group 6 rats. All rats survived for 8 weeks after grafting at which time the
saline treated rats (c) had several fold more DiI+ve cells (white arrows) in the dorsal
funiculus of T11 as compared to that of minocycline treated rats (b). Bar = 100 µm and
applies to both ‘b’ and ’c’.
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FIGURE 4.22:  Microglial and astrocytic reactivity in the dorsal funiculus of T11
in Group 7 rats.
OX-42+ve (a, b) and OX-18+ve (c, d) microglia, and GFAP+ve (e, f) and vimentin+ve
(g, h) astrocytes in the dorsal funiculus of T11 at 8 weeks after grafting OECs at T12 in
Group 7 rats. The minocycline treatment dramatically reduced the microglial reactivity
as evidenced by both OX-42 (b) and OX-18 (d) immunostaining as compared to vehicle
controls (a, c).  There was no significant difference in the density of GFAP+ve (e, f) or
vimentin+ve (g, h) astrocytes between the vehicle and minocycline treated groups. Bar
= 400 µm
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some accumulating in groups within the right dorsal funiculus of Group 7 rats treated
with either saline (Fig. 4.22e) or minocycline (Fig. 4.22f).  There was an accumulation
of vimentin-expressing astrocytes in the right dorsal funiculus and at the pial surface of
T11 of all Group 7 rats regardless of treatment (Fig. 4.22g & h).  In contrast to observed
differences in microglia distribution, there was no such effect of minocycline on either
GFAP- or vimentin-expressing astrocytes in comparison to that after saline treatment.
The location and the numbers of DiI+ve OECs were also determined in the
rostral, middle and caudal thirds of the T11 spinal cord segment in Group 7 rats.  In the
three saline-treated rats of this group, the number of DiI+ve OECs averaged 60.4 per 40
µm tissue section, which was similar to that observed in Group 5 rats at 8 weeks
survival (Fig. 4.23a).  However, the average numbers of DiI+ve OECs found in the right
dorsal funiculus of T11 in minocycline-treated Group 7 rats was significantly lower,
being only 19.9 DiI+ve OECs per 40 µm tissue section, which was 3 fold less than that
observed in saline-treated rats.  Single DiI+ve OECs were found migrating along septi
of T11 dorsal funiculi in Group 7 rats treated with minocycline (Fig. 4.23b).  However,
migrating DiI+ve OECs were found throughout the neuropil and along septi of the T11
spinal cord segment of the Group 7 rats injected with saline instead (Fig. 4.23c).
4.7 Grafting Retroviral-Infected OECs
To address specific aim #5, OECs were infected with a replication-deficient
retrovirus (RV) containing the Lac-Z gene and a neomycin-resistance gene (Fig. 4.24).
Geneticin-selected LacZ-expressing OECs were either injected into the right dorsal
funiculus of the T12 spinal cord segment or grafted onto the pial surface at the level of
the T12 spinal cord segment.
4.7.1 Retroviral-Infected OECs In Vitro
OEC cultures were obtained from the olfactory bulbs of E18 rat embryos as
described in Section 2.1.1.  After 10 days in mG5 medium (Fig. 4.24a), the cells were
exposed to the RV (Fig. 4.24b).  One control flask from each set of cultures was fed
with DMEM/F12/10%FBS medium containing no RV (Fig. 4.24c).  After the two week
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FIGURE 4.23:  DiI+ve OECs in the dorsal funiculus of T11 in Group 7 rats.
a) A histogram depicting the mean number (+/- SEM) of DiI+ve cells (Y-axis) in the
dorsal funiculus of the T11 spinal cord segment of rats injected with EtBr at both T10
and T12 (EtBr@T10, T12/OECs@T12; Group 7) and OECs at T12 and treated with
either saline or with minocycline for the first 4 weeks after EtBr injections (n = 3 for
each Group).  The Mann-Whitney U test was applied to the data.  The resulting value of
U (9.0) was statistically significant (p < 0.05; 1 asterisk) thus supporting the hypothesis
of the importance of the microglial reactivity in contributing to the strength of the
migratory signal(s).  b & c) Fluorescent images of the dorsal funiculus of the T11 spinal
cord segment of Group 7 rats. All rats survived for 8 weeks after grafting at which time
the saline treated rats (c) had several fold more DiI+ve cells (white arrows) in the dorsal
funiculus of T11 as compared to that of minocycline treated rats (b). Bar = 100 µm and
applies to both ‘b’ and ’c’.
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FIGURE 4.24:  Schematic description of retroviral infection of OEC cultures.
(a) OEC cultures in serum-free medium (mG5). b) RV-infection starts when the OEC
cultures are switched from mG5 to serum-containing medium. c) As a control, selected
flasks are fed with medium containing no RV supernatant. d & e)  Both control and RV-
infected flasks are fed with medium containing geneticin for the duration of time in
vitro. Cells in the control flasks were killed by the geneticin treatment within 4-5 days
in vitro. g) RV-infected and geneticin-selected OECs are frozen for long term storage in
the vapor phase of liquid nitrogen. f & h) x-Gal staining of representative OECs from an
RV-infected cell culture at the time they were harvested for freezing (f) and in a cell
culture initiated from a cell suspension of OECs that had been grafted onto the pial
surface of the spinal cord (h). Bar = 200 µm
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period, both infected (Fig. 4.24d) and uninfected control (Fig. 4.24e) cells were exposed
to geneticin.  Close monitoring of control cultures determined that treatment with
geneticin for 4-5 days killed 99% cells in uninfected cultures.  At this time, 50-70% of
the cells in cultures infected with RV survived the geneticin treatment.  Then, OEC
cultures were expanded with the DMEM/F12/10%FBS medium with no geneticin.  Cell
cultures approached confluency within one month.  In order to eliminate persisting
uninfected cells if present, OEC cultures were exposed to geneticin for 2 additional days
at this time.  After the second treatment with geneticin, OEC cultures from each set
were harvested to assay the cells for β-galactosidase expression.  Every single cell in all
OEC cultures with a fusiform cell body and flat processes contained blue particles, the
protein products of β-galactosidase activity, which densely packed the entire cell
cytoplasm but not cell nuclei (Fig. 4.24f).  The remaining OEC cultures were then
harvested for storage at -70°C (Fig. 4.24g).  RV-infected OECs were used later for
implantation in experiments described in Sections 4.7.2 and 4.7.3.  After grafting, the
remaining cell suspensions were plated onto glass coverslips and grown in vitro for 48
hours to assay the Lac-Z-expression in OECs after freezing and thawing.  As prior to
freezing, all OECs expressed β-galactosidase as seen by the presence of blue particles
throughout the cell cytoplasm but not in cell nuclei (Fig. 4.24h).
4.7.2 OEC Grafts Into Dorsal Funiculus
Prior to addressing the Specific Aim #5, RV-infected OECs were grafted into the lower
thoracic spinal segment in order to confirm that β-Gal-expressing OECs could be
detected in vivo.  RV-infected OECs were stereotactically injected into the right dorsal
funiculus of the T12 spinal cord segment of one rat.  This rat did not receive any other
experimental manipulations and was sacrificed 4 days after grafting.  The rat was
perfused with 4% paraformaldehyde and free-floating 40 µm thick coronal sections
were cut through the spinal cord.  The tissue sections were stained with x-Gal (to
identify β-galactosidase+ve cells) and counterstained with Fast Red (to identify all cells
in the tissue section) (see Section 2.5.8).  The grafted OECs occupied the entire right
dorsal funiculus at the grafting site and were easily identified by virtue of their blue, x-
Gal-staining (Fig. 4.25a).  Within the graft, OECs were closely packed in groups of 20-
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FIGURE 4.25:  β-Gal+ve OECs in the spinal cord, brainstem and cerebellum
a & b) These micrographs are of the T12 segment of the spinal cord in a rat that had
received an injection of OECs expressing β-Gal into the dorsal funiculus of this
segment 4 days previously. Numerous β-Gal+ve cells (blue staining) can be seen
(arrows in ‘b’).  c-f) After being grafted onto the pial surface at the level of T12, β-
Gal+ve cells could be seen in close association with blood vessels in rostral spinal cord
segments (e.g. the dorsal horn of T9 as shown in 'c').  These β-Gal+ve were also found
along the pial surface of the cerebellum (d), which presumably represents one possible
route by which the cells could gain access to the neuropil of the CNS such as the
molecular layer of the cerebellum (e). The β-Gal+ve cells were also seen associated
with blood vessels in the tegmentum of the brainstem (f). All of these sections were
counter stained with Neutral fast Red. Bar = 400 µm (a), 400 µm (b, d), and 200 µm (c,
e & f).
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30.  X-Gal stained OECs had round cell bodies with short processes (Fig. 4.25b).
4.7.3 OEC Grafts Onto Pial Surface
RV-infected OECs were also grafted onto the pial surface of the right dorsal
funiculus of the T12 spinal cord segment of three rats, with one rat being killed at each
of 11 days, 1 month and 2 months after grafting.  These rats received no other
experimental manipulation aside from the OEC graft.  In the spinal cord tissue obtained
from the cervical and thoracic levels of the rat killed at 11 days after grafting, β-Gal+ve
cells were distributed across the coronal plane of the spinal cord sections with no
particular pattern.  These cells were lying along the septi/blood vessels of the dorsal,
lateral and anterior funiculi, but were never seen lying close to the pial surface of the
spinal cord.  The β-Gal+ve cells were found singly or in small groups of 2-4 cells.
Within the white matter, β-Gal+ve cells were sometimes found within the perivascular
space in close apposition to the endothelial lining of blood vessels.  Some β-Gal+ve
cells were also found in the grey matter, including the dorsal and anterior horns and
Clark's nucleus.  Within the grey matter the β-Gal+ve cells were found in close
apposition to blood vessels whereas others were closely apposed to neuronal cell
bodies.  The RV-infected OECs very likely had floated into the CSF shortly after the
graft had been placed on the pial surface, since no cells were found on the pial surface
of the spinal cord of any tissue section examined.  The number of migrating cells varied
from 40 to 50 cells per section at the rostral part of T12 to 20-30 per section at the
midportion of T8 to 5-10 per section in the lower medulla.  Cell counts for sections of
rostral part of T12 and for sections from the middle part of T8 are presented in Table
4.2.  The medulla was the most rostral part of the CNS examined in this rat.  No cell
count was performed on tissue sections from cervical and lumbar segments of this rat.
In the remaining rats, one killed one month after grafting and the second rat at
two months, β-Gal+ve cells were found within the white and grey matter of the cervical,
thoracic and lumbar spinal cord segments in a similar distribution to that described
above for the rat killed 11 days after receiving a pial surface graft.  In addition, the brain
stem, cerebellum, cerebral hemispheres and olfactory bulbs were also examined to
determine whether they contained any β-Gal+ve cells.  β-Gal+ve OECs were found in
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the white and grey matter of the brain stem where they were found along septi/blood
vessels or located close to neuronal cell bodies.  A few single β-Gal+ve cells were also
found within the olfactory bulbs and on the pial surface of the cerebellum as well as
within the Purkinje cell layer (Fig. 4.25d).  β-Gal+ve OECs were not seen in the cortex
or white matter of the frontal, parietal and temporal lobes of either rat brain in coronal
sections collected from the anterior pole of the frontal lobe back to the level of the optic
chiasm.  β-Gal+ve OECs were also absent from the basal ganglia and diencephalon.
155
Table 4.2 Number of β-Gal-expressing OECs found in the T12 and T8 spinal
cord segments after a pial surface graft
Spinal Cord Segment T12, rostral part T8, middle part
Section: 1st 2nd 3rd 1st 2nd 3rd
WHITE MATTER
Anterior funiculus 4 3 5 3 3 3
Right lateral funiculus 3 0 1 3 2 1
Left lateral funiculus 2 0 1 2 1 3
Dorsal funiculi 3 0 1 5 5 0
GREY MATTER
Right anterior horn 9 7 4 4 6 7
Left anterior horn 8 7 8 6 4 6
Right dorsal horn including
Clark's nucleus
5 8 8 4 3 2
Left dorsal horn including
Clark's nucleus
8 3 5 2 1 3
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5 DISCUSSION.
5.1 Animal Models of CNS Demyelination for Studying the In Vivo Migratory
Ability of Myelinating Glia
Several animal models have been developed to study the morphological, cellular
and molecular mechanisms regulating demyelination and remyelination of CNS axons.
Each model is designed to mimic some, but not all, of the pathological and neurological
sequelae of MS.  The most commonly used animal models (see Section 1.6) are: a)
toxin-induced demyelination, such as with EtBr (Yajima and Suzuki, 1979), lysolecithin
(Hall, 1972) or cuprizone (Blakemore, 1972, 1973; Matsushima and Morell, 2001); b)
autoimmune-induced demyelination, the most common being experimental autoimmune
encephalomyelitis (EAE) (Lyman et al., 1985; Traugott et al., 1985); and c) viral-
induced demyelination [e.g., hepatitis virus (Herndon et al., 1977) or murine viral
encephalomyelitis (Lang et al., 1984)].  Although each of these models are useful for
addressing some of the questions concerning the mechanisms driving the demyelination
and remyelination of CNS axons, most are of limited use in identifying factors
important for inducing migration of the cells needed to assist in neural repair.  Cell
migration towards the site of injury is an important area of concern as part of any
therapeutic approach to treating hypomyelinating or demyelinating disorders that
involve glial cell transplantation.  The grafted cells must be able to respond to migratory
signals directing them to migrate towards focal areas of demyelination, such as the
isolated plaques in the spinal cord of an MS patient.  For this research project, the EtBr
model of CNS demyelination was chosen because with the concentration (0.03%) and
volume (1 µl) of injected neurotoxicant chosen both the location and the size of the
lesion could be controlled.
The EtBr model used in this research project was modified in two major ways
from that used by other investigators (Yajima and Suzuki, 1979; Blakemore, 1984;
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Iwashita and Blakemore, 2000).  Firstly, the neurotoxicant was injected at a
concentration [i.e., 0.03% as opposed to 0.1% (Yajima and Suzuki, 1979; Franklin et
al., 1996; Iwashita and Blakemore, 2000) or 0.3% (Honmou et al., 1996)] that
demyelinated only one half of the dorsal funiculus over a rostral-caudal length of less
than 1 mm.  Secondly, x-irradiation was not used thus permitting host glial cells to
respond properly to the lesion and initiate neural repair.  Previous investigators have
made much larger EtBr-demyelinated lesions (7-8 mm in length) in the spinal cord of
adult rats in combination with x-irradiation (Akiyama et al., 2001, 2002a, 2002b;
Blakemore and Crang, 1985; Franklin et al., 1996; Honmou et al., 1996) to study the
migratory ability of oligodendrocyte progenitor cells (Duncan et al., 1992; Franklin and
Blakemore, 1997; Groves et al., 1993; Nait-Oumesmar et al., 1999; O’Leary and
Blakemore, 1997; Reynolds et al., 2001; Warrington et al., 1993) and Schwann cells
(Baron-Van Evercooren et al., 1992; Blakemore and Crang, 1985, 1989; Blakemore et
al., 1995; Franklin et al., 1997; Gilson and Blakemore, 2002).  In spite of the larger size
of these lesions, there was no detectable Schwann cell migration nor did the
oligodendrocyte progenitor cells migrate more than a couple of mm towards the lesion
(Baron-Van Evercooren et al., 1992; Blakemore et al., 2002; Chari et al., 2003;
Franklin et al., 1996, 1997; Franklin and Blakemore, 1997).   Other than these few
studies, there has been no systematic examination of the factors inducing or guiding the
migration of myelinating glia using an in vivo model in the CNS of adult mammals.
The EtBr model used in the present research project can be used to study the migratory
ability of myelinating glia in response to single or multiple small, focal (<1 mm long)
gliotoxin-induced demyelinated lesions in the dorsal funiculus (unilaterally) of the adult
rat spinal cord.  Due to the small size of the lesions, the EtBr can even be injected at
variable distances from the site of the graft.  With this EtBr model it will be possible to
identify factors that induce or guide the migration of myelinating glia, as was done in
the present project where microglial reactivity was identified as one potential source of
a migratory signal inducing OECs to migrate over distances of up to 20 mm towards a
more rostrally located focal demyelination.
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This research project focused on the migratory abilities of OECs grafted into the
adult rat spinal cord in either the presence or absence of a focal demyelinated lesion(s).
One µl of a 0.03% EtBr solution was injected at different levels of the lower thoracic
spinal cord (i.e., at T8, T10 or T12, or at both T10 and T12) in separate groups of rats.
Three days after the EtBr injection, OECs were grafted into the right dorsal funiculus of
the T12 spinal cord segment.  The experimental design gave control over both the
location and the size of the demyelinated lesion as well as the distance of the lesion
from the OEC graft.  This EtBr model was used to study: a) the migration of OECs
towards a single demyelinated lesion located either two or four spinal cord segments
away from the cell graft; b) the migration of OECs away from a focal EtBr-
demyelinated area of CNS white matter in the presence and absence of a second EtBr
lesion located two spinal cord segments away; c) the contribution of microglial
reactivity to the migratory signal(s) inducing OECs to migrate when EtBr was used to
make a focal demyelinated lesion in CNS white matter.
In order to study the migratory ability of any type of myelinating glia grafted
into an animal’s CNS, it is important to have a model in which the number, location and
size of the demyelinated lesions can be reproducibly controlled.  The EtBr model used
in this research project has several advantages over the models used by other
investigators to study demyelination and remyelination of CNS axons.  First, the precise
location of the EtBr injection can be controlled as well as the size of the demyelinated
area.  Second, by eliminating x-irradiation from the experimental design, host glia can
contribute to neural repair at the site of the EtBr injection thus contributing to the
generation of a more natural response by cells of the host animal.  By allowing the host
glial cells to contribute to neural repair, the dorsal funiculus at the site of EtBr injection
appeared to be almost completely repaired by 8 weeks, as judged by Luxol Fast Blue
staining (Fig. 4.2f).  With these modifications included in the EtBr model used in this
research project, reactive microglia were identified as one potential source of a
migratory signal inducing OECs to migrate towards a focal EtBr-induced
demyelination.
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In the autoimmune- or viral-induced in vivo animal models of CNS
demyelination the lesions are typically induced by injections of MBP or MOG (i.e., the
EAE model; Raine et al., 1974, 1977, Raine and Traugott, 1983, 1984; Steinman, 1999)
or by infecting the animal with Theiler’s virus (murine encephalomyelitis model; Dal
Canto et al., 1996; Lipton and Jelachich, 1997; Monteyne et al., 1997; Oleszak et al.,
1995; Tsunoda and Fujinami, 1996), respectively.  The demyelinated lesions in these
animal models are found scattered throughout the CNS white matter with no consistent
location or size.  It would be extremely difficult to identify factors regulating the
migration of any of the myelinating glia when both the location and the size of the
demyelinated lesion cannot be consistently controlled.  Therefore, a direct injection of a
chemical agent  (e.g., EtBr) into the CNS white matter is much more appropriate for
creating a focal demyelination in each animal that is in a precise location and is of a
predetermined size.   If these criteria are met, then the myelinating glia can be injected
at variable distances from the focal demyelination to study their migratory abilities and
the signal(s) regulating their migration.
5.2 Migration of Myelinating Glia in the CNS
Remyelination of CNS axons remains an important goal of researchers who are
working towards developing therapeutic approaches to treating neurological diseases
such as MS and spinal cord injury.  With respect to demyelinating diseases, any
therapeutic approach to treating hypomyelinating or demyelinating disorders that
involve the migration of myelinating glia must take into account factors responsible for
inducing or guiding not only the migration of grafted cells but also that of the host
myelinating glia (i.e. oligodendrocyte progenitors and Schwann cells) whose
remyelinating ability is known to decrease as one gets older (Ando et al., 2003; Berlet
and Volk, 1980; Chari et al., 2003; Franklin et al., 2002c).   Any therapeutic approach
must also take into account that in demyelinating diseases such as MS the endogenous
migratory signals, which direct the migration of host and grafted myelinating glia
towards focal areas of demyelination, are actually arising from numerous spatially
separated lesions, such as for example the isolated plaques in the spinal cord of an MS
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patient.  It is important to have a better understanding of these migratory signals and/or
be able to induce them so appropriate therapeutic approaches can be developed to
enhance the migration of myelinating glia without impeding the process of neural
repair.
5.2.1 Host Myelinating Glia
In order for spontaneous remyelination to occur either adjacent oligodendrocytes
have to remyelinate the axons or oligodendrocyte progenitor cells must migrate into the
lesion.  Within the oligodendrocyte lineage, oligodendrocyte progenitors have the
highest migratory abilities (Gansmuller et al., 1991; Small et al., 1987).  Endogenous
oligodendrocyte progenitor cells located in the subventricular zone respond to a
lysolecithin-induced demyelination in the corpus callosum by migrating towards the
lesion and expressing PSA-NCAM all the way to the lesion (Nait-Oumesmar et al.,
1999).  The migration of the oligodendrocyte progenitors can be facilitated by FGF-2
and PDGF (Lachapelle et al., 2002) and neutrin-1 (Spassky et al., 2002). On the other
hand, oligodendrocyte progenitor migration can be inhibited by the chemokine CXCL1
(Tsai et al., 2002), by apotransferrin (Paez et al., 2002) and by class 3 semaphorins
(Spassky et al., 2002).  Several studies indicate that oligodendrocyte progenitors are
present in the demyelinating lesions of an MS patient’s CNS (Chang et al. 2002;
Wolswijk, 2002) indicating that in spite of the slower recruitment of progenitors that
occurs as one gets older this is not the sole obstacle impeding remyelination in the
plaques in MS.
However, there is an age-related decline in the rate of recruitment and
differentiation of oligodendrocyte progenitor cells in the repair of a demyelinated lesion
(Ando et al., 2003; Berlet and Volk, 1980; Chari et al., 2003; Franklin et al., 2002),
which is of obvious relevance to MS patients who may suffer for several decades.
Franklin et al. (2002) and Sim et al. (2002) suggested that impairment both of the
recruitment of oligodendrocyte progenitors cells into the lesion as well as the
differentiation of these cells into myelinating glia recently observed in the CNS of aged
animals collectively are primarily responsible for the age-associated decline in
remyelination efficiency.  The expression of growth factors, including PDGF, IGF and
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TGF-β, has been shown to be important for the development, migration and maturation
of oligodendrocytes (Milner et al., 1997).  A temporal delay in the expression profiles
of these growth factors was observed in old animals in comparison to that observed in
younger animals (Franklin et al., 2002; Hinks and Franklin, 2000).  The decreased
expression of myelin genes (i.e. MBP and PLP) was also shown in old rats (>12 months
of age; Ibanez et al., 2003).  Therefore, the recruitment and differentiation of
oligodendrocyte progenitors in older people likely occurs more slowly than in younger
individuals.
A number of developmental and pathological studies have shown the ability of
endogenous Schwann cells to migrate into the CNS toward a chemically induced (EtBr,
lysolecithin) demyelinated lesion and to remyelinate CNS axons (Blakemore, 1975,
1976, 1979; Graca and Blakemore, 1986).  The exposure of the neonatal spinal cord to
x-irradiation results in prevention not only of the generation of myelin-forming
oligodendrocytes just prior to myelination (Gnatack et al., 1973) but also compromises
the generation of astrocytes needed to populate the developmentally increasing size of
the spinal cord.  In an environment where astrocytes fail to maintain the CNS-PNS
border, Schwann cells now can enter the CNS, passing through the incomplete glia
limitans to myelinate axons (Blakemore and Patterson, 1978; Sims and Gilmore, 1983;
Sims et al., 1985).  In myelin-deficient rats myelinating oligodendrocytes degenerate
leading to a failure in myelination (Duncan et al., 1987).  However, astrocytes in
myelin-deficient rats are not compromised and thus maintain an intact glia limitans
throughout development and into adulthood.  In contrast to what is seen with x-
irradiation of the neonatal spinal cord of wild-type rats, no Schwann cell invasion is
detected in myelin-deficient rats.  However, Schwann cells will migrate into the CNS
and myelinate axons if the spinal cord of neonatal myelin-deficient rats is x-irradiated
neonatally.  This illustrates the importance of an intact glia limitans, which is formed by
astrocytes, in preventing Schwann cell invasion into the CNS (Duncan et al., 1988).
In a different animal model, where gliotoxins like EtBr (see Section 1.6.1) or
lysolecithin (see Section 1.6.2) are injected into white matter tracts of the spinal cord,
Schwann cells can be observed migrating into the CNS and contributing to
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remyelination of the axons (Blakemore, 1975, 1976, 1979; Graca and Blakemore,
1986).  EtBr kills oligodendrocytes, microglia and astrocytes resulting in demyelination
as well as breaking down the glia limitans that had been formed by the astrocytes,
whereas lysolecithin is more selectively toxic to oligodendrocytes, thus largely sparing
astrocytes.  Therefore, Schwann cells extensively repopulate EtBr-induced
demyelinated areas (e.g. caudal cerebellar peduncle) and remyelinate CNS axons in
these lesions (Woodruff and Franklin, 1999), but in lysolecithin demyelinated lesions
Schwann cell invasion is restricted only to the central, astrocyte-poor core of the area of
demyelination (Blakemore, 1976).  Itoyama et al. (1983) showed that Schwann cells
could be identified inside the astrocyte-poor central area of MS plaques.  Thus,
Schwann cell migration into the CNS and their remyelination of CNS axons are related
to the presence or absence of an intact astrocytic environment.
Schwann cell migration in vivo is likely to involve several cellular interactions
acting in concert, even though each interaction alone may promote sufficient migration
in vitro.  For example, molecules such as laminin, fibronectin and N-cadherin (Itoyama
et al., 1983; Iwashita et al., 1983; Jasmin et al., 2000), the CD9 glycoprotein (Anton et
al., 1995), the NG2 proteoglycan (Schneider et al., 2001), and the p75NGFR (Anton et
al., 1994) have all been implicated in the migratory ability of these glial cells.  Anton et
al. (1994) demonstrated that the CD9 glycoprotein enhances Schwann cell migration
both on rat pup DRG neurites and on rat pup sciatic nerve pieces in vitro.  The CD9-
induced increase in migratory ability of Schwann cells was correlated with elevation of
intracellular calcium level and tyrosine phosphorylation (Anton et al., 1995).  Studies
on the development of peripheral nerves (Heumann et al., 1987; Yan and Johnson,
1988; Di Stefano and Johnson, 1988; Rush, 1984) and on peripheral nerve injury (Fields
et al., 1989; Williams et al., 1983) have demonstrated an increased NGF and p75NGFR
expression by migrating Schwann cells.  Although the mechanisms by which NGF
binding to p75NGFR activates Schwann cell motility are not known, NGF was reported
to increase the expression of the L1 cell adhesion molecule by Schwann cells in vitro
and it was suggested that this neurotrophin may control cell migration (Seilheimer and
Schacher, 1987).  Which interaction or combination of interactions regulates Schwann
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cell migration in vivo may depend on the immediate environment and the molecular
characteristics of the migrating cells.  For example, in contrast to oligodendrocyte
progenitor cells, the intense inflammation and glial reactivity that accompanies
infection with Theiler's virus in highly susceptible strains of mice appears to prevent
Schwann cells from migrating into the CNS (Ozden et al., 1993).
Although not the focus of this study, there was a contribution of host
myelinating glia (i.e. oligodendrocytes and Schwann cells) to the repair of the EtBr
lesion induced in the model used in this research project.  At 2 weeks after injection of
EtBr into the right dorsal funiculus of the adult rat spinal cord, demyelination was still
evident at the lesion site (Fig. 2e) but by 8 weeks this region of white matter was almost
entirely remyelinated (Fig. 2f).  Based on studies by Yajima and Suzuki (1979),
Blakemore (1984) and Felts et al. (1997), this remyelination would be by both
oligodendrocyte progenitors and Schwann cells that had migrated into the EtBr-induced
lesion.  Whether the grafted OECs also contributed to this neural repair, since we now
know they will migrate to an EtBr-induced lesion, is a topic for future investigations;
the focus of the present study was on the migration of the OECs, not what the cells did
upon reaching the lesion.
5.2.2 Donor-Derived Myelinating Glia
The transplantation of myelin forming cells including oligodendrocytes and their
progenitors, Schwann cells, OECs, neuronal precursor cells or bone marrow cells has
shown therapeutic potential in promoting CNS repair (see Section 1.7).  The
transplanted cells have been examined for their ability to remyelinate CNS axons, to
survive within damaged CNS environment, and to migrate in the presence or absence of
reactive astrocytes and microglia.  The ability of donor-derived myelinating glial cells
to respond to migratory signals arising from focal areas of demyelination has to be
carefully investigated in order to identify the ideal cell candidate for therapeutic
transplantation.
In the EtBr model used in this study, OECs were grafted at T12 and the EtBr
was injected either at T8, T10, or T12 to induce demyelination at various distances (0
mm to > 15 mm) from the cell graft.  With an average length of each spinal cord
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segment in the lower thoracic area of 5 mm, OECs were able to migrate through the
dorsal funiculus at least as far as the T8 spinal cord segment (most rostral segment
examined), which was located as far as 15 - 20 mm from the grafting site.  When the
OECs were injected directly into an EtBr-induced demyelinated lesion at T12 there was
limited cell migration.  Perhaps in the latter instance the majority of OECs stayed within
the lesion vicinity to help in neural repair, maybe even being “instructed” to provide
such assistance by activated microglia.  OECs can, however, be induced to migrate
away from such a demyelinated lesion provided a second lesion is made a short distance
away from the first.
This is not the first study to find that OECs can migrate after grafting into the
CNS of an adult rat.  Using other models, OECs were shown to migrate from the dorsal
root entry zone of the spinal cord into dorsal horn and were thought to promote axonal
regeneration through laminae 1 to 5 of the grey matter (Ramon-Cueto and Nieto-
Sampedro, 1994).  The farthest distance to which OECs are thought to have migrated
after being grafted at T9 in the proximal stump of the transected spinal cord of an adult
rat is as far as the caudal cervical level (i.e. C7; Ramon-Cueto et al., 1998).  However, a
recent report suggested that OECs, derived from either the lamina propria of the mouse
olfactory mucosa (Ramer et al. (2004) or neonatal rat olfactory bulb (Riddell et al.,
2004), grafted directly into the DRG failed to migrate across the DREZ and also failed
to promote the regeneration of dorsal root axons across the DREZ.
Other myelinating glial cells (e.g. Schwann cells and oligodendrocyte progenitor
cells) have been shown to migrate for only limited distances after being grafted into the
CNS (Baron-Van Evercooren et al., 1992; Blakemore et al., 1986; Fawcett and Asher,
1999).  Transplanted into the cerebral hemisphere of newborn shiverer mice, Schwann
cells stayed within the vicinity of the graft and eventually disappeared from the CNS
parenchyma.  The migration and survival of CG4 cells (an oligodendrocyte progenitor
cell line) was found to be limited to areas of the injection site after transplantation into
the normal rat spinal cord (Franklin et al., 1996).  Host oligodendrocyte progenitors
were also shown to be unable to migrate over distances greater than 2 mm into the areas
of demyelination (Franklin et al., 1997).  Reactive astrocytes appear to impede the
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migration of both oligodendrocyte progenitor cells and Schwann cells (Fawcett and
Asher, 1999; Lakatos et al., 2003; Shields et al., 2000).  In contrast, OECs in our
experiments were able to migrate through areas containing reactive astrocytes provided
reactive microglia were also present along the migratory pathway.
Our data indicate that reactive microglia enhance OEC migration.  The distance
over which migratory signals were distributed in most of the experiments performed
using this in vivo model was only one spinal cord segment (~ 5 mm).  This distance was
still 2-3 times further than oligodendrocyte progenitors (~ 2 mm; Nait-Oumesmar et al.,
1995; Franklin and Blakemore, 1997) or Schwann cells (around the implantation site;
Baron-Van Evercooren et al., 1992; Blakemore et al., 1986) migrated in response to a
demyelinated lesion even in the presence of activated host glia in the intervening CNS
tissue.  Thus, not only do oligodendrocyte progenitor cells and Schwann cells very
likely differ in their ability to respond to migratory signals emanating from an area of
tissue injury, but the migratory ability of both of these cell types within the injured CNS
of adult mammals is also far less that of OECs.
5.3 Contribution of Reactive Microglial Cells to Migration of Myelinating Glia
Microglia are extraordinarily sensitive to any changes within the CNS
microenvironment (Barron, 1995; Gabicke-Haerter et al., 1996; Kreuzberg, 1996;
Moore and Thanos, 1996).  In response to CNS injury (i.e., trauma, inflammation, etc.)
microglial reactivity is sometimes detrimental (Piani et al., 1991; Chao et al., 1992;
Giulian et al., 1993) and sometimes beneficial (Mallat et al., 1989; Elkabes et al., 1996;
Rabchewsky and Streit, 1998) in terms of contributing to the repair of neural tissue.
They play a major role in orchestrating the contribution of multiple cell types to
immune reactivity, inflammation, and demyelination within the CNS (Chao et al., 1995;
Giulian and Lachman, 1985; Giulian et al., 1986; Lee et al., 1993; Righi et al., 1989;
Selmaj et al., 1990), and thus in many instances exacerbate the inflammatory response
associated with CNS injury (Benveniste, 1997).  Microglia have been shown to release
cytokines, including IL-1, TNF-α, IL-6 (Dickson et al., 1993; Hetier et al., 1988; Lee et
al., 1993), excitatory amino acids (i.e. glutamate), oxidative radicals, and nitric oxide
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(reviewed in Banati et al., 1994; Gordon, 1995; Gehrmann et al., 1995), all of which
contribute to the inflammatory reaction in the damaged CNS.  The proinflammatory
cytokines (i.e. IL-1, TNF-α, IL-6) are secreted early in the glial cell response to brain
injury (Eddleston and Mucke, 1993; Hebert et al., 2003; Ridet et al., 1997) and in
addition to promoting the inflammatory response also stimulate astrogliosis (Tetzlaff et
al., 1988).  The inflammatory environment of the damaged CNS, where activated
microglia and astrocytes are present, has been suggested to limit the migration of
myelinating glia including oligodendrocyte progenitors (Fawcett and Asher, 1999) and
Schwann cells (Baron-Van Evercooren et al., 1992; Fawcett and Asher, 1999; Shields et
al., 2000).
Activated microglia in MS also express proteinases such as MMPs (Colton et
al., 1993; Gehrmann et al., 1995; Gottschall et al., 1995).  MMPs represent a family of
23 zinc-containing endopeptidases characterized in mammals (reviewed in Yong et al.,
2001), which are known to degrade proteins of the extracellular matrix during
embryogenesis and wound healing (Basbaum and Web, 1996; Werb, 1997).  Increased
expression of MMPs has been implicated in several neurological diseases such as MS
and ischemic stroke, in which inflammation occurs (reviewed in Yong et al., 2001).
Pro-inflammatory cytokines (i.e. IL-1, TNF-α,) can up-regulate MMP expression, in
part through NFkB transcription activity (Lee et al., 2001).  MMPs, in turn, can
proteolytically cleave precursor molecules such as pre-IL-6, pre-TNF-α, pre-TGF-α
(Black et al., 1997; Yu and Stamenkovic, 2000), and thus significantly promote
inflammation in the CNS.  In further contribution to the pathogenesis of MS, MMPs
cause the disruption of blood-brain barrier and facilitate leukocyte invasion into the
CNS parenchyma (Yong et al., 1998), where activated leukocytes make their
contribution to the inflammatory response by secreting proinflammatory cytokines (i.e.
INF-γ, IL-6, TNF-α, TGF-α; Merrill and Benveniste, 1996; Selmaj and Raine, 1988).
Gelatinase B (MMP9), in particular, was shown to degrade MBP in the myelin sheath in
vitro (Gijbelts et al., 1993; Chandler et al., 1995) and this action of MMP9 could be an
important contributor to demyelination in neuroinflammatory disease.  Breakage of cell-
extracellular matrix contacts by MMPs leads to cell apoptosis as a result of cell
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detachment and loss of integrin signaling (Ruoslanti and Reed, 1994; Chen and
Strichland, 1997).  Production of these cytokines and MMPs by host glia and infiltrating
inflammatory cells plays therefore a detrimental role in MS.
How increased secretion of proinflammatory cytokines and MMPs might
influence the migration of myelinating glia remains to be elucidated.  Tourbah et al.
(1997) noted that migrating CG4 cells were often associated with reactive astrocytes.
However, the migration of these cells was limited possibly due to an inhibitory effect of
the CCL3 chemokine (i.e. macrophage inflammatory protein-1α; Nguyen et al., 2003)
via CCR1, which is the the CCL3 chemokine receptor that is expressed by CG4 cells
(Nguyen and Stangel, 2001; Stangel et al., 1999).  Filipovic et al. (2003) observed the
expression of one chemokine, growth-related oncogene-alpha (GRO-alpha) and its
receptor CXCR2 by oligodendrocyte progenitors in the highly proliferative
subventricular zone of the telencephalon of human fetuses.  However, neither GRO-
alpha nor CXCR2 were present in oligodendrocyte progenitors found on autopsy in the
brain sections of MS patients. Instead, activated microglia localized on the border of
demyelinated plaques expressed both GRO-alpha and CXCR2.  Thus, the change in the
chemokine receptor profile of oligodendrocyte progenitors, for example downregulating
the expression of CXCR2 and possibly up-regulating the expression of CCR1, may
partially explain the limited migration of oligodendrocyte progenitors within areas of
inflammation in the CNS and why remyelination is not more efficient in MS.
There is very little data on how and whether microglial reactivity can influence
the migration of oligodendrocytes and Schwann cells during the remyelination phase of
neural repair.  Among the cells of the oligodendrocyte lineage, O4+ve/GalC-ve
oligodendrocyte progenitor cells possess the best migratory ability (Gansmuller et al.,
1991; Small et al., 1987).  The presence of EAE was reported to enhance CG4 cell
migration (Tourbah et al., 1997).  Although Tourbah et al. (1997) did not mention the
association of migrating CG4 cells with reactive microglia, one could assume that
microglia would be an important player within the inflammatory environment of the
CNS in EAE.  Microglial reactivity in response to trauma can also be beneficial to
neural repair and facilitate axonal regeneration through areas of injured CNS tissue
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(Prewitt et al., 1997; Rabchevsky and Streit, 1997; Lazarov-Spiegler et al., 1996;
Stichel et al., 1999).  Schwann cells migrate into such areas of injury, which may be
under both the facilitatory control of microglia (Zeev-Brann et al., 1998; Dezawa et al.,
1999) and the inhibitory influence of astrocytes (Fawcett and Asher, 1999).  On the
other hand, the depletion of microglia and macrophages by clodronate in young adult
female rats that have a lysolecithin-induced demyelinated lesion in their spinal cord had
no effect on Schwann cell remyelination but resulted in a decreased remyelination by
oligodendrocytes (Kotter et al., 2001).  The specific response of microglia to CNS
damage may well depend on the type of injury and, depending on how the
demyelination was induced, could potentially change the profile of migratory signals
expressed by these glial cells and to which myelinating glia respond.
The contribution of reactive microglia to the generation of migratory signals for
cells of the blood has been known for some time now (Babcock et al., 2003; Gehrmann
et al., 1993), but only recently has it been suggested that these chemotactic signals
likely also induce the migration of other cell types (Aarum et al., 2003; Bettinger et al.
2002).   Aaron et al. (2003) have shown that EGF released from mouse microglial cells
influence the directional migration of neural precursor cells of the CNS and
hypothesized that activated microglia play a role in directing the replacement of cells
damaged or lost from injury to the brain or spinal cord.  Bettinger et al. (2002) reported
a similar chemotactic effect on GL261 mouse glioma cells and suggested microglial
reactivity may promote the invasive phenotype of astrocytoma cells.
The findings reported in this thesis also implicate microglial cells in contributing
to the generation of a migratory signal for cells other than lymphocytes, monocytes,
neural precursor cells or glioma cells.  The numbers of OECs that migrated into the T11
segment of the spinal cord after grafting into the dorsal funiculus of T12 varied
depending on the presence, location, and number of small, focal, EtBr-induced
demyelinated lesions.  It was also observed that as increased numbers of OECs entered
the T11 segment they were found within the area of astrocytic and microglial reactivity
in the ipsilateral dorsal funiculus.  In contrast to other studies concentrating on the
association between reactive astrocytes and migrating oligodendrocyte progenitors
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(Armstrong et al., 1990; Fruttiger et al., 1999; Milner et al., 1997; Osterhout et al.,
1999; Tourbah et al., 1998) or Schwann cells (Fawcett and Asher, 1999; Franklin and
Blakemore, 1993; Harrison, 1985; Itoyama et al., 1983), the migration of OECs in the
animal model used in this research project seemed to be dependent on the presence of
reactive microglia since it was significantly diminished when the microglial response
was dampened by a 4 week exposure to daily injections of minocycline.  The
minocycline had no apparent effect on the astrocytic reactivity, at least as evidenced by
staining with vimentin and GFAP antisera, thus implicating reactive microglia as one
potential source, either directly or indirectly, of the migratory signal(s) driving OEC
migration in this animal model.
Microglial activity observed at the EtBr-induced lesion (i.e. at T10) and along
the migratory path (i.e. T11) may well differentially contribute to the generation of a
migratory signal for myelinating glia.  Similar to that reported in previous studies
(Yajima and Suzuki, 1979), an EtBr injection in our experiments resulted in killing all
glial cells including oligodendrocytes, microglia, and astrocytes in the vicinity of the
injection site with the demyelination of the right dorsal funiculus still being evident at 2
weeks survival (Fig. 4.2e).  At the lesion site, dying cells release various signals
including growth factors, cytokines, etc., that activate microglia, macrophages, and
astrocytes to begin the process of neural repair.  These cells, as well as oligodendrocyte
progenitor cells and Schwann cells, migrated into the lesion and contributed to the
injury repair that was observed by 8 weeks survival (Fig. 4.2f).  Microglia and
astrocytes of the adjacent spinal cord segments also become activated under signals
(e.g. cytokines, MMPs, etc.) released from the cells of the damaged area and in turn also
secrete cytokines and MMPs.  Along with those factors secreted at the site of injury,
these additional induced signals may facilitate not only the migration of host
myelinating glia but also that of grafted OECs.  The specific signals generated by this
glial reactivity and that contributed to OEC migration in the present study require
additional investigation.  It is possible OECs express cytokine receptors that can bind
microglial-derived cytokines, which in turn could facilitate their migration
chemotactically through areas of neuropil containing reactive microglia.  OECs are
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known to express the IL-6 receptor (Nan et al., 2001), but it is not known which
additional cytokine receptors they might also express.  In addition, MMPs released by
microglia in response to injury may have also contributed to inducing migration of
OECs along the path of glial reactivity by reconstructing the extracellular matrix,
breaking cell-matrix contacts and activating cytokine precursors (e.g., pre-IL-6), all of
which may contribute to generating a chemotactic gradient for the migration of OECs.
Why does it take more than 4 weeks for a significant number of OECs to
migrate into T11 when a single lesion is made at T10 even though microglia in the T11
segment react much sooner than this?  The glial reactivity detected at T11 appeared to
be more intense in rats surviving for 8 weeks in comparison to those at shorter survival
times (fig. 4).  Whatever the reason is, it was found in this study that a 4 week treatment
with minocycline diminished microglia activity and resulted in decreased OEC
migration, thus implicating the microglial response during the first 4 weeks after injury
in contributing to the generation of a migratory signal.  In contrast, precocious (at 2
weeks) migration of OECs away from a demyelinated lesion was noted in rats in which
a second lesion had been made 2 segments away.  This may indicate that two EtBr-
induced lesions result in the migratory signal(s) being generated faster and/or more
intensely when there are 2 lesions rather than one, even though the OX-42 and OX-18
immunostaining could not detect a difference in the microglial response.  To further
complicate matters, OECs did not migrate away when injected directly into the EtBr
lesion of a single lesioned rat even though the intensity of the microglial reactivity
detected by staining with anti-OX-18 antibody in the adjacent segment (i.e. T11) was
similar to those of rats that had received an EtBr injection at T10 and an OEC graft at
T12.  Clearly, these experimental manipulations reveal variations in the generation of a
migratory signal(s) that may be of use in identifying the molecules involved.
5.4 Relevance of Migratory Ability of OECs to Neural Repair
MS pathology is characterized by the presence of multiple plaques of
demyelination scattered throughout the CNS.  In order to contribute to neural repair in
these demyelinated lesions, myelinating glia transplanted into the CNS of an MS patient
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as part of a therapeutic approach to repairing the damage would have to migrate through
both normal and inflammed areas of neuropil to reach the numerous isolated plaques.
Upon reaching each demyelinated lesion the myelinating glia will then have to
contribute to remyelination of the axons in the presence of myelin debris and of reactive
astrocytes and microglia.  In addition to remyelination, the ability to promote the
regeneration of transected axons that are often found in MS plaques (Bitsch et al., 2000;
Davie et al., 1995; De Stefano et al., 1998; Ferguson et al., 1997; Kornek et al., 2000;
Trapp et al., 1998) would be an additional benefit of myelinating glia following
transplantation.  OECs have a greater likelihood of being able to perform the migratory,
remyelination, and axonal growth promoting tasks than either oligodendrocyte
progenitors or Schwann cells, which is why they are being considered as potential
candidates as part of a therapeutic approach to treating neurological disorders including
MS and spinal cord injury (Barnett and Chang, 2004; Barnett and Riddell, 2004; Boyd
et al., 2003, 2004; Doucette, 1995, 2001; Franklin and Barnett, 2000; Li et al., 1997,
1998; Nieto-Sampedro, 2003; Ramon-Cueto et al., 1998, 2000).
The beneficial contribution of OECs to neural repair include their abilities: 1) to
facilitate remyelination of CNS axons in vivo in animal models with demyelination and
spinal cord injury, as well as to remyelinate DRG axons in vitro (see Section 1.2.5);  2)
to promote the regeneration of not only olfactory axons but also of other PNS and CNS
axons, with the axon regeneration leading to functional recovery (see Section 1.2.5);  3)
to integrate into the neuropil of the CNS, coming into close contact with astrocytes with
no intervening basal lamina (see Section 1.2.5);  4) to secrete growth factors such as
NGF, express cell adhesion molecules such as L1, N-CAM, PSA-N-CAM, and express
extracellular matrix molecules such as laminin and fibronectin, which collectively play
key roles in neural repair (see Section 1.2); 5) to migrate through CNS neuropil
containing reactive astrocytes and microglia (see Section 1.8.3); and 6) to respond to
migratory signal(s) arising as a result of a focal demyelination and move towards the
demyelinated lesion, as described in this research project.
The main goal of transplanting myelinating glia as part of a therapeutic approach
to treating neurological disorders such as MS and spinal cord injury is to facilitate host
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tissue repair processes including remyelination and axonal regeneration.  There is a
great possibility that implanted OECs will facilitate the remyelination of CNS axons
after they have migrated some distance from the grafting site.  OEC remyelination of
CNS axons in vivo has been reported in animals with EtBr-induced demyelination
(Akiyama et al., 2004; Franklin et al., 1996; Imaizumi et al., 1998, 2000; Kato et al.,
2000; Smith et al., 2002) and after spinal cord injury when the OECs were grafted into
the lesion (Li et al., 1997, 1998).  The in vitro remyelination of DRG neurites by OECs
was also previously shown (Devon and Doucette, 1992; 1995).  In addition to their
remyelinating ability, OECs have been shown to enhance axonal conduction through
previously demyelinated areas of the spinal cord (Imaizumi et al., 1998, 2000).
However, the ability to remyelinate either CNS (Boyd et al., 2004; Takami et al., 2002)
or PNS (Plant et al., 2002) axons by OECs has been questioned.
Although Boyd et al. (2004) recently reported that Lac-Z expressing OECs
implanted into a cystic cavity of the adult rat spinal cord facilitated axonal regeneration
and remyelination, these OECs did not associate directly with the remyelinated CNS
axons.  Peripheral type remyelination of the regenerating axons was observed, however,
and was found to be due to Schwann cell migration into the lesion in the presence of
transplanted OECs.  This indicates that OECs may facilitate axonal regeneration in the
damaged spinal cord by providing a microenvironment conducive to Schwann cell
migration into the site of injury, which in turn provides support for axonal growth and
results in remyelination of the axons.  When grafted into the cystic cavity of the adult
rat spinal cord, OECs may not only be “instructed” by reactive glia, and perhaps also by
other cells comprising the inflammatory response, to stay in the vicinity of the lesion
but they themselves may also be playing an “instructive” role in attracting host
Schwann cells to migrate into the lesion.  In addition, NGF secreted in part by OECs
(Boruch et al., 2001; Ramon-Cueto et al., 1993) may bind to the p75NGFR on Schwann
cells, possibly facilitating their migration chemotactically as has been shown in vitro
(Anton et al., 1994). The OECs in the lesion cavity may also shelter the Schwann cells
that migrate into the lesion, effectively allowing them to function as axonal growth
promoting and remyelinating glia in an area of extensive astrocytic and microglial
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reactivity.  Such sheltering may especially protect these Schwann cells from activated
astrocytes previously shown to inhibit Schwann cell migration into the CNS (Fawcett
and Asher, 1999).
The very first clinical signs of disability experienced by MS patients are due to
axonal injury that occurs inside the earliest forming plaques (Bitsch et al., 2000; Davie
et al., 1995; De Stefano et al., 1998; Ferguson et al., 1997; Kornek et al., 2000; Trapp
et al., 1998).  Therefore, transplantation of myelinating glia for the treatment of
demyelinating diseases should also address the regeneration of these transected axons to
restore function and reverse the disability.  OECs have been shown to promote the
regeneration of not only olfactory axons (Graziadei and Monti Graziadei, 1978, 1979;
Barber and Lindsay, 1982; Doucette et al., 1983; Doucette, 1990) but also of other PNS
(Guntinas-Lichius et al., 2001, 2002; Ramon-Cueto and Nieto Sampedro, 1994) and
CNS (Li et al., 1997, 1998; Nash et al., 2002; Ramon-Cueto et al., 1998; Smale et al.,
1996) axons.  Transplantation of OECs into animal models of spinal cord injury
enhances functional recovery of spinal reflexes (Navarro et al., 1999), locomotion
(Keyvan-Fouladi et al., 2003; Li et al., 2003; Lu et al., 2001, 2002; Plant et al., 2003;
Ramon-Cueto et al., 2000), forepaw reaching (Nash et al., 2002), and breathing (Li et
al., 2003).  However, recent reports have tempered the excitement surrounding the
therapeutic potential of OECs in promoting the regeneration (Gomez et al., 2003;
Riddell et al., 2004; Ramer et al., 2004; Takami et al., 2002) and remyelination
(Takami et al., 2002; Boyd et al., 2004) of damaged CNS axons.  Possible failure of
OECs to survive after being grafted into the cystic cavity of a compression injury in the
adult rat spinal cord in a study by Takami et al. (2002) was associated with far less
axonal regeneration and locomotor recovery in comparison to that of grafted Schwann
cells   OECs derived from either the lamina propria of the mouse olfactory mucosa
(Ramer et al., 2004) or neonatal rat olfactory bulb (Riddell et al., 2004) also failed to
promote the regeneration of dorsal root axons across the DREZ.  The type of injury and
the complexity of the reparative processes due to the host cell response to tissue
damage, as well as the origin of OECs used for grafting, may all potentially influence
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the survival and subsequent response of the grafted OECs to neural repair of the CNS
tissue.
In order for myelinating glia to perform the migratory, remyelination, and
axonal growth promoting tasks discussed above, these cells must integrate into the CNS
neuropil thus coming into close contact with host glial cells, especially reactive
astrocytes. Reactive astrocytes impede the migration of both oligodendrocyte progenitor
cells and Schwann cells (Fawcett and Asher, 1999; Lakatos et al., 2003; Shields et al.,
2000).  In contrast, OECs in the present research project migrated through areas
containing both reactive astrocytes and reactive microglia.  Grafting of OECs into the
spinal cord of Group 2-7 rats (Table 4.1) resulted in activation of microglia and
astrocytes at the site of the graft as well as in adjacent spinal cord segments, as detected
with OX-18 and vimentin immunostaining, respectively.  The migration of OECs into
the neuropil of the lower thoracic spinal cord segments rostral to the site of injection
(i.e., T11-T8) at all survival times (2-8 weeks) in these experimental groups shows that
OECs can coexist with reactive astrocytes and microglia within the CNS.  Lakatos et al.
(2003) reported lessening of the response of host astrocytes and of the expression of
chondroitin sulphate proteoglycans at the site of injection after grafting neonatally-
derived OECs into the non-lesioned dorsal funiculus of the adult rat spinal cord in
comparison to that seen after grafting Schwann cells.  In addition, OECs can
intermingle with astrocytes in co-culture without causing astrocytes to undergo
hypertrophy and to increase their expression of chondroitin sulphate proteoglycan in
comparison to that of Schwann cells and astrocytes (Lakatos et al., 2000).  Collectively,
these data suggest the OECs have little difficulty integrating into the neuropil of
damaged CNS tissue primarily because they can co-exist, unlike Schwann cells, with
astrocytes without being rejected, much as occurs normally in the CNS portion of the
primary olfactory pathway (see Section 1.2.3).
Originally identified as critical mediators of neuronal survival and nerve fiber
outgrowth during development, neurotrophic factors have been shown to protect
neurons and facilitate repair in areas of CNS injury in adult animals (Campenot et al.,
2004; D'Ambrosi et al., 2004; Jones et al., 2001; Pierchala et al., 2004; Tuszynski et al.,
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1999).  The infusion of neurotrophic factors such as BDNF and NT-3 into Schwann
cell-containing guidance channels connecting the proximal and distal stumps of the
transected spinal cord promoted regeneration of axons in descending pathways from the
brainstem that grew into these guidance channels (Xu et al., 1995).  OECs have been
shown to produce PDGF (Kott et al., 1994), NGF (Boruch et al., 2001; Guthrie and
Gall, 1991; Ramon-Cueto et al., 1993), neuropeptide Y (Ubnik et al., 1994), and S100
(Barnett et al., 1993; Cummings and Brunjes, 1995; Doucette and Devon, 1995;
Franceschini and Barnett, 1996; Gong et al., 1994).  Furthermore, Ramon-Cueto and
Avila (1994) suggested that OECs might secrete additional growth factors including
BDNF, neurotrophin-3 and neurotrophin-4 based on evidence that these cells express
the mRNAs for these growth factors.  The action of secreted neurotrophins on neurons
and Schwann cells might be facilitated by the OEC expression of the p75NGFR with
which OECs might use to present the specific neurotrophins, such as NGF, to these
other cells types (Barnett et al., 1993; Franceschini and Barnett, 1996; Goodman et al.,
1993; Ramon-Cueto and Nieto Sampedro, 1992; Turner and Perez-Polo, 1993, 1994;
Vickland et al., 1991).  This close contact putative chemotactic effect of the OEC
expression of the p75NGFR and NGF secretion would be in addition to a possible
longer range migratory signal(s) that the OECs may provide to induce p75NGFR+ve
Schwann cells to migrate into the lesion.  Migration of Schwann cells in vitro has been
shown to be influenced by levels of NGF (Anton et al., 1994).  OECs also express
several adhesion molecules including N-CAM (Key and Akeson, 1990), PSA-N-CAM
(Franceschini and Barnett, 1996; Miragall et al., 1988), and L1 (Doucette, 1995;
Miragall et al., 1988; Ramon-Cueto and Avila, 1994), as well as extracellular matrix
molecules such as laminin (Doucette, 1996; Kafitz and Greer, 1997; Liesi, 1985), and
other growth promoting molecules such as glia-derived nexin (Reinhardt et al., 1988).
All of these molecules are known to facilitate axonal growth both in vivo and in vitro
(Bixby et al., 1988; Boyd and Gordon, 2003; Fu and Gordon, 1997; Kleitman et al.,
1988).
Transplantation of myelinating glia and the administration of growth factors to
areas of CNS injury have helped to overcome the normally abortive regeneration of
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CNS axons and to facilitate their remyelination within the injured CNS.   Researchers
have used various molecular genetic techniques to transfer selected growth factor genes
into cells that will then be used to deliver growth factors constitutively to all cells at the
site of injury.  Both retroviral and adenoviral vectors have been utilized to introduce the
genes of interest (Owens, 1991).  Menei et al. (1998) transfected Schwann cells in vitro
with a replication deficient Moloney murine leukaemia retrovirus carrying the human
preproBDNF cDNA.  These BDNF-secreting Schwann cells were transplanted into the
transected adult rat spinal cord and were found to enhance axonal regeneration across
the injury in comparison to wild-type Schwann cells.  OECs transfected with the gene
for glial cell line-derived neurotrophic factor (GDNF) were also found to promote CNS
repair after being grafted into the transected adult rat spinal cord (Cao et al., 2004).  The
expression of either BDNF by Schwann cells or GDNF by OECs enhanced the growth-
promoting properties of these cells within the microenvironment of the lesion site
during recovery period that followed the spinal cord injury.
The migration of OECs towards a focal demyelination after being grafted into
normal or demyelinated areas of the adult rat spinal cord, as found in this thesis, is a
very important ability of these cells.  Several previous studies have reported
circumstantial evidence that OECs can migrate within the microenvironment of the
injured spinal cord when Hoechst prelabelled OECs were grafted very close (1 mm) to
the site of injury (Navarro et al., 1999; Ramon-Cueto and Nieto-Sampedro, 1994;
Ramon-Cueto et al., 1998, 2000), or when unlabelled OECs are injected directly into a
very small lesion (Li et al., 1997, 1998).  An important finding arising from the present
study is the ability of OECs to respond to migratory signals arising as a result of making
a small, focal demyelination two to four spinal segments rostral to the site of grafting.
This migratory ability of OECs, coupled with their potential ability to respond to
endogenous migratory signal(s) arising from the numerous isolated plaques in the spinal
cord of an MS patient, are invaluable qualities that make OECs very attractive as part of
a therapeutic approach to treating the pathology of MS.
An additional important finding of this research project is that the migration of
OECs within the spinal cord is in response to a signal(s) associated with the activation
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of microglia, as opposed to activation of astrocytes, at the lesion site and/or along the
migratory path.  The injection of EtBr into the spinal cord at different distances from the
site of an OEC graft in Group 2, 3 and 5 rats (see Table 4.1) resulted in an activation of
astrocytes and microglia in the right dorsal funiculus at the site of the EtBr injection as
well as along the migratory path between the cell graft and the lesion.  In these rats, an
increased number of OECs migrated preferentially through the neuropil of the
ipsilateral dorsal funiculus, which was highly populated by reactive astrocytes and
microglia.  In addition to their being microglial-derived migratory signal(s) generated in
the chemically induced demyelinated area, one has to also consider the possibility that
there are concentration gradients of the migratory signal(s) along the migratory path
between the cell graft and the lesion.  In contrast to the migration of OECs when they
were grafted at a distance from the EtBr lesion in Group 2 and 3 rats, when they were
grafted directly into a small, focal demyelinated lesion (i.e., Group 4 rats) far fewer
OECs migrated away from the grafting site even though reactive microglia were present
in the adjacent spinal cord segments, as has been also reported by other neuroscientists
(Boyd et al., 2004; Plant et al., 2003; Takami et al., 2002).  However, when two EtBr
lesions were made 2 spinal cord segments apart (i.e., Group 5 rats) and the OECs were
grafted directly into one of these lesions the OECs were found to migrate precociously
towards the second lesion. Activated microglia at the lesion site in the Group 4 rats
might have “instructed” grafted OECs to contribute to the repair process of
demyelinated lesion, perhaps by creating a microenvironment conducive to Schwann
cell migration.
The minocycline data reported in this thesis implicate microglial reactivity as a
major contributor to the generation of the migratory signal(s) driving the migration of
OECs in the EtBr model used in this study (see Section 5.3).  Specifically, decreasing
the reactivity of microglia by a four week daily exposure to minocycline resulted in a
corresponding decrease in the number of OECs that migrated into the T11 segment of
the spinal cord.  There was no indication, as judged by GFAP and vimentin
immunostaining, that the minocycline treatment reduced the astrocytic reactivity. Thus,
this research project did not identify astrocytes as contributors of any potential signals
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inducing OECs to migrate away from the site of a cell graft towards a small, focal
demyelinated lesion.  Although, the minocycline experiments identified the microglial
reactivity as contributing to the EtBr lesion-induced OEC migration, it is possible the
astrocytic reactivity may also have played a role in generating a migratory signal(s) but
that the generation and secretion of such a signal(s) might be dependent on the presence
of a microglial response.  Therefore, even if the reactive astrocytes in the T11 segment
of Group 2, 3 and 5 rats may have contributed to the migration of OECs away from the
grafting site, the signal obviously was not powerful enough in rats in which the
microglial reactivity was impeded by minocycline treatment (i.e., Group 6 and 7 rats).
It is also possible that the presence of an astrocyte-derived signal(s) is totally dependent
on the presence of reactive microglia.
The present study focused on the ability of OECs to respond to migratory
signal(s) arising as a result of a small, focal demyelination in the spinal cord of adult
rats and on the ability of these grafted cells to migrate through areas of neuropil
containing reactive microglia and astrocytes.  Both reactive astrocytes and microglia are
important players in the complex repair processes that must occur to repair the
demyelinated lesions in MS as well as during the regeneration and remyelination of
damaged axons following spinal cord trauma.  Because OECs are not rejected from the
neuropil of the CNS, this enables them to migrate amongst reactive microglia and
reactive astrocytes without obstructing the ability of these host glial cells to do the job
of neural repair.  Whether the OECs that migrate towards the demyelinated lesion
contribute to neural repair upon reaching the lesion is an area for future study.  Based
on what is known about the growth promoting ability of OECs (see Section 1.2.5),
however, it can be hypothesized that upon reaching the lesion the OECs will create a
more favorable microenvironment for axonal regeneration and remyelination by host-
derived myelinating glia, including even host Schwann cells.
5.5 Prelabelling Cells Prior to Grafting
Transplantation of myelinating glia for the purpose of neural repair is a
promising approach in the treatment of demyelinating diseases and spinal cord injury. It
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is critically important to determine the efficacy of grafting the different types of
myelinating glia using animal models before the approach is translated to humans.  A
proper evaluation of the contribution of grafted oligodendrocyte progenitor cells,
Schwann cells or OECs to neural repair cannot be made unless the cells are prelabelled
prior to grafting.  Otherwise there is no way to tell whether the oligodendrocyte
remyelination is due to host oligodendrocytes or ones that arose from the grafted cells.
Likewise with OECs and Schwann cells, which both remyelinate axons with peripheral
type myelin (see Section 1.7), it is essential for the experimenter to determine the source
of the remyelinating cells; i.e. are they host or donor in origin. For example, following
intraspinal implantation, OECs are believed to transform into Schwann cell-like cells
that are thought to be the ones facilitating the axonal regrowth and responsible also for
remyelinating the axons (see Section 1.2.5).  One fact often overlooked in these studies
is that Schwann cells, which share several phenotypic features with OECs (see Section
1.2), migrate into the spinal cord after injury (Beattie et al., 1997; Brook et al., 1998;
Namiki et al., 2000; West et al., 2001; Takami et al., 2002).  Given that the invasion of
Schwann cells likely coincides with the retention of grafted OECs at sites of spinal cord
injury, new questions are raised as to which glial cell type is responsible for supporting
the regeneration of central axons.  The study by Boyd et al. (2004) was the first
ultrastructural study to use prelabelled OECs in a compression injury model and
provided direct evidence that OECs do not associate with axons nor do they form
myelin or basal lamina after implantation into the injured spinal cord of adult rats.
None of the previous studies provided ultrastructural evidence of the fate of prelabelled
OECs after intraspinal implantation into or adjacent to the site of injury, even though
they attempted to describe in detail the interactions of these grafted cells with central
axons and other neural elements (e.g., invading Schwann cells) (Li et al., 1998, 2003;
Plant et al., 2003; Takami et al., 2002).   Instead, the researchers assumed the Schwann
cell-like cells seen at the site of injury arose from the implanted OECs.  Because Boyd
et al. (2004) used prelabelled OECs in their grafting experiments, they could determine
that grafts of OECs are indeed beneficial, but not necessarily for the reasons proposed
previously in the literature.
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5.5.1 Fluorescent dyes
Fluorescent dyes such as DiI and Hoechst, as well as transfections with a viral
vector containing the reporter gene for green fluorescent protein (discussed in Section
5.5.2), have all been widely used to label cells before grafting into host CNS tissue and
to visualize the transplanted cells using fluorescent microscopy (Baron-Van Evercooren
et al., 1996; Gansmuller et al., 1992; Ramon-Cueto and Nieto-Sampedro, 1994; Ramon-
Cueto et al., 2000; Verdu et al., 2001).  Prelabeling cells before grafting into the CNS
of experimental animals is necessary to determine whether the cells survive grafting
into an area of CNS injury, to track their migration (or lack thereof), their migratory
routes, and the cells with which they come into intimate contact.
DiI, a carbocianone, is a lipophilic dye that has been utilized in some studies to
prelabel cells (e.g. Schwann cells, oligodendrocyte progenitors, astrocytes) prior to
grafting (Baron-Van Evercooren et al., 1996; Gansmuller et al., 1992).   Soluble in
100% ethanol but not in aqueous solution (Honig and Hume, 1986), DiI is inserted into
the plasma membrane and diffuses within the plane of the membrane to label the entire
cell surface.   As noted by Gansmuller et al. (1992), DiI labeling does not affect the
survival, migratory ability of astrocytes, oligodendrocyte progenitors and the Schwann
cell line MSC80, transplanted into the newborn Shiverer and normal mouse brain.
Baron-Van Evercooren et al. (1996) also showed that DiI-labeling did not impinge on
the migration of oligodendrocyte progenitors and Schwann cells in response to
migratory signals arising from a lysolecithin induced demyelinated lesion in the adult
wild type and Shiverer mouse spinal cord.
In this research project, DiI-labelled OECs were frozen and stored at -70°C until
needed for grafting in one of the cell migration experiments (see Section 2.4.4).  Similar
to that of unlabelled OECs, the viability of the cells after thawing was approximately
75%.  Furthermore, some animals included in Group 1 to 5 rats and all animals in
Group 6 and 7 rats survived for 8 weeks, at which time they were perfused, their spinal
cords were dissected and then processed for fluorescent microscopy.  After all this time,
DiI-labelled OECs were easily detected within the rat’s spinal cord rostral to the cell
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graft.   Therefore, DiI is a reliable marker, which can help identify grafted cells within
host animal tissue, without compromising the viability of the grafted cells.
One disadvantage to the use of DiI for prelabelling cells is the possibility that
the dye may leak out of the cell.  If leakage does occur, then cells of the host animal
may incorporate the dye into their plasma membrane and be mistakenly identified as
grafted cells.  In the present study, DiI+ve particles were found intra- and
extracellularly in spinal cord sections obtained from experimental animals.  Spinal cord
tissue in our experiments was additionally stained with Hoechst dye in order to label
cell nuclei.  Each DiI+ve/Hoechst+ve cell had an elongated cell body and unbranched
cytoplasmic processes and these were the cells counted for statistical analysis (Fig. 4.2).
Several spinal cord sections chosen for staining with the microglial markers OX-18 and
OX-42 were also studied using fluorescent microscopy and in none of these sections
were microglia seen to be DiI+ve, nor did any of the DiI+ve cells have a multipolar
morphology characteristic of microglia or astrocytes.  Furthermore, leakage of DiI from
the grafting site into the adjacent spinal cord segment is extremely unlikely since there
was no staining of axons in the dorsal funiculi of any of the rats in this study.
Hoechst (2'-(4-Ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-
benzimidazole trihydrochloride, bisBenzimide Hoechst 33342) is membrane-permeable
fluorescent dye, which intercalates in A-T regions of DNA and stains nuclei with low
cytotoxicity.  Labeling with Hoechst was used to identify cells within host tissue after
transplantation of either Schwann cells in animal models with lysolecithin–induced
demyelination (Baron-Van Evercooren et al., 1992, 1993) or OECs in animals with
spinal cord injury (Ramon-Cueto and Nieto-Sampedro, 1994; Ramon-Cueto et al.,
2000; Verdu et al., 2001).  Both Schwann cells and OECs were visualized by virtue of
their blue stained nuclei.  Baron-Van Evercooren et al. (1992) also demonstrated that
the Hoechst-labelled Schwann cells, transplanted into or at a short distance (2-8 mm)
from a demyelinated lesion in Shiverer mouse spinal cord, were able to migrate into the
lesion and remyelinate CNS axons.  Limited migration of both Hoechst-labelled
Schwann cells and a Schwann cell line MSC80 was observed in wild type (2-3 mm) or
shiverer (8 mm) mouse spinal cord towards a focal demyelination, with some of these
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cells contributing to myelin repair upon reaching the lesion and expressing the
peripheral myelin protein, P0.  Hoechst labeling did not impede the expression of O4,
Gal-C or MBP by oligodendrocyte progenitors and their progeny after being
transplanted into the newborn shiverer mouse brain.  However, tissue from animals that
received Hoechst-labelled cells has to be processed very carefully as Ramon-Cueto and
Nieto-Sampedro (1994) reported that a long paraformaldehyde incubation results in the
loss of Hoechst flourescence.  In addition, it has been suggested that phagocytosis of
cellular debris by microglia and/or macrophages at the site of implantation can result in
an overestimation of the survival and migration of transplanted cells because the
phagocytosed Hoechst dye and the nuclear staining do not reveal the morphology of the
cells and therefore it is impossible to exclude reactive glia or macrophages from the
quantification (Ruitenberg et al., 2002).
Labelling cells with fluorescent dyes (e.g. DiI, Hoechst) have advantages over
other prelabelling methods.  Firstly, this method consumes less time and secondly, it is
more cost effective in comparison to other methods such as viral infection.  Prelabelling
of cells with DiI prior to grafting does not impede the phenotype or the function of the
cells after transplantation.  In the present study the DiI could be detected for at least 8
weeks after grafting, although there was a tendency for the fluorescence to fade after a
2-3 minute exposure to light while performing the cell counts on the fluorescent
microscope.  However, DiI is easiest to use when fluorescent microscopy is being used
to detect the presence of prelabelled cells.
5.5.2 Viral Infection
Advances in molecular biology allow scientists to transfer a foreign gene(s) into
different cells.  Transfer of such a foreign gene into a cell results in the production of
the foreign gene’s protein, which in turn serves as a “reporter” protein or marker of
transfected cells.  Viral vectors such as RV (Langford and Owens, 1990; Homnou et al.,
1996), the Meloney Murine Leukemia Virus packaging cell line PT67 (Mosahebi et al.,
2001), adenovirus (Cot et al., 1998; Ruitenberg et al., 2002; Shy et al., 1995), and HIV-
1-derived lentivirus (Kosaka et al., 2004; Ruitenberg et al., 2002) have been utilized to
transfect cells designated for transplantation.  Genes encoding chloramphenicol
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acetyltransferase, luciferase, and β-galactosidase have been widely as reporter genes in
viral vectors (reviewed by Kosaras and Snyder, 2002).  For example, the Lac-Z gene
encodes the “reporter” enzyme protein, β-galactosidase.  RV vectors harboring the Lac-
Z gene have been utilized for infection of Schwann cells (Langford and Owens, 1990;
Homnou et al., 1996) and OECs (Boyd et al., 2004; Ruitenberg et al., 2002) before
transplanting these cells into the adult rat spinal cord.
In the experiments reported in this thesis, OEC cultures were exposed to the
BAG replication-deficient RV harboring Lac-Z gene.  Lac-Z-expression by OECs did
not alter the morphology of these cells either in vitro or in vivo.  After grafting onto the
pial surface of the lower thoracic segment of the adult rat spinal cord, Lac-Z expressing
OECs were detected within the cerebellum, brainstem and spinal cord 4 weeks after
transplantation in Group 8 rats.  The morphology of these cells was similar to that of the
DiI-labelled OECs found in the spinal cord of Group 1-7 rats, being elongated cells with
unbranched cytoplasmic processes.  The expression of β-galactosidase by OECs
transplanted into a one-week-old cystic cavity in the adult rat spinal cord was also
detected three weeks after transplantation (Boyd et al., 2004).  The expression of Lac-Z
gene did not appear to affect the phenotype, survival or migratory ability of the OECs in
either the present study or the study of Boyd et al. (2004).  Moreover, Arroyo et al.
(1998) reported that Lac-Z expression does not hinder the ability of Schwann cells to
produce myelin or associate with unmyelinated axons in vivo.  Remyelination of spinal
cord axons was also observed by either Schwann cells or OECs derived from a
transgenic rat expressing human placental alkaline phosphatase (Akiyama et al., 2004).
A fluorescent marker, GFP (Clontech, Palo alto, CA), can be also incorporated
into a cell by transfecting it with adenovirus (Li et al., 2003).  GFP expressing mice
bred in the Jackson Laboratory (Bar Harbor, ME, USA) have been used as a source for
obtaining various GFP expressing cells, e.g. bone marrow cells (Akiyama et al., 2002a).
In addition, GFP can be delivered into cells (e.g. OECs) in vitro by means of infection
with either adenovirus or lentivirus harboring the GFP gene.  GFP-expression by OECs,
which were transplanted into an adult rat spinal cord, did not alter the phenotype of
grafted cells, which displayed a bipolar morphology similar to that seen in the present
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study with DiI+ve cells and β-Gal+ve cells, and also expressed the p75NGFR
(Ruitenberg et al., 2002).  In contrast to DiI, GFP does not leak out of a cell.  However,
Ruitenberg et al. (2002) found that only approximately 50 % of the OECs expressed
GFP in vitro after the infection of cultures with either adenovirus or lentivirus.  In
addition, the expression of GFP by OECs was detected for only up to 12-14 days after
cell transplantation into an adult rat spinal cord (Ruitenberg et al., 2002), in contrast to
being able to see DiI+ve cells and β-Gal+ve cells as long as 2 months after grafting into
the dorsal funiculus or onto the pial surface of the spinal cord, respectively (present
study).
It is still unclear whether viral transfection has any long-term consequences on
the phenotype of infected cells.  Based on the data presented in this research project and
that reported by others it would appear that transfection with a viral vector has no
cytopathic effect on the cells (Akiyama et al., 2004; Boyd et al., 2004; Homnou et al.,
1996; Mosahebi et al., 2001; Shy et al., 1995).  Genetic labeling is therefore a stable
and reliable method for prelabeling cells prior to grafting (Mosahebi, et al., 2001)
provided the viral vector has a selectable marker gene for purifying the cell culture.
5.6 Methods of Delivery of Cells to Injured CNS
Manipulation of the cellular environment within and adjacent to injured CNS
tissue through the use of cell transplantation is being studied in animal models of
demyelinating disease (e.g., EtBr or lysolecithin) and of spinal cord injury (e.g., spinal
compression).   These manipulations have included the transplantation of Schwann cells
(Neuberger et al., 1992; Ramon-Cueto et al., 1998; Xu et al., 1997), OECs (Imaizumi et
al., 1998; Li et al., 1997; Navarro et al., 1999; Ramon-Cueto et al., 2000; Smale et al.,
1996), immature astrocytes (Silver, 1998; Smith et al., 1986), oligodendrocyte
progenitor cells (Franklin, 1996; Lachapelle et al., 1994; Milward et al., 2000; O’Leary
and Blakemore, 1997), and bone marrow progenitor cells (Akiyama et al., 2002a;
Sasaki et al., 2001).   Cells that have been genetically modified to secrete large amounts
of specific growth factors have also been used to make the microenvironment more
conducive to axonal growth (Cunningham et al., 1991; Kawaja et al., 1991; Kawaja et
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al., 1992).  Although the usual method of delivery of such cells to the damaged neural
tissue is by injection, a procedure that by its very nature is traumatic to the brain and
spinal cord, there are other less invasive options that have also been explored.
5.6.1 Grafting Cells Directly into CNS Tissue
Bony structures form a protective shield around the fragile brain and spinal cord.
Therefore, in order for the cells to be grafted directly into the CNS tissue the
investigator must inflict various degrees of destruction on either the bones of the skull
or on the vertebrae, unless perhaps these bones have already been broken as the intial
injury was induced.  In most of the animal models, however, the cells have been
injected into the neuropil of the spinal cord or brain only after mechanical removal of
part of the bony protection.  Directly injecting cells into an EtBr-induced (Akiyama et
al., 2001, 2002a, 2004; Barnett et al., 2000; Blakemore and Crang, 1989; Franklin et al.,
1996, 1997; Jeffery et al., 1999; Sasaki et al., 2001) or lysolecithin-induced (Baron-Van
Evercooren et al., 1992, 1996; Duncan et al., 1981; Vignais et al., 1993) demyelinated
lesion, into the cystic cavity that forms after spinal injury (Boyd et al., 2003; Lu et al.,
2002; Resnick et al., 2003; Takami et al., 2002), or into the proximal and/or distal
stumps of the transected spinal cord (Lu et al., 2001; Ramon-Cueto et al., 1998, 2000),
has been one of the favoured approaches for delivering cells of interest to injured neural
tissue.   In many of these cell grafting experiments a stereotaxic apparatus was used to
deliver the cells to a precise location, which was especially important when the
migratory abilities of the transplanted cells were being studied.  The cell suspensions
were mostly injected into the neural tissue using either 5 or 10 µl Hamilton syringes
with an attached glass or metal (30-32 G) needle.  Compared to cell injection done by
hand, a syringe pump like the one used in the present experiments makes cell grafting
far more accurate by being able to control both the flow rate and the volume injected.
There is no way to avoid some mechanical damage to the neural tissue when a needle,
no matter how small, is inserted into the brain or spinal cord.   Moreover, it would be
inappropriate, as part of a therapeutic approach to neural repair in humans, to inflict yet
additional damage on the patient’s nervous tissue during the delivery of cells meant to
facilitate the tissue repair.
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Most of the experimental cell therapies being developed in animal models for
delivering myelinating glia to the site of demyelination have used a cell grafting
approach (see Section 1.7).  Although this approach shows promise in terms of neural
repair, facilitating functional recovery, and restoring axonal conduction, the limited
migration of oligodendrocyte progenitor cells and Schwann cells through the CNS
parenchyma restricts the beneficial effect of transplanting these two cell types to the
immediate vicinity of the site of injury (Baron-Van Evercooren et al., 1992; Blakemore
et al., 1986; Fawcett and Asher, 1999; Franklin and Blakemore, 1993, 1997).  The
therapeutic usefulness of focal cell grafts, therefore, is of limited benefit in the
treatment of diseases such as MS in which multifocal demyelination is the main
pathological feature.  Thus, in an MS patient there would have to be multiple such
injections of myelinating glia, even taking into account the ability of OECs to respond
to a migratory signal(s) arising as a result of the multiple lesions of focal demyelination.
5.6.2 The Vascular Route
The intravenous route of administration is widely used in modern medicine to
deliver various drugs to target tissues and has also been used to deliver cells to an EtBr-
induced and x-irradiated demyelinated lesion (Akiyama et al., 2002; Inoue et al., 2003)
or to an ischemic area of the cerebral hemisphere induced by occlusion of the middle
cerebral artery (Chen et al., 2001).  Bone marrow cells (Akiyama et al., 2002; Li et al.,
2001; Inoue et al., 2003), Schwann cells and OECs (Akiyama et al., 2002) are the cell
types that have been delivered via this route. Intravenous administration of bone
marrow cells in animals with demyelinated lesions resulted in varying degrees of
remyelination, with the myelin formed being of both peripheral (i.e., Schwann cell-like)
and central (i.e., oligodendrocyte-like) type myelin, as well as improving the conduction
velocity of the remyelinated axons (Akiyama et al., 2002; Inoue et al., 2003).  An
improvement on the adhesive-removal behavioral test and the modified neurologic
severity scores in adult rats with cerebral ischemia were also reported subsequent to an
intravenous infusion of bone marrow cells (Li et al., 2001).
Adverse effects, if any, on non-neural organs such as the liver, spleen, etc
through administration of cells derived from bone marrow via the intravenous route has
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yet to be determined, and especially whether there are effects that may arise in animals
after long survival times.  Inoue et al. (2003) reported that they had to inject 100 times
more bone marrow cells via the femoral vein to achieve a comparable density of
remyelination relative to that achieved after direct intraspinal injection of these cells.
However, although a relatively large number of axons were remyelinated in such a
lesion subsequent to transplantation of Lac-Z expressing bone marrow cells directly into
the demyelinated lesion, Akiyama et al. (2002) reported that only a small percentage of
the myelinating cells were β-galactosidase positive. Further studies are needed to
determine whether intravenously injected bone marrow cells do actually give rise to
myelinating glia or whether the tissue repair is due to the facilitation of an endogenous
repair mechanism.  Furthermore, in contrast to that seen with the bone marrow cells, no
remyelination was seen in areas of x-irradiation/EtBr-induced demyelination after
intravenous delivery of either Schwann cells or OECs (Akiyama et al., 2002).
Akiyama et al. (2002) suggested that intravenously delivered cells (e.g., bone
marrow cells) are unlikely to migrate across the blood brain barrier into normal spinal
cord or brain tissue, because this barrier would continue to function as it normally does
in restricting access to the nervous system parenchyma.  In support of this suggestion
they reported that no intravenously delivered bone marrow cells were observed in CNS
areas other than in the lesion.  The focused entry of prelabeled bone marrow cells into
sites of CNS injury in experiments where they were delivered intravenously is likely
due to the ability of the cells to respond to chemotactic factors (e.g., monocyte
chemoattractant protein 1), the expression of which is increased in damaged CNS tissue
(Kim, 1996).  In addition, the expression of cell adhesion molecules, such as
intercellular adhesion molecule (Zhang et al., 1995), vascular adhesion molecule 1, and
E-selectin (Blann et al., 1990; Haraldsen et al., 1996) may also contribute to the
migration of the prelabeled bone marrow cells across the blood brain barrier and into
the damaged neuropil.   Therefore, the vascular route is an approach that may prove
benefical in the treatment of neurological diseases like MS and spinal cord injury where
complex neurosurgical interventions can and should be avoided.
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5.6.3 Injection of Cells Into CSF
There have been a few studies using an animal model of CNS demyelination in
which progenitor cells have been delivered intracisternally (Einstein et al., 2003;
Learish et al., 1999; Pluchino et al., 2003).  For example, neuronal progenitor cells
prelabelled with bromodeoxyuridine have been injected into the lateral ventricle of
C57BL/6 mice that are suffering from EAE (Einstein et al., 2003).  Transplantation of
these neuronal progenitor cells resulted in attenuation of clinical severity of EAE and
brain inflammation of animals, indicated by reduction in perivascular infiltrates.
Pluchino et al. (2003) injected neuronal progenitor cells infected with lentivirus
harboring a Lac-Z gene into the lateral ventricle of mice with EAE and observed an
increased number of oligodendrocyte progenitors and remyelinated axons within
demyelinated areas.  Learish et al. (1999) injected Lac-Z-expressing oligodendrocyte
progenitor cells into the cerebral ventricles of embryonic myelin-deficient mice.  The
donor progenitor cells migrated into the CNS parenchyma including the corpus
callosum, inferior hippocampus, thalamus, and inferior colliculus and facilitated neural
repair.  Learish et al. (1999) suggested that an intraventricular injection is a feasible
approach to cell delivery in patients with demyelinating disorders, particularly for the
demyelinated lesions located in periventricular white mater.   However, an
intraventricular injection of cells still involves some degree of mechanical injury to the
cerebral hemisphere because the injection needle must pass through normal brain tissue
before the tip enters the ventricular system.
In clinical practice and in experimental studies that involve the use of large
animals, lumbar puncture is a widely used technique for collecting CSF or for delivery
of drugs.  An alternative approach for cell delivery is an intrathecal injection into the
subarachnoid space, which is located between the arachnoid and pia mater and is filled
with CSF.  Since the pia mater intimately adheres to the surface of the brain and spinal
cord, the subarachnoid space widens where the brain surface exhibits a deep sulcus, for
example between the cerebellum and medulla, thus forming a cistern (e.g., cisterna
magna).  The lumbar cistern is formed as a pouch by the extension of the arachnoid
mater caudally into the lumbar and sacral portions of the vertebral column leaving
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behind the pia mater covering the conus medularis and fillum terminalis, as well as the
lumbar and sacral rootlets.  In adult humans, the spinal cord ends at the level of the first
lumbar vertebra although it is much lower in the vertebral column in children.  A needle
insertion into the lumbar cistern is called a lumbar puncture and is considered a
relatively safe procedure in comparison to needle insertion into the cisterna magna.
Only one study so far has reported on an intrathecal injection of neuronal
progenitor cells in an EAE animal model (Ben-Hur et al., 2003).  Injected into the CSF,
neuronal precursor cells were found exclusively within demyelinated areas of brain and
spinal cord white matter.  Recently, De la Calle and Paino (2002) described a detailed
procedure for direct lumbar puncture in rats, which was modified from that described
previously by Hylden and Wilcox et al. (1980).  Under isofluorane anesthesia, a 2 cm
longitudinal percutaneous incision was made with a scalpel at the lower lumbar level
and a 25G neonatal lumbar puncture needle was inserted through the intervertebral
space between the L5 and L6 vertebrae.  De la Calle et al. (2002) used this lumbar
puncture technique to inject a cell suspension of Hoechst-prelabelled NB69
neuroblastoma cells, which are known to synthesize and secrete monoamines into the
subarachnoid space of the rat with chronic contusion injury.  Intrathecally grafted NB69
neuroblastoma cells survived and maintained their ability to secrete monoamines, thus
abolishing chronic contusion injury-induced heat hyperalgesia.
The use of a direct lumbar puncture rather than injecting the cells into the
cisterna magna or through brain tissue into the lateral ventricles is of particular clinical
relevance.  A lumbar puncture can be done relatively quickly, on the order of 10
minutes or less, and in comparison to needle insertion into the cisterna magna or the
ventricles is far less traumatic for the patient.  An additional advantage of injecting the
cells directly into the CSF is that instead of the grafted cells immediately encountering
the aggressive, inflammatory environment of the lesion epicenter, and thus possibly
compromising the survival of the grafted cells, the myelinating glia could potentially
benefit from the CSF in terms of being a source of nutrients.  Admittedly, there is also a
concern with possible damage to the spinal cord and/or the rootlets at the level of the
lumbar puncture.  Other possible complications that might arise after lumbar puncture
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include headache, CNS infection (especially in immunocompromised patients), and
intraspinal hemorrhage in patients receiving anticoagulation therapy.  However, these
risks are relatively low.   In their study, De la Calle and Paino (2002) detected no signs
of motor or sensory deficit in the rats subjected to lumbar puncture and saw no grossly
detectable lesions in or on the lumbar spinal cord on post mortem examination.
5.7 General Conclusions
An in vivo model for studying the migratory ability of OECs within the adult rat
spinal cord was developed for the present research study.  A small focal (< 1 mm long)
demyelination was induced by injecting 1µl of a 0.03% EtBr solution into the right
dorsal funiculus of the spinal cord.  This lesion was made at variable distances from the
site of an OEC graft.  In this model, the strength of the migratory signal(s) inducing
OECs to migrate increased as the demyelinated lesion was located closer to the grafting
site, with a significant increase in the number of OECs in the dorsal funiculus of the
intervening segments being first apparent by 8 weeks after grafting.  OECs grafted at
T12 migrated as far as four spinal cord segments to reach a focal EtBr-induced
demyelinated lesion located at T8.  There was minimal migration of OECs when the
cells were grafted directly into a demyelinated lesion unless a second demyelinated
lesion was made two spinal cord segments away from the first, in which case there was
precocious migration of OECs.  The OEC migration occurred along a migratory path
containing many reactive astrocytes and microglia and this migration of OECs was
significantly reduced when the microglial reactivity was dampened using minocycline.
OECs also survived grafting into cerebrospinal fluid (i.e. subarachnoid space) and
migrated into the neuropil of the brain and spinal cord.  The major conclusions are that
OECs can respond to migratory signal(s) arising as a result of a focal EtBr-induced
demyelination and that microglia are one potential source of these migratory signal(s).
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5.8 Future Directions
The EtBr-induced demyelination animal model used in the present
research project will be extremely useful for determining:
1) the time frame of microglial response contributing to the generation of the
migratory signal(s) that induces OECs to migrate towards the lesion;
2) the molecular mechanisms facilitating and impeding the migration of OECs, for
example:
a. whether proinflammatory cytokines contribute to a migratory signal
inducing OECs to migrate;
b. whether anti-inflammatory cytokines attenuate the migratory signal;
c. whether OECs express specific cytokine receptors to facilitate or impede
their migration in response to proinflammatory or anti-inflammatory
cytokines.
3) the contribution of grafted OECs to neural repair (including remyelination) once
they have migrated into the neuropil of a focal demyelination lesion;
4) the ability of OECs to migrate towards a focal demyelination of spinal cord
white matter and contribute to neural repair when the cells are grafted into the
CSF via a lumbar puncture.
Before adopting a therapeutic approach that involves glial cell transplantations
in treating demyelinated diseases, it is important to get a better understanding of host
cell-grafted cell interactions in order to maximize the beneficial consequences of
myelinating glial cell grafting.  In MS multiple demyelinated lesions are not only
scattered throughout the CNS neuropil, but the pathogenesis of each plaque develops
with its own time frame with each new relapse adding to the pathology and creating
new lesions.  Thus, at any point during the pathogenesis of the disease in the same MS
patient plaques can be found at different stages of progression.  The host glial cell
response within the demyelinated area and within the surrounding tissue depends on the
stage of plaque progression with the highest level of glial reactivity being seen at the
early, acute stages and lower reactivity at later, chronic stages.  As presented in this
research project, microglia are implicated as one potential source, either directly or
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indirectly, of the migratory signal(s) driving OEC migration in an EtBr-induced
demyelination animal model.  Why is it important to identify the source of these
migratory signals?  Cell migration would be a far more efficient way of delivering
myelinating glia to multiple areas of CNS injury, such as the isolated MS plaques, than
trying to deliver the cells directly to each injured area.
Although the distances over which migratory signals are working in the present
study is only one spinal cord segment, this is still 2-3 times further than either
oligodendrocyte progenitors or Schwann cells will migrate in response to a
demyelinated lesion.  OEC migration occurred along a migratory path containing many
reactive astrocytes and microglia and this migration was significantly reduced when the
microglial reactivity was dampened using a 4 week minocycline treatment.  This
indicates that the first 4 week period after cell grafting and EtBr injection is the time
period when the microglia contributed to the generation of a migratory signal(s).  By
varying the duration and when in the first 4 week period the minocycline treatment is
started, it will be possible to determine whether it is the early (i.e. 3-7 days) or late (1-4
weeks) microglial response to injury that is likely to be most important in contributing
to the generation of a migratory signal(s).  Knowing this time frame is important for the
design of experiments to identify the molecular mechanisms.  One can hypothesize that
the microglial reactivity during the first two weeks after EtBr injection is the most
critical for generating a migratory signal(s) and for creating a migratory pathway
conducive to OEC migration because this would be the time interval during which the
microglial cells would be the most reactive.  For example, the early treatment with
clodronate of young adult female rats that have a lysolecithin-induced demyelinated
lesion in their spinal cord resulted in the depletion of microglia and macrophages and in
a decreased remyelination by oligodendrocytes, whereas a late clodronate
administration had no effect on the repair outcome even though still depleting numbers
of activated macrophages (Kotter et al., 2001).  In MS the microglial response to a
progression of the pathogenesis in each plaque is reflected in the profile of released
cytokines (e.g., the type and level of cytokine), excitatory amino acids, oxidative
radicals, and nitric oxide.  By identifying the time frame of the microglial response to
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plaque progression, we can predict whether early (e.g., IL-1b) vs. late (e.g., IL-12)
proinflammatory and/or anti-inflammatory (e.g., IL-10) cytokines contribute to the
migratory signal(s) inducing OECs to migrate.
Transplantation of myelinating glia will be an essential part of potential
therapeutic approaches to neural repair in MS and spinal cord injury.  In addition to
finding the best cell candidate, the method of cell delivery is also an important issue of
any therapeutic approach involving cell transplantation.  Although various degrees of
success in CNS tissue regeneration and remyelination have been achieved after cell
transplantation, several aspects specific to MS remain neglected in these animal models.
The demyelinated lesions in MS are disseminated throughout the brain and spinal cord
and, thus, it is certainly not possible to transplant cells into each and every lesion.
Moreover, some demyelinating lesions can be located within vitally important areas
such as the brain stem or located in CNS areas that are surgically inaccessible without
causing undue mechanical damage to surrounding tissues (e.g., the optic nerve).
Therefore, delivery of cells into the CSF by means of a lumbar puncture has many
advantages over direct injection into the neuropil of the CNS.  Without inflicting
unnecessary additional damage to the CNS tissue, the lumbar puncture route could use
the CSF to distribute the grafted cells to those parts of the CNS that were demyelinated.
As reported in this thesis, OECs grafted into either normal or demyelinated areas of the
CNS neuropil can be induced to migrate towards a focal area(s) of demyelination.
When the OECs were grafted into the CSF, some were found attached to the pia mater
at some distance from the site of grafting as well as being found within the neuropil of
the same brain areas.  One can hypothesize, therefore, that once OECs are grafted into
the subarachnoid space they will float in the CSF, attach to the pia matter at various
levels of the neuraxis, and then migrate across the damaged blood-brain barrier into the
demyelinated lesions where they will contribute to neural repair.
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